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Resumo Alargado 
 
 
 
 
 
A biodisponibilidade oral é uma característica farmacocinética fundamental, 
pois condiciona a administração dos fármacos por esta via. Sendo a 
administração entérica, pela sua facilidade e economia, a via por excelência na 
administração de fármacos, esta é um objectivo preponderante no 
desenvolvimento de novas entidades terapêuticas. Vários factores podem 
condicionar a biodisponibilidade oral de uma molécula. Estes podem ser 
agrupados em 3 classes principais, nomeadamente 1) a solubilização do fármaco 
no tracto gastro-intestinal, 2) a capacidade de atravessar a membrana intestinal e 
chegar à corrente sanguínea e 3) a sua estabilidade quer no lúmen intestinal quer 
a nível do metabolismo na parede intestinal e no fígado. Assim, de forma a 
aumentar a eficácia nos programas de desenvolvimento de novos fármacos, a 
utilização de modelos in silico e in vitro para caracterizar cada um destes factores 
de perda, teve um aumento extraordinário nos últimos anos e são hoje 
ferramentas fundamentais na escolha das potenciais moléculas a incluir em 
ensaios clínicos. 
 
Previsão da Permeabilidade 
 
As células CACO-2 em cultura constituem actualmente o ensaio in vitro 
mais utilizado para a previsão da permeabilidade intestinal de novos fármacos. A 
criação de modelos computacionais baseados em valores de permeabilidade em 
CACO-2 pode facilitar e acelerar o processo de selecção de novas entidades 
farmacêuticas. Os vários modelos computacionais actualmente existentes para 
previsão desta característica são, no entanto, construídos com base num número 
limitado de casos ou num espaço molecular reduzido. Desta forma, a sua 
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capacidade preditiva para novos moléculas é questionável. Com o objectivo de 
aumentar a aplicabilidade prática destes modelos, neste trabalho é apresentada 
uma rede neuronal artificial desenvolvida com base em descritores moleculares e 
296 valores de permeabilidades aparentes determinadas in vitro em células 
CACO-2 recolhidos na literatura. Os valores de LogPapp foram divididos 
aleatoriamente em dois grupos: (i) um grupo de treino com 192 fármacos e (ii) um 
grupo de teste com outros 59 fármacos, utilizado para paragem do processo de 
aprendizagem e para validação interna. Foi também utilizado um procedimento de 
redução do número de entradas da rede (descritores moleculares), de forma a 
reduzir a dimensionalidade da rede e promover a sua capacidade preditiva. Após 
o treino da rede, os grupos de treino e de teste apresentaram correlações de 
0.843 e 0.702 bem como um RMSE1 de 0.546 e 0.791. A validação externa foi 
realizada com um grupo adicional de 45 fármacos, tendo sido obtida uma 
correlação de 0.774 e um RMSE de 0.601, semelhante à do grupo de treino. Para 
além de o modelo apresentado demonstrar boas capacidades preditivas, os 
descritores moleculares utilizados na rede contêm informação relacionada com a 
lipofilia, hidrofilia, electronegatividade, dimensão, forma e flexibilidade molecular, 
características moleculares frequentemente associadas à permeabilidade em 
membranas biológicas.  
 
Previsão da Distribuição no Sangue 
 
A distribuição de fármacos no sangue, definida como a razão de 
concentrações entre o sangue e o plasma (Rb), é um parâmetro farmacocinético 
fundamental. Relaciona a clearance plasmática com a clearance sanguínea, 
permitindo a interpretação fisiológica deste parâmetro. Por esta razão, é um factor 
importante para a avaliação estatística de correlações in silico / in vitro – in vivo 
relacionadas com a clearance hepática. Apesar de ser facilmente determinado 
experimentalmente, os valores de Rb são desconhecidos para a maioria dos 
fármacos. Assim, com o objectivo de melhor caracterizar a distribuição de 
fármacos no sangue e aumentar a precisão da determinação dos valores de 
                                                          
1 Root Mean Square Error 
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clearance sanguínea, é apresentada uma abordagem sistemática usando 
modelos mecanicistas, regressão parcial em mínimos quadrados (PLS) e redes 
neuronais artificiais (ANN) utilizando vários descritores moleculares obtidos in 
vitro e in silico e uma base de dados de valores de Rb com 93 fármacos 
publicados na literatura. Após transformação dos dados em Log(CBC/Cp) com CBC 
a concentração de fármaco nas células sanguíneas e Cp a concentração de 
fármaco no plasma, o modelo ANN apresentou os melhores resultados com 
valores de r2 = 0.927 para o grupo de treino e r2 = 0.871 para o grupo de teste. O 
modelo PLS apresentou valores de r2 = 0.557 para o grupo de treino e r2 = 0.656 
para o grupo de teste. O modelo mecanicista apresentou os piores resultados 
estatísticos com um r2 = 0.342 sendo que, devido aos seus pressupostos, apenas 
é aplicável a fármacos acídicos, neutros ou com grupos básicos de pKa < 7. O 
modelo ANN para a distribuição de fármacos no sangue pode ser uma ferramenta 
útil na farmacocinética clínica bem como no desenvolvimento de novos fármacos, 
pois apresentou uma capacidade de previsão dos valores de Rb de 86%, 84% e 
87% valores correctos dentro de um erro aceitável de 1.25 vezes nos grupos de 
dados de treino, teste e em 7 moléculas de validação externa. 
 
Previsão da Clearance Hepática 
 
O uso de suspensões de hepatócitos humanos é actualmente aceite como 
a ferramenta in vitro mais promissora para a previsão da clearance metabólica de 
novos fármacos. Assim, a criação de modelos computacionais baseados nestes 
dados pode facilitar o processo de selecção de novas entidades farmacêuticas, ao 
permitir a previsão da clearance hepática em humanos. Com este objectivo, foi 
desenvolvido um modelo ANN para a previsão da clearance intrínseca em 
hepatócitos humanos (CLint) utilizando apenas descritores moleculares calculados 
computacionalmente. Dados in vitro de CLint determinados em suspensões de 
hepatócitos humanos e recolhidos na literatura foram transformados 
logaritmicamente e divididos entre um grupo de treino com 71 fármacos para a 
aprendizagem da rede neuronal e num grupo de teste com outros 18 fármacos 
para paragem do processo de aprendizagem e para validação interna. Foi, de 
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novo, utilizado um procedimento de redução do número de descritores 
moleculares, de forma a reduzir a dimensionalidade da rede e promover a sua 
capacidade preditiva. Obtiveram-se correlações de 0.953 e 0.804 para os grupos 
de treino e teste respectivamente. A validação externa foi feita com um grupo 
adicional de 5 fármacos apresentando uma correlação de 0.467. A aplicabilidade 
do modelo na previsão da clearance hepática foi testada num grupo adicional de 
112 fármacos, comparando os valores de CLint previstos in silico com os valores in 
vivo de CLint estimados utilizando o modelo do fígado com distribuição 
homogénea. Observou-se uma correlação aceitável com um valor de 0.508 e 63% 
dos fármacos correctamente previstos dentro de um intervalo de aceitação de 
10x, quando considerando apenas a distribuição do fármaco no sangue para 
moléculas ácidas.  
 
Modelo Fisiológico de Absorção 
 
Finalmente, e com o objectivo de integrar a informação dos modelos 
anteriores, foi desenvolvido um modelo de absorção de base fisiológica capaz de 
fornecer estimativas da biodisponibilidade absoluta em humanos. Este utiliza a 
solubilidade no pH gastrointestinal, a permeabilidade aparente (Papp) em células 
CACO-2, a clearance intrínseca (CLint) em suspensões de hepatócitos humanos e 
ainda a correcção devida à distribuição do fármaco no sangue (Rb) no cálculo da 
clearance, como parâmetros descritivos do comportamento do fármaco. A 
capacidade preditiva do modelo foi testada em 164 fármacos divididos em 4 níveis 
de procedência da informação: (i) dados in vitro para Papp e CLint; (ii) apenas 
dados in vitro para a CLint; (iii) apenas dados in vitro para a Papp  e (iv) dados in 
silico para a Papp e para a CLint. A solubilidade foi sempre estimada in silico. A 
avaliação dos resultados mostrou uma boa capacidade preditiva quando foram 
utilizados apenas dados in vitro para a Papp e a CLint, apresentado 82% das 
previsões correctas num intervalo absoluto de ±20%. Com a adição de 
parâmetros de origem in silico, observou-se uma redução da capacidade preditiva 
do modelo, principalmente considerando os valores in silico de  CLint. Assim, e 
num cenário de previsão com a utilização de estimativas in silico do valor de Papp 
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e Clint, apenas 46% das previsões apresentaram valores correctos no intervalo 
absoluto de ±20%. No entanto, esse valor subiu para 66% quando considerado 
um intervalo absoluto de ±35%, compatível com uma previsão qualitativa da 
biodisponibilidade absoluta. Desta forma, a conjugação dos modelos in silico 
apresentados no modelo de absorção de base fisiológica pode ser uma 
ferramenta útil para a previsão e simulação durante o processo de 
desenvolvimento de novos fármacos, fornecendo estimativas da 
biodisponibilidade oral absoluta, bem como uma interpretação mecanicista acerca 
dos passos limitantes da biodisponibilidade dos fármacos. 
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Resumo 
 
 
 
 
 
Foram criados vários modelos QSAR com o objectivo de prever a 
biodisponibilidade oral de fármacos em humanos. Assim, criaram-se redes 
neuronais artificiais (ANN) para a previsão da permeabilidade aparente (Papp) em 
células CACO-2; ANN para a previsão da razão da concentração entre o sangue 
e o plasma (Rb); e ANN para a previsão da clearance intrínseca (CLint) 
determinada em suspensões de hepatócitos humanos. Estes modelos foram 
utilizados, juntamente com estimativas da solubilidade dos fármacos no pH do 
tracto gastrointestinal, como parâmetros para caracterizar o comportamento de 
fármacos num modelo de absorção de base fisiológica. A capacidade preditiva do 
modelo foi testada em 164 fármacos divididos por 4 classes de proveniência de 
dados: (i) dados de Papp e CLint obtidos in vitro; (ii) dados de CLint obtidos in vitro; 
(iii) dados de Papp obtidos in vitro e (iv) dados de Papp e CLint obtidos in silico. A 
solubilidade foi sempre estimada in silico. A avaliação dos resultados mostrou 
uma boa capacidade preditiva quando foram utilizados apenas dados in vitro para 
a Papp e a Clint, apresentado 82% das previsões correctas num intervalo absoluto 
de ± 20%. Com a adição de parâmetros de origem in silico, observou-se uma 
redução da capacidade preditiva do modelo, principalmente considerando os 
valores in silico de CLint. Assim, e num cenário de previsão com a utilização de 
estimativas in silico do valor de Papp e Clint, apenas 46% das previsões 
apresentaram valores correctos no intervalo absoluto de ±20%. No entanto, esse 
valor subiu para 66% quando considerado um intervalo absoluto de ±35%, 
compatível com uma previsão qualitativa da biodisponibilidade absoluta. A 
abordagem apresentada pode ser uma ferramenta útil para a previsão e 
simulação durante o processo de desenvolvimento de novos fármacos, 
Resumo 
viii 
fornecendo quer estimativas da biodisponibilidade oral quer uma interpretação 
mecanicista dos seus passos limitantes. 
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Abstract 
 
 
 
 
 
With the purpose to predict the human oral bioavailability, various QSAR 
models were developed, namely an artificial neural network (ANN) to predict 
apparent permeabilities (Papp) in CACO-2 cells; an ANN to predict the drug blood-
to-plasma concentration ratio (Rb); and an ANN to predict intrinsic clearance (CLint) 
obtained in human hepatocytes suspensions. These QSAR models were 
introduced, together with estimates of the drug solubility at the gastrointestinal pH, 
as drug related parameters in a physiologically-based pharmacokinetic model of 
absorption in order to estimate the human absolute bioavailability. The global 
model predictive ability was tested in 164 drugs divided in four levels of input data: 
(i) in vitro data for both Papp and CLint; (ii) in vitro data for CLint only; (iii) in vitro data 
for Papp only and (iv) in silico data for both Papp and CLint. In all scenarios, solubility 
was estimated in silico. Evaluation of the model performance resulted in excellent 
predictive abilities when in vitro data for both Papp and CLint was used with 82% of 
drugs with bioavailability predictions within a ±20% interval of the correct value. 
Model performance was reduced when in silico estimated parameters were 
introduced, especially when CLint is considered. Performance of the model using in 
silico data for both Papp and CLint provided only 46% of drugs with bioavailability 
predictions within a ±20% acceptance interval. However, 66% of drugs in the 
same scenario resulted in bioavailability predictions within a ±35% interval, which 
indicates that a qualitative prediction of the absolute bioavailability is still possible. 
This model is a valuable tool to estimate a fundamental pharmacokinetic 
parameter, using data typically collected in the drug discovery environment, 
providing also mechanistic information of the limiting bioavailability steps of the 
drug. 
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 1 
Chapter 1  
 
 
 
 
Introduction and work goals 
 
 
 
In order to meet convenience and patient compliance requirements, oral 
administration is often a major goal during the new drugs development program. 
However, not all leads have the chemical properties required to be administered 
via this route. This fact may result in either a prolongation of the development time 
or even in the discontinuation of the development phase for that particular 
molecule, thus contributing to the attrition rate in drug development. Economical 
and ethical consequences are evident, especially if the molecule had already 
entered the clinical development phase (Venkatesh and Lipper, 2000). This 
prompted pharmaceutical companies to aim at identifying, as soon as possible,  
the potentially well absorbed and bioavailable compounds in their discovery 
pipeline (Saxena et al., 2009). A large variety of in vitro and in vivo models were 
developed in order to accomplish this goal. However, due to the advent of 
combinatorial chemistry and high-throughput pharmacological screening, the 
number of possible lead compounds has increased exponentially. Additionally, the 
molecules resulting from these techniques often contain chemical properties not 
compatible with the oral administration (Lipinski et al., 2001). Therefore, there is a 
growing research effort aimed at developing theoretical methods to predict drug 
bioavailability before the potential molecule actually exists (van de Waterbeemd, 
2002; Yamashita and Hashida, 2004). The pursued goal of this work is to 
contribute to the success of this research effort. 
 After administration by the oral route, an active drug must be able to reach 
unchanged the systemic circulation in order to exert its pharmacological action. 
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Bioavailability is defined as the fraction of the administered dose that effectively 
reaches the blood in its initial chemical form and is the result of a series of rather 
complex processes. Typically, a drug is administered as particles within a solid 
pharmaceutical form. The release of these particles, in such a release form, is 
usually optimized to be complete within minutes and with minimal consequences 
to the bioavailability of the drug, but the release and the dissolution of the drug 
particles are the first processes that could reduce the drug bioavailability (Takano 
et al., 2006). When in solution, in the gastrointestinal track (GIT), the drug may 
also undergo a variety of either chemical or biological degradation processes (Di 
and Kerns, 2008; Sousa et al., 2008). After dissolution of the drug molecules, 
permeability in the GIT wall is a fundamental drug characteristic for a sufficient 
bioavailability. Drugs may be absorbed by a variety of mechanisms, passive 
diffusion and active transport being the most relevant ones (Lennernas, 1998). 
However, drugs may also be subjected to both efflux and metabolism mechanisms 
at the enterocyte that will result in reduced bioavailability (Ayrton and Morgan, 
2001; Benet et al., 2004). Finally, drug absorbed in the GIT will be directed by the 
portal vein to the liver where a large number of enzymatic systems are present. 
These can also reduce bioavailability by metabolisation of the administered drug 
(Ritschel, 2000).  
 
In vitro Models 
 
 Absolute bioavailability is easily determined in vivo if the drug is also 
available to be administered by intravenous (IV) route. In this case, it is defined as 
the ratio of AUC obtained by the oral and the IV routes. However, not all drugs can 
be administered IV. Additionally, if a reduced bioavailability is observed, it is 
difficult to determine the reasons behind this fact. With the purpose to characterize 
the drug bioavailability limiting steps, various in vitro models were developed. 
These are focused on the drug solubility, permeability and metabolization, which 
are considered the major determinants of drug bioavailability in vivo (Amidon et al., 
1995; Kasim et al., 2004; Wu and Benet, 2005).  
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Solubility is usually determined at equilibrium by a shake-flask method, 
where the supernatant of a previously centrifuged saturated solution is quantified 
by HPLC. Alternatively, kinetic solubility may also be determined by inducing drug 
precipitation in a solution by pH changes (Vogel, 2006). Kinetic solubility 
measurements are much faster than shake-flask, but the values obtained are often 
much higher than measured equilibrium solubilities (Box et al., 2006). Various 
high throughput solubility assays, based on the detection of turbidity caused by 
precipitation, are also available in order to rank compound solubilities (Lipinski et 
al., 2001). Due to the large amount of drug solubility data, solubility is a drug 
property for which numerous in silico models were developed (Dearden and 
Worth, 2007; Dearden, 2006; Johnson and Zheng, 2006; Sanghvi et al., 2003; 
Tetko et al., 2001; Votano et al., 2004). Some of these models present good 
prediction capabilities, with predictive errors in the same order of magnitude as the 
in vitro experimental error (Dearden and Worth, 2007). 
Permeability, as a measure of the ability of a drug to pass through the GIT 
membrane, has been determined by many different models like in vivo intestinal 
segments (Lennernas et al., 1997), in situ models with perfused intestinal mucosa 
(Kim et al., 2006), in vitro intestinal mucosal tissue (Lennernas et al., 1997), 
cellular models (Artursson and Karlsson, 1991; Irvine et al., 1999; Ranaldi et al., 
1992), filter immobilized artificial membranes (Avdeef et al., 2004), to name a few. 
Cellular assays, within which CACO-2 cells are probably the most widely accepted 
model both in industry and academia, are the source of the majority of 
permeability screening at the drug development stage. CACO-2 cells resemble the 
morphological and biochemical characteristics of enterocytes. They present 
polarization and microvilli in their apical side, and are connected with tight 
junctions and adherence junctional complexes (Vogel, 2006). Although in different 
concentrations, they also express essentially the same enzymatic and transport 
enzymes of the intestinal enterocytes (Sun et al., 2002). Additionally, reasonable 
accurate predictions of human permeability are obtained with this cell model 
(Artursson and Karlsson, 1991; Rubas et al., 1993; Yee, 1997) making it an ideal 
source of data for in silico prediction. The Chapter 2 of this thesis describes the 
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building of an in silico model based on in vitro apparent permeability (Papp) data 
obtained in CACO-2 cells.  
On a typical permeability experiment in CACO-2 cells, a single 
concentration of drug is added to the apical side of the cell system and samples 
are collected from both the basolateral and apical compartments after a pre-
specified time (usually 1 h). Papp coefficients are calculated according to the 
following equation 1.1, 
 
0
1 )(
CA
V
dt
dQscmPapp ⋅⋅=⋅
−      (1.1) 
 
where A is the surface area of the support filter, C0 is the initial 
concentration of the compound on the donor side, dQ/dt is the rate of 
compound appearance on the basolateral side and V is the volume of the 
receiving chamber.  
 
 
This type of experiment is sufficient for passively diffused drugs and is easily 
performed in a high throughput scenario. However, a range of initial 
concentrations should ideally be used in order to identify the possible occurrence 
of transport mechanisms (Vogel, 2006). Papp values can be used to compare 
compounds within a series for ranking, as theses values have shown to be related 
both to the effective jejunal permeability and in vivo absorption for a vast series of 
drugs (Artursson and Karlsson, 1991; Lennernas, 1998). However, some 
limitations have been described when comparing Papp values from different 
laboratories, as a large variability is observed (Artursson et al., 2001).  The use of 
standards for intra and inter-laboratory comparison has been proposed as a 
possible approach to standardise results (Yamashita et al., 2002) and, in Chapter 
2, we tested a data normalisation procedure based on this assumption. 
 Metabolic clearance may also be determined in vitro by using liver 
preparations such as isolated perfused livers, liver slices, liver homogenates, 
isolated hepatocytes, subcellular liver fractions or recombinant metabolizing 
enzymes, in decreasing order of tissue organization (Brandon et al., 2003). Each 
of these in vitro systems has both advantages and disadvantages (Table 1.1), and 
the choice of the liver model is frequently dependent on the research goal. If 
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compounds are only to be screened for their metabolic stability in a high 
throughput assay, usually microsomes or recombinant metabolizing enzymes are 
used (Vogel, 2006). However, when correlation to in vivo is pursued, higher tissue 
organization is frequently needed.  
 
Table 1.1 - Comparison of in vitro test systems to study biotransformation 
(adapted from (Vogel, 2006)) 
In vitro 
System Pros Cons 
Perfused 
organs 
• Phase I and II present 
• Whole metabolic profile observed 
• Best correlation to in vivo 
• Expensive 
• Ex vivo animal trial 
• Complex methodology 
• Batch variability 
• Quality control 
• Limited use for multiple compounds 
Slices 
• Phase I and II present 
• Whole metabolic profile observed 
• Best correlation to in vivo 
• Expensive 
• Ex vivo animal trial 
• Complex methodology 
• Batch variability 
• Quality control 
• Diffusion limited 
• Limited use for multiple compounds 
Cells in primary 
culture  
(e.g. hepatocytes) 
• Phase I and II present 
• Whole metabolic profile 
• Induction modelled 
• Population pools for cryopreserved 
hepatocytes possible 
• Good correlation to in vivo 
• Expensive 
• Batch variability 
• Quality control 
• Complex methodology 
• Limited use for multiple compounds 
Microsomes 
• Easy to use 
• Cheap 
• Population pools 
• Addition of cofactors  
• Only membrane-bound metabolizing 
enzymes such as CYPs 
• Partial metabolic profile 
• Induction not modeled 
 
In this context the use of hepatocytes suspensions for in vitro drug 
metabolism studies is the most equilibrated system and its use is now well 
established. Although some differences in metabolic capacity are described 
between freshly prepared and cryopreserved hepatocytes (Griffin and Houston, 
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2004), a good correlation appears to exist between the intrinsic clearances 
obtained by the two protocol types (Jouin et al., 2006; Lau et al., 2002). 
Cryopreservation of hepatocytes leads to the increase in both availability as well 
as diversity of cell sources, fundamental to the creation of population pools 
(Gomez-Lechon et al., 2003) and the number of compounds with described 
intrinsic clearances (CLint) is growing. Chapter 4 presents an in silico model built 
based in this data. 
When used to determine the metabolic clearance value for a drug, usually 
the rate of parent disappearance is measured (Obach, 1999). In this method, a low 
concentration of the drug – chosen to be sufficiently below the expected KM but at 
the same time quantifiable – is added to a hepatocytes suspension with a know 
number of cells (1 – 3 × 106 cells/mL) and aliquots are collected at pre-specified 
time points (no longer that 4 - 8 h). After quantification of the total parent drug 
concentration in the incubation, the CLint of the drug is calculated according to the 
following equation 1.2, 
 
AUC
DcellsLCL =)10min//( 6int μ        (1.2) 
 
where D is the total amount of compound added to the cells and AUC is 
the area under the total drug concentration vs time curve (Vogel, 2006).  
 
CLint values are used to predict the human hepatic clearance, typically by using 
physiologically based models (Iwatsubo et al., 1997). In this approach, a liver 
model like the “well-stirred” or the “parallel tube” model is used to relate the in vitro 
CLint data to the CLH values in vivo. Blood flow and hepatocellularity are included 
as physiological meaningful parameters. Blood binding, plasma protein binding, 
hepatocyte binding and in vitro CLint data are frequently used as drug related 
parameters (Iwatsubo et al., 1997). Although some differences in performance are 
described related to the use of different liver models and inclusion of physiological 
and drug related parameters, good predictions are frequently obtained with less 
than 25% error for half the drugs and appropriate ranking of metabolization is 
obtained (Fagerholm, 2007).  Within the drug related parameters, drug blood 
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binding is still a matter of debate. In order to further elucidate its use, Chapter 3 
describes the building of an in silico model to predict the drug blood to plasma 
concentration ration (Rb). This model, in conjunction with both in vitro and in silico 
generated CLint data, was used in Chapter 4 to test the effect of its inclusion to 
predict the hepatic clearance of drugs. 
 
In silico Methodologies 
 
 The previously presented in vitro models are being used to monitor 
compounds as early as possible, seeking for favourable ADME properties in the 
new hits. However, all these techniques require the actual synthesis of the 
compound to be tested. To save time and chemical resources, it is desirable to 
predict some characteristics of the compounds prior to their synthesis, i.e. to 
computacionally (in silico) model the in vivo behaviour of a compound and 
therefore be able to build a priority list of the most promising compounds to be 
synthesised. This goal is already being pursued in the pharmaceutical industry 
where initial screening of hits in a number of thousands is done typically by using 
in silico approaches. Subsequent in vitro tests are responsible to reduce the 
number of compounds from hundreds to dozens and in vivo animal models to 1 - 5 
finally potential drugs that are included in clinical trials (Venkatesh and Lipper, 
2000). 
In silico models can be divided into structure-based or data-based 
approaches. The first case includes the three-dimensional molecular modeling of 
ligands and proteins, using quantum mechanical methods. However, when 
studying properties whose molecular mechanism is hardly defined, data-based 
approaches are usually performed (Butina et al., 2002). In this case, a typical 
approach is the quantitative structure-activity relationships (QSAR), where 
quantitative relationships between molecular descriptors based on the chemical 
structure of the compounds and ADME properties are sought by using multivariate 
statistical analyses (Yamashita and Hashida, 2004). The typical construction and 
utilization of a QSAR model is presented in Figure 1.1 where characteristics like 
accuracy, parameter economy, uniqueness, predictability and utility are pursued 
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(Smye and Clayton, 2002). The first three characteristics are dealt within the 
internal validation of the model, whereas the last two ones are resolved by the 
external validation of the model. 
 
Figure 1.1 – Construction and utilization of a QSAR model in the typical drug 
development program. Existing data is divided into training and test groups in order to 
build and validate the model prior to utilization using molecular descriptors as model 
inputs. If the model shows sufficient predictive abilities, new potential drugs are tested 
within the model and results are used either to lead selection or to propose new molecules 
for synthesis (adapted from Todeschini and Consonni, 2000). 
 
Molecular descriptors (MD) play a fundamental role in QSAR, since they are 
the drug inputs for the model itself. These are mathematical representations of a 
molecule obtained by a well-specified algorithm applied to a defined molecular 
representation. This molecular representation is the way a molecule is 
symbolically represented and influences the dimensionality of the MD (Figure 1.2). 
For example, molecular weight can be calculated by the chemical formula of the 
compound and is independent of the molecular structure. These types of MD are 
called 0D-descriptors (zero dimension). 1D-descriptors (one dimension) are based 
on a list of structural fragments of a molecule, and thus not requiring a complete 
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knowledge of the molecule structure. 2D-descriptors describe how the atoms in 
the molecule are connected, considering the presence and nature of the chemical 
bonds, and are calculated based on the linear drawing of the molecule. 
3D-descriptors encode information not only on the nature and connectivity of the 
atoms but also on the overall spatial configuration of the molecule. Finally, 
4D-descriptors also encode molecular properties arising from electron distribution, 
namely the interaction of the molecule with probes characterizing the space 
surrounding them (Todeschini and Consonni, 2000). MD may also be classified by 
their physico-chemical meaning, and are frequently grouped into electronic, steric, 
lipophilicity, hydrogen-bonding, shape, charge descriptors, to name a few. 
 
 
Figure 1.2 – Relationship between the structural representation of the molecule and the 
type of molecular descriptor calculation. 
 
These MD are then related to the ADME property by using a multivariate 
approach to the problem, building models with relevant MD and properly validated 
in order to test the predictive power for new potential drugs. Although various 
statistical tools may be utilized in QSAR, due to modeling and prediction 
capabilities, regression analysis is frequently used. Within the regression analysis 
various methodologies, either linear or non-linear, are available like ordinary least 
squares regression (OLS), principal component regression (PCR), partial least 
squares regression (PLS), nonlinear least squares regression, artificial neural 
networks (ANN), to name a few. Among these, PLS and ANN are frequently used 
in QSAR (Sutherland et al., 2004). 
PLS, like multiple linear regression, models the relationship between two 
matrices, X and Y. However, the PLS method extracts orthogonal linear 
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combinations of predictors, known as factors or latent variables, from the X data 
that explain variance in both the X variables and the Y variable. In practice, PLS 
starts by computing the factor score matrix T = X·W for an appropriate weight 
matrix W, which reflects the covariance structure between the X and Y variables. 
Then considers the linear regression model Y = T·Q + E, where Q is a matrix of 
regression coefficients for T, and E is an error term. Once the regressions 
coefficients are computed, this model is equivalent to a multiple linear regression 
model Y = X·B + E, where B = W·Q. Since PLS is based on latent variables that 
are linear combinations of the original X variables computed in a manner that there 
is no correlation between the factor scores used in the regression model, it can 
analyze data with strongly colinear, noisy and numerous X-variables, typically 
found in the QSAR problem (Wold et al., 2001).  
The ANN’s are a biologically inspired computational models formed from a 
number of single units, known as artificial neurons (perceptrons). These are 
connected (with coefficients) to the previous and following neurons forming a 
neural structure. Each neuron receives arriving signals, or inputs, each one 
multiplied by the connection weights and all summed prior to be included in a 
transfer function that produces the output for that neuron (Figure 1.3). In practice, 
a neuron is essentially an equation which balances inputs and outputs. In a fully 
connected, supervised network with the backpropagation learning rule, the ANN is 
trained to map a set of input data by iterative adjustment of the weights in order to 
reduce the error between the network output and the expected output (Nestorov et 
al., 1999). In a biological meaning, weights represent the memory of the system 
and adjustment of the weights is the learning process.  
Although a single neuron can perform some simple data relationships, the 
power of ANN comes from the possibility to connect a large number of neurons. In 
this case, the ANN represents a promising modeling technique especially for data 
sets having the kind of highly non-linear relationships frequently encountered in 
physiological processes (Agatonovic-Kustrin and Beresford, 2000).  
Both PLS and ANN are prone to overfitting. This is especially important 
when too many input parameters are considered or the number of training cases is 
low. In the case of PLS, overfitting is avoided by removing predictors (X) and 
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reducing the number of PLS factors included in the regression process (Wold et 
al., 2001). In the case of ANN, again reduction of predictors may result in a lower 
tendency to overfitting. However, it is generally assumed that the generalization 
error decreases in an early period of training, reaches a minimum and then 
increases as training goes on, while the training error monotonically decreases 
(Amari et al., 1997). Therefore, stopping the learning process of the ANN before 
“memorization” starts to occur is one of the most frequent methodologies used to 
avoid overfitting (Cataltepe et al., 1999).  
 
 
Figure 1.3 – Schematic representation of a neuron in a ANN model. Input information (Xi) 
is passed to the neuron with a particulate weight (Wi) that represents the relevance of the 
input for the final output. Activation function (sum of Xi.Wi) is introduced in a transfer 
function (sigmoid or other) that produces the output signal for that neuron. 
 
Both in PLS and ANN, the procedures to reduce overfitting requires the 
utilization of data outside the training data set, in order to characterize the 
generalization error. This is usually done by a leave-n-out approach, and this data 
may be used in an internal validation (cross-validation) of the model. However, 
although indirectly, this data is used in the training process and a convenient 
validation of any regression model requires the use of external data (not used nor 
in the training nor in the internal validation processes) in order to test its 
predictability and utility (Ekins, 2003). 
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In Silico Models 
 
Various in silico models already exist to predict drug absorption potential. 
One of the most known is the “Lipinski rule of 5” (Lipinski et al., 2001), built by the 
analysis of successful drugs, in which indications for poorly absorbed hits are 
based on the number of H-bond donors and acceptors, molecular weight and 
ClogP. After that initial effort, various models were proposed to quantitatively 
predict oral absorption. Models were developed based on the in vivo Human 
Intestinal Absorption (Abraham et al., 2002; Butina, 2004; Klopman et al., 2002; 
Norinder and Osterberg, 2001; Zhao et al., 2001), in vivo absorption rate constants 
(Linnankoski et al., 2006) and in vivo jejunal effective permeability (Winiwarter et 
al., 2003; Winiwarter et al., 1998). These models, are based on commercially 
available drugs with optimized properties, and thus were built in a limited 
parametric space. Additionally, their confirmation can only be made in the later 
stages of the drug development phase. To overcome this limitation, models based 
on in vitro data, like in vitro apparent permeability in artificial membranes (Fujikawa 
et al., 2005; Fujikawa et al., 2007; Nakao et al., 2009; Verma et al., 2007) and in 
vitro apparent permeability in CACO-2 cells (Castillo-Garit et al., 2008; Degim, 
2005; Di Fenza et al., 2007; Fujiwara et al., 2002; Hou et al., 2004; Nordqvist et 
al., 2004; Ponce et al., 2004; Santos-Filho and Hopfinger, 2008; Yamashita et al., 
2002) were also developed. However again, the low number of drugs used in 
these models presents limitations both in the capacity to deduce relationships 
between the structure and activity and in the ability to properly validate the models. 
Chapter 2 of this work presents a QSAR model to predict the in vitro apparent 
permeability in CACO-2 cells based on a large number of data, in order to try to 
resolve these questions. 
Considering the important contribution of the first-pass effect to the absolute 
bioavailability of drugs, some in silico methods to estimate the CLH have also 
already been published. Quantitative models were developed based on in vivo 
human clearance data (Li et al., 2008; Turner et al., 2004). These, however, used 
a limited number of drugs and their predictive utility is questionable. Some 
additional models, with either qualitative (Chang et al., 2008; Lee et al., 2007) or 
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quantitative (Ekins, 2003; Ekins and Obach, 2000) purposes, were built based on 
a large number of in vitro microsome CLint data. These proved to have interesting 
prediction abilities, specially when predicting the drug metabolic stability, but the 
extrapolation of the microsome in vitro CLint to the human in vivo CLH presents a 
poor performance (Fagerholm, 2007), specially for drugs with predominant phase 
II metabolic routes (Stringer et al., 2008). Chapter 3 and Chapter 4 describe two 
modelling approaches to predict both Rb and in vitro hepatocytes CLint values, and 
explore the ability to predict the in vivo human CLH, based on this data. 
 
Physiologically – based pharmacokinetic models 
 
 Normally, the in silico and the in vitro methods are used at an early time of 
the drug development phase. Information from these sources is usually used as a 
yes or no input for further development. However, the use of integrating models, 
namely physiologically – based pharmacokinetic (PBPK) models, is increasing as 
simulating tools in the very early phase of drug candidate selection (Rowland et 
al., 2004). PBPK models take in vitro and in silico data as inputs and are used to 
predict concentration versus time profiles before any in vivo experiment is 
performed. If sufficiently reliable, such simulations could be an additional tool to 
prioritize compounds for the more costly in vivo testing (Parrott et al., 2005). More 
importantly, since these models integrate all the available predictive data on a 
compound, if comparison of simulations to in vivo data shows a large discrepancy, 
their mechanistic interpretation may indicate the need for further experiments to 
enlighten additional ADME processes.  
 PBPK models are defined as mechanistic models as opposed to the 
empirical approach models. In the latter case, all information regarding the model 
is derived from the available concentration versus time data and the choice of the 
pharmacokinetic model is based on statistical grounds. This may only be made 
once the drug reaches the clinical phase of the development program. On the 
contrary, when using a PBPK approach, the mathematical model precedes the 
data adjustment. Additionally, the model itself is built based on the anatomic 
structure of the organism and the existing mass transfer scheme between the 
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organs (Nestorov, 2007). In this way, in whole body PBPK models, most of the 
organs are represented by individual compartments, interconnected by the closed 
blood circulation (Figure 1.4).  
 
Figure 1.4 – Schematic representation of a whole-body PBPK model. Organs are 
represented by compartments typically with “well-stirred” assumptions and defined by 
physiologic volumes.  Rate of drug arriving to the organ is defined both by the drug 
concentration in blood and the specific blood flow for each individual organ. Elimination 
organs may be defined by either linear or saturable kinetics (Adapted from Nestorov, 
2007). 
 
Model equations are usually based on the “well-stirred” assumption 
assuming one or multiple compartments for each organ. The number of 
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considered organs is variable and dependent of the simulation goal. Typically a 
number of “core” tissues are included in the majority of the PBPK models and 
include the blood circulation, sites of major elimination, sites of drug action or 
toxicity, sites of administration and tissues where peculiar kinetics can be 
expected (Nestorov, 2003). The remaining of the body may be represented with 
varying degree of detail, resulting in more or less complicated models.  
In order to simulate the drug pharmacokinetic behavior two types of 
parameters are used, namely: (1) physiologic parameters defining the anatomic 
and physiologic part of the model and include the tissues blood flows and 
volumes; and (2) drug-dependent parameters, defining the process that the 
compound is undergoing in each individual organ and include permeabilities, 
tissue:blood partition coefficients, blood binding, clearances, to name a few 
(Nestorov, 2003; 2007; Rowland et al., 2004).  
This makes PBPK models particularly interesting in the early part of the 
drug development program, since the drug parameters may be obtained by in 
silico or in vitro approaches (Theil et al., 2003) and interspecies extrapolations 
may be done by simply changing the physiologic parameters from one species to 
another (De Buck et al., 2007).  
 Various mechanistic models are also available in order to predict drug 
absorption. As in whole-body PBPK models, a large span of structure complexity 
is possible, and a model classification based upon the dependence on spatial and 
temporal variables was proposed (Yu et al., 1996). It considers three categories, 
namely, quasi-equilibrium models, steady-state models and dynamic models. The 
latter, which include dispersion models (Ni et al., 1980) and compartmental models 
(Agoram et al., 2001; Grass, 1997; Huang et al., 2009; Yu and Amidon, 1999; Yu 
et al., 1996), have the advantage of being able to predict both the rate and extent 
of oral drug absorption. This is of particular interest since it allows the link of the 
absorption process to distribution, metabolization and elimination in a whole-body 
pharmacokinetic model. Chapter 5 presents the evaluation of a compartmental 
absorption model in predicting the oral bioavailability when using in vitro and/or in 
silico drug parameters. 
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Aims of the work 
 
The overall aim of this work was to develop and evaluate computational 
models for the in silico prediction of human absolute bioavailability. This was done 
by modelling the drug ability to permeate the GIT wall, by modelling the metabolic 
stability in the liver and the integration of these models in a generic physiologically 
based model of the GIT. In the following chapters the specific aims are present: 
1 – Building of a QSAR model to predict the Papp values in CACO-2 cells in 
a structurally diverse dataset (Chapter 2). 
2 – Building of a QSAR model for a vast series of drugs with blood to 
plasma concentration ratios (Chapter 3). 
3 – Building of a QSAR model for CLint values determined in human 
hepatocytes suspensions in a structurally diverse dataset (Chapter 4). 
4 – To investigate the ability of CLint data from both in vitro and in silico 
sources, as well as the effect of blood binding, in predicting human CLH using a 
PBPK model of the liver (Chapter 4) 
5 – To investigate the ability of a PBPK model of absorption to predict 
human absolute bioavailability using in vitro data on permeability and metabolism 
(Chapter 5). 
6 – To investigate the ability of a PBPK model of absorption to predict 
human absolute bioavailability using combinations of in vitro and in silico data, and 
pure in silico data (Chapter 5). 
 
Chapter 1. Introduction and work goals 
Paulo J. P. A. Paixão, 2010 17 
 
References 
 
Abraham, M.H., Ibrahim, A., Zissimos, A.M., Zhao, Y.H., Comer, J., Reynolds, D.P., 2002. 
Application of hydrogen bonding calculations in property based drug design. Drug Discov 
Today 7, 1056-1063. 
Agatonovic-Kustrin, S., Beresford, R., 2000. Basic concepts of artificial neural network 
(ANN) modeling and its application in pharmaceutical research. J Pharm Biomed Anal 22, 
717-727. 
Agoram, B., Woltosz, W.S., Bolger, M.B., 2001. Predicting the impact of physiological and 
biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 Suppl 1, S41-
67. 
Amari, S., Murata, N., Muller, K.R., Finke, M., Yang, H.H., 1997. Asymptotic statistical 
theory of overtraining and cross-validation. IEEE Trans Neural Netw 8, 985-996. 
Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a 
biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and 
in vivo bioavailability. Pharm Res 12, 413-420. 
Artursson, P., Karlsson, J., 1991. Correlation between oral drug absorption in humans and 
apparent drug permeability coefficients in human intestinal epithelial (CACO-2) cells. 
Biochem Biophys Res Commun 175, 880-885. 
Artursson, P., Palm, K., Luthman, K., 2001. CACO-2 monolayers in experimental and 
theoretical predictions of drug transport. Adv Drug Deliv Rev 46, 27-43. 
Avdeef, A., Nielsen, P.E., Tsinman, O., 2004. PAMPA--a drug absorption in vitro model 
11. Matching the in vivo unstirred water layer thickness by individual-well stirring in 
microtitre plates. Eur J Pharm Sci 22, 365-374. 
Ayrton, A., Morgan, P., 2001. Role of transport proteins in drug absorption, distribution 
and excretion. Xenobiotica 31, 469-497. 
Chapter 1. Introduction and work goals 
18 Paulo J. P. A. Paixão, 2010 
 
Benet, L.Z., Cummins, C.L., Wu, C.Y., 2004. Unmasking the dynamic interplay between 
efflux transporters and metabolic enzymes. Int J Pharm 277, 3-9. 
Box, K.J., Volgyi, G., Baka, E., Stuart, M., Takacs-Novak, K., Comer, J.E., 2006. 
Equilibrium versus kinetic measurements of aqueous solubility, and the ability of 
compounds to supersaturate in solution--a validation study. J Pharm Sci 95, 1298-1307. 
Brandon, E.F.A., Raap, C.D., Meijerman, I., Beijnen, J.H., Schellens, J.H.M., 2003. An 
update on in vitro test methods in human hepatic drug biotransformation research: pros 
and cons. Toxicology and Applied Pharmacology 189, 233-246. 
Butina, D., 2004. Performance of Kier-hall E-state descriptors in quantitative structure 
activity relationship (QSAR) studies of multifunctional molecules. Molecules 9, 1004-1009. 
Butina, D., Segall, M.D., Frankcombe, K., 2002. Predicting ADME properties in silico: 
methods and models. Drug Discov Today 7, S83-88. 
Castillo-Garit, J.A., Marrero-Ponce, Y., Torrens, F., Garcia-Domenech, R., 2008. 
Estimation of ADME properties in drug discovery: predicting CACO-2 cell permeability 
using atom-based stochastic and non-stochastic linear indices. J Pharm Sci 97, 1946-
1976. 
Cataltepe, Z., Abu-Mostafa, Y.S., Magdon-Ismail, M., 1999. No free lunch for early 
stopping. Neural Computation 11, 995-1009. 
Chang, C., Duignan, D.B., Johnson, K.D., Lee, P.H., Cowan, G.S., Gifford, E.M., 
Stankovic, C.J., Lepsy, C.S., Stoner, C.L., 2008. The development and validation of a 
computational model to predict rat liver microsomal clearance. J Pharm Sci. 
De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E., Gilissen, R.A., 2007. 
Prediction of human pharmacokinetics using physiologically based modeling: a 
retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35, 1766-1780. 
Dearden, J., Worth, A., 2007. In Silico Prediction of Physicochemical Properties. JRC 
Scientific and Technical Reports. European Commission, Luxembourg. 
Chapter 1. Introduction and work goals 
Paulo J. P. A. Paixão, 2010 19 
 
Dearden, J.C., 2006. In silico prediction of aqueous solubility. Expert Opinion on Drug 
Discovery 1, 31-52. 
Degim, Z., 2005. Prediction of permeability coefficients of compounds through CACO-2 
cell monolayer using artificial neural network analysis. Drug Dev Ind Pharm 31, 935-942. 
Di Fenza, A., Alagona, G., Ghio, C., Leonardi, R., Giolitti, A., Madami, A., 2007. CACO-2 
cell permeability modelling: a neural network coupled genetic algorithm approach. J 
Comput Aided Mol Des 21, 207-221. 
Di, L., Kerns, E.H., 2008. Solution stability--plasma, gastrointestinal, bioassay. Curr Drug 
Metab 9, 860-868. 
Ekins, S., 2003. In silico approaches to predicting drug metabolism, toxicology and 
beyond. Biochem Soc Trans 31, 611-614. 
Ekins, S., Obach, R.S., 2000. Three-dimensional quantitative structure activity relationship 
computational approaches for prediction of human in vitro intrinsic clearance. J Pharmacol 
Exp Ther 295, 463-473. 
Fagerholm, U., 2007. Prediction of human pharmacokinetics--evaluation of methods for 
prediction of hepatic metabolic clearance. J Pharm Pharmacol 59, 803-828. 
Fujikawa, M., Ano, R., Nakao, K., Shimizu, R., Akamatsu, M., 2005. Relationships 
between structure and high-throughput screening permeability of diverse drugs with 
artificial membranes: application to prediction of CACO-2 cell permeability. Bioorg Med 
Chem 13, 4721-4732. 
Fujikawa, M., Nakao, K., Shimizu, R., Akamatsu, M., 2007. QSAR study on permeability of 
hydrophobic compounds with artificial membranes. Bioorg Med Chem 15, 3756-3767. 
Fujiwara, S., Yamashita, F., Hashida, M., 2002. Prediction of CACO-2 cell permeability 
using a combination of MO-calculation and neural network. Int J Pharm 237, 95-105. 
Gomez-Lechon, M.J., Donato, M.T., Castell, J.V., Jover, R., 2003. Human hepatocytes as 
a tool for studying toxicity and drug metabolism. Current Drug Metabolism 4, 292-312. 
Chapter 1. Introduction and work goals 
20 Paulo J. P. A. Paixão, 2010 
 
Grass, G.M., 1997. Simulation models to predict oral drug absorption from in vitro data. 
Advanced Drug Delivery Reviews 23, 199-219. 
Griffin, S.J., Houston, J.B., 2004. Comparison of fresh and cryopreserved rat hepatocyte 
suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 32, 552-
558. 
Hou, T.J., Zhang, W., Xia, K., Qiao, X.B., Xu, X.J., 2004. ADME evaluation in drug 
discovery. 5. Correlation of CACO-2 permeation with simple molecular properties. J Chem 
Inf Comput Sci 44, 1585-1600. 
Huang, W., Lee, S.L., Yu, L.X., 2009. Mechanistic approaches to predicting oral drug 
absorption. Aaps J 11, 217-224. 
Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove, J.R., 
1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability 
screening. J Pharm Sci 88, 28-33. 
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, 
C.E., Tyson, C.A., Sugiyama, Y., 1997. Prediction of in vivo drug metabolism in the 
human liver from in vitro metabolism data. Pharmacol Ther 73, 147-171. 
Johnson, S.R., Zheng, W., 2006. Recent progress in the computational prediction of 
aqueous solubility and absorption. Aaps J 8, E27-40. 
Jouin, D., Blanchard, N., Alexandre, E., Delobel, F., David-Pierson, P., Lave, T., Jaeck, 
D., Richert, L., Coassolo, P., 2006. Cryopreserved human hepatocytes in suspension are 
a convenient high throughput tool for the prediction of metabolic clearance. European 
Journal of Pharmaceutics and Biopharmaceutics 63, 347-355. 
Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernas, H., Hussain, 
A.S., Junginger, H.E., Stavchansky, S.A., Midha, K.K., Shah, V.P., Amidon, G.L., 2004. 
Molecular properties of WHO essential drugs and provisional biopharmaceutical 
classification. Mol Pharm 1, 85-96. 
Chapter 1. Introduction and work goals 
Paulo J. P. A. Paixão, 2010 21 
 
Kim, J.S., Mitchell, S., Kijek, P., Tsume, Y., Hilfinger, J., Amidon, G.L., 2006. The 
suitability of an in situ perfusion model for permeability determinations: utility for BCS 
class I biowaiver requests. Mol Pharm 3, 686-694. 
Klopman, G., Stefan, L.R., Saiakhov, R.D., 2002. ADME evaluation. 2. A computer model 
for the prediction of intestinal absorption in humans. Eur J Pharm Sci 17, 253-263. 
Lau, Y.Y., Sapidou, E., Cui, X., White, R.E., Cheng, K.C., 2002. Development of a novel in 
vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-
cultured hepatocytes. Drug Metab Dispos 30, 1446-1454. 
Lee, P.H., Cucurull-Sanchez, L., Lu, J., Du, Y.J., 2007. Development of in silico models 
for human liver microsomal stability. J Comput Aided Mol Des 21, 665-673. 
Lennernas, H., 1998. Human intestinal permeability. Journal of Pharmaceutical Sciences 
87, 403-410. 
Lennernas, H., Nylander, S., Ungell, A.L., 1997. Jejunal permeability: a comparison 
between the ussing chamber technique and the single-pass perfusion in humans. Pharm 
Res 14, 667-671. 
Li, H., Sun, J., Sui, X., Liu, J., Yan, Z., Liu, X., Sun, Y., He, Z., 2008. First-principle, 
structure-based prediction of hepatic metabolic clearance values in human. Eur J Med 
Chem. 
Linnankoski, J., Makela, J.M., Ranta, V.P., Urtti, A., Yliperttula, M., 2006. Computational 
prediction of oral drug absorption based on absorption rate constants in humans. Journal 
of Medicinal Chemistry 49, 3674-3681. 
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 2001. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv Drug Deliv Rev 46, 3-26. 
Nakao, K., Fujikawa, M., Shimizu, R., Akamatsu, M., 2009. QSAR application for the 
prediction of compound permeability with in silico descriptors in practical use. J Comput 
Aided Mol Des 23, 309-319. 
Chapter 1. Introduction and work goals 
22 Paulo J. P. A. Paixão, 2010 
 
Nestorov, I., 2003. Whole body pharmacokinetic models. Clin Pharmacokinet 42, 883-908. 
Nestorov, I., 2007. Whole-body physiologically based pharmacokinetic models. Expert 
Opin Drug Metab Toxicol 3, 235-249. 
Nestorov, I.S., Hadjitodorov, S.T., Petrov, I., Rowland, M., 1999. Empirical versus 
mechanistic modelling: comparison of an artificial neural network to a mechanistically 
based model for quantitative structure pharmacokinetic relationships of a homologous 
series of barbiturates. AAPS PharmSci 1, E17. 
Ni, P.F., Ho, N.F.H., Fox, J.L., Leuenberger, H., Higuchi, W.I., 1980. Theoretical model 
studies of intestinal drug absorption V. Non-steady-state fluid flow and absorption. Int J 
Pharmaceut 5, 33-47. 
Nordqvist, A., Nilsson, J., Lindmark, T., Eriksson, A., Garberg, P., Kihlen, M., 2004. A 
general model for prediction of CACO-2 cell permeability. Qsar & Combinatorial Science 
23, 303-310. 
Norinder, U., Osterberg, T., 2001. Theoretical calculation and prediction of drug transport 
processes using simple parameters and partial least squares projections to latent 
structures (PLS) statistics. The use of electrotopological state indices. J Pharm Sci 90, 
1076-1085. 
Obach, R.S., 1999. Prediction of human clearance of twenty-nine drugs from hepatic 
microsomal intrinsic clearance data: An examination of in vitro half-life approach and 
nonspecific binding to microsomes. Drug Metab Dispos 27, 1350-1359. 
Parrott, N., Paquereau, N., Coassolo, P., Lave, T., 2005. An evaluation of the utility of 
physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 
94, 2327-2343. 
Ponce, Y.M., Perez, M.A.C., Zaldivar, V.R., Diaz, H.G., Torrens, F., 2004. A new 
topological descriptors based model for predicting intestinal epithelial transport of drugs in 
CACO-2 cell culture. Journal of Pharmacy and Pharmaceutical Sciences 7, 186-199. 
Chapter 1. Introduction and work goals 
Paulo J. P. A. Paixão, 2010 23 
 
Ranaldi, G., Islam, K., Sambuy, Y., 1992. Epithelial cells in culture as a model for the 
intestinal transport of antimicrobial agents. Antimicrob Agents Chemother 36, 1374-1381. 
Ritschel, W.A., 2000. Handbook of basic pharmacokinetics, 5th edition ed. Drug 
Intelligence Publications Inc., Hamilton. 
Rowland, M., Balant, L., Peck, C., 2004. Physiologically based pharmacokinetics in drug 
development and regulatory science: a workshop report (Georgetown University, 
Washington, DC, May 29-30, 2002). AAPS PharmSci 6, E6. 
Rubas, W., Jezyk, N., Grass, G.M., 1993. Comparison of the permeability characteristics 
of a human colonic epithelial (CACO-2) cell line to colon of rabbit, monkey, and dog 
intestine and human drug absorption. Pharm Res 10, 113-118. 
Sanghvi, T., Jain, N., Yang, G., Yalkowsky, S.H., 2003. Estimation of aqueous solubility 
by the General Solubility Equation (GSE) the easy way. Qsar & Combinatorial Science 22, 
258-262. 
Santos-Filho, O.A., Hopfinger, A.J., 2008. Combined 4D-fingerprint and clustering based 
membrane-interaction QSAR analyses for constructing consensus CACO-2 cell 
permeation virtual screens. J Pharm Sci 97, 566-583. 
Saxena, V., Panicucci, R., Joshi, Y., Garad, S., 2009. Developability assessment in 
pharmaceutical industry: An integrated group approach for selecting developable 
candidates. J Pharm Sci 98, 1962-1979. 
Smye, S.W., Clayton, R.H., 2002. Mathematical modelling for the new millenium: medicine 
by numbers. Med Eng Phys 24, 565-574. 
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., Basit, A.W., 2008. 
The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 
363, 1-25. 
Stringer, R., Nicklin, P.L., Houston, J.B., 2008. Reliability of human cryopreserved 
hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. 
Xenobiotica 38, 1313-1329. 
Chapter 1. Introduction and work goals 
24 Paulo J. P. A. Paixão, 2010 
 
Sun, D., Lennernas, H., Welage, L.S., Barnett, J.L., Landowski, C.P., Foster, D., Fleisher, 
D., Lee, K.D., Amidon, G.L., 2002. Comparison of human duodenum and CACO-2 gene 
expression profiles for 12,000 gene sequences tags and correlation with permeability of 
26 drugs. Pharm Res 19, 1400-1416. 
Sutherland, J.J., O'Brien, L.A., Weaver, D.F., 2004. A comparison of methods for 
modeling quantitative structure-activity relationships. J Med Chem 47, 5541-5554. 
Takano, R., Sugano, K., Higashida, A., Hayashi, Y., Machida, M., Aso, Y., Yamashita, S., 
2006. Oral absorption of poorly water-soluble drugs: computer simulation of fraction 
absorbed in humans from a miniscale dissolution test. Pharm Res 23, 1144-1156. 
Tetko, I.V., Tanchuk, V.Y., Kasheva, T.N., Villa, A.E., 2001. Estimation of aqueous 
solubility of chemical compounds using E-state indices. J Chem Inf Comput Sci 41, 1488-
1493. 
Theil, F.P., Guentert, T.W., Haddad, S., Poulin, P., 2003. Utility of physiologically based 
pharmacokinetic models to drug development and rational drug discovery candidate 
selection. Toxicol Lett 138, 29-49. 
Todeschini, R., Consonni, V., 2000. Handbook of molecular descriptors. Wiley-VCH, 
Weinheim. 
Turner, J.V., Maddalena, D.J., Cutler, D.J., 2004. Pharmacokinetic parameter prediction 
from drug structure using artificial neural networks. Int J Pharm 270, 209-219. 
van de Waterbeemd, H., 2002. High-throughput and in silico techniques in drug 
metabolism and pharmacokinetics. Curr Opin Drug Discov Devel 5, 33-43. 
Venkatesh, S., Lipper, R.A., 2000. Role of the development scientist in compound lead 
selection and optimization. J Pharm Sci 89, 145-154. 
Verma, R.P., Hansch, C., Selassie, C.D., 2007. Comparative QSAR studies on 
PAMPA/modified PAMPA for high throughput profiling of drug absorption potential with 
respect to CACO-2 cells and human intestinal absorption. J Comput Aided Mol Des 21, 3-
22. 
Chapter 1. Introduction and work goals 
Paulo J. P. A. Paixão, 2010 25 
 
Vogel, H.G., 2006. Drug Discovery and Evaluation - Safety and Pharmacokinetic Assays. 
Springer - Verlag, Berlin. 
Votano, J.R., Parham, M., Hall, L.H., Kier, L.B., Hall, L.M., 2004. Prediction of aqueous 
solubility based on large datasets using several QSPR models utilizing topological 
structure representation. Chemistry & Biodiversity 1, 1829-1841. 
Winiwarter, S., Ax, F., Lennernas, H., Hallberg, A., Pettersson, C., Karlen, A., 2003. 
Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J 
Mol Graph Model 21, 273-287. 
Winiwarter, S., Bonham, N.M., Ax, F., Hallberg, A., Lennernas, H., Karlen, A., 1998. 
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and 
theoretically derived parameters. A multivariate data analysis approach. J Med Chem 41, 
4939-4949. 
Wold, S., Sjostrom, M., Eriksson, L., 2001. PLS-regression: a basic tool of chemometrics. 
Chemometrics and Intelligent Laboratory Systems 58, 109-130. 
Wu, C.Y., Benet, L.Z., 2005. Predicting drug disposition via application of BCS: 
transport/absorption/ elimination interplay and development of a biopharmaceutics drug 
disposition classification system. Pharm Res 22, 11-23. 
Yamashita, F., Fujiwara, S., Hashida, M., 2002. The "latent membrane permeability" 
concept: QSPR analysis of inter/intralaboratory variable CACO-2 permeability. J Chem Inf 
Comput Sci 42, 408-413. 
Yamashita, F., Hashida, M., 2004. In silico approaches for predicting ADME properties of 
drugs. Drug Metab Pharmacokinet 19, 327-338. 
Yee, S., 1997. In vitro permeability across CACO-2 cells (colonic) can predict in vivo 
(small intestinal) absorption in man--fact or myth. Pharm Res 14, 763-766. 
Yu, L.X., Amidon, G.L., 1999. A compartmental absorption and transit model for 
estimating oral drug absorption. Int J Pharm 186, 119-125. 
Chapter 1. Introduction and work goals 
26 Paulo J. P. A. Paixão, 2010 
 
Yu, L.X., Lipka, E., Crison, J.R., Amidon, G.L., 1996. Transport approaches to the 
biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. 
Adv Drug Deliv Rev 19, 359-376. 
Zhao, Y.H., Le, J., Abraham, M.H., Hersey, A., Eddershaw, P.J., Luscombe, C.N., Butina, 
D., Beck, G., Sherborne, B., Cooper, I., Platts, J.A., 2001. Evaluation of human intestinal 
absorption data and subsequent derivation of a quantitative structure-activity relationship 
(QSAR) with the Abraham descriptors. J Pharm Sci 90, 749-784. 
 
 
 27 
Chapter 2  
 
 
 
 
 
 
Prediction of the In Vitro Permeability 
Determined in CACO-2 Cells by Using 
Artificial Neural Networks 
 
 
 
 
 
Introduction 
 
Oral administration of drugs, due to its ease and patient compliance, is the 
preferred route and a major goal in the development of new drug entities. It is also 
traditionally one of the reasons for either discontinuation or prolongation of the 
development time of compounds. These problems lead to a new paradigm, a 
multivariate approach,  in compound lead selection and optimization (Venkatesh 
and Lipper, 2000). In this context, and as a consequence of combinatorial 
chemistry, initial screening of hits in a number of thousands is done typically by 
using in silico approaches. In vitro tests are responsible to reduce the number of 
compounds from hundreds to dozens and in vivo animal models to 1 – 5 finally 
potential drugs that are included in clinical trials. 
Various in silico models already exist to predict drug absorption potential. 
One of the most known is the “Lipinski rule of 5” (Lipinski et al., 2001), based on 
the analysis of successful drugs, in which indications for poor absorbed hits are 
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based on the number of H-bond donors and acceptors, molecular weight and 
ClogP. After that initial effort, various models were proposed to quantitatively 
predict oral absorption. These were based in the search to correlate some 
molecular descriptors to measures of bioavailability by means of multivariate 
regression tools. Models were developed based on the in vivo Human Intestinal 
Absorption (Abraham et al., 2002; Butina, 2004; Klopman et al., 2002; Norinder 
and Osterberg, 2001; Zhao et al., 2001), in vivo absorption rate constants 
(Linnankoski et al., 2006), in vivo jejunal effective permeability (Winiwarter et al., 
2003; Winiwarter et al., 1998), in vitro apparent permeability in artificial 
membranes (Fujikawa et al., 2005; Fujikawa et al., 2007; Nakao et al., 2009; 
Verma et al., 2007) and in vitro apparent permeability (Papp) in CACO-2 cells 
(Castillo-Garit et al., 2008; Degim, 2005; Di Fenza et al., 2007; Fujiwara et al., 
2002; Hou et al., 2004; Nordqvist et al., 2004; Ponce et al., 2004; Santos-Filho and 
Hopfinger, 2008; Yamashita et al., 2002a).  
In vivo based data, although obviously the target for the lead drug, presents 
some drawbacks. In vivo global bioavailability results from different physical-
chemical and biological processes that are difficult to isolate. To be absorbed, a 
drug needs first to be in its soluble form. Passive diffusion may be the principal 
driving force for drug absorption, but either active transport or efflux mechanisms 
may condition the final bioavailability. Instability in the gastro-intestinal fluids and 
metabolization may also reduce the amount of drug that effectively reaches the 
systemic circulation. For these reasons, calculation of the absorption rate 
constants, which uses pharmacokinetic data after intravenous and oral 
administration, may underestimate the absorption. Collection of data on Human 
Intestinal Absorption is also experimentally demanding. It requires the evaluation 
of the fraction of dose, either as parent or metabolites, eliminated by the faeces 
and urine which may easily result in underestimation of the actual fraction of dose 
absorbed. Finally, data on jejunal effective permeability, which isolates the 
absorption process but is experimentally complex, is limited to only a small 
number of drugs. Another drawback in these three approaches is that prediction 
confirmation is only possible when the drug is administered to humans in the end 
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stages of drug discovery, leaving no room for “fine-tuning” during the development 
phase.   
In vitro tests, on the contrary, are routinely performed by pharmaceutical 
companies in an early stage of drug development. For this reason, a large number 
of Papp values for different molecules are being produced and are/will be available 
to build databases with a large span of values from high to low bioavailabilities. 
Parallel artificial membrane permeation assays (PAMPA) are a very promising tool 
to predict absorption, but there are various experimental variables to be 
considered and in practice it appears to produce the same outcome that a simple 
LogD7.4 assay in predicting high and low absorption (Galinis-Luciani et al., 2007). 
CACO-2 cells, on the contrary, are a widely preformed in vitro test with interesting 
properties when extrapolating results to bioavailability.  It is a cell system, 
characterized by easy handling and at the same time resemble morphological and 
biochemical characteristics of the intestinal cells (Vogel, 2006), that shows a 
sigmoid relationship between the fraction absorbed in humans and the Papp across 
the cells (Artursson and Karlsson, 1991). 
A number of statistical multivariate methods for developing in silico models 
are currently used. Artificial neural networks (ANN), however, have shown superior 
performance to the linear multivariate class of methods in various QSAR models 
(Fujiwara et al., 2002; Paixao et al., 2008; Sutherland et al., 2004; Votano et al., 
2004). To the best of our knowledge, only three studies were previously reported 
to predict in vitro apparent permeability (Papp) in CACO-2 cells using ANN and 
molecular descriptors. Of these, two studies (Degim, 2005; Fujiwara et al., 2002) 
were based in a small number of drugs, did not made any particulate approach to 
avoid overfitting, nor made a convenient search of optimal molecular descriptors to 
predict the in vitro CACO-2 permeability. The other study (Di Fenza et al., 2007) 
resolved some of these problems, but was based on proprietary analogue drugs. 
Since the proposed model was built with the use of molecules contained in a very 
similar chemical space, it was proved to be less competent in predicting LogPapp 
values in a more chemical diverse external data set.  
With the purpose to overcome these limitations, we present a back-
propagation ANN model using early stop to predict in vitro CACO-2 LogPapp based 
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in 296 structurally different drugs and drug like molecules collected in the 
literature. This large data set would provide a broad molecular space, ideal to 
enlarge the applicability of the proposed model. Various molecular descriptors, 
encoding different molecular characteristics were initially used. Reduction of the 
number of possible molecular descriptors was made by a simple pruning 
procedure, allowing to point out some possible factors influencing the drugs 
absorption process. Use of early stop during the whole modelling procedure also 
ensured that optimal prediction capabilities were maintained in the final model. 
This model, and proposed methodology, may be a valuable tool in early drug 
development. 
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Materials and Methods 
 
Data collection 
 
In vitro logPapp values (Table 2.1) for 296 different drugs were obtained from 
published studies of drug absorption in CACO-2 cells. Examples of drugs 
absorbed by passive diffusion using either the paracellular or transcellular route, 
and cases of active transportation by different transporters were included. 
Examples of drugs suffering efflux mechanisms were also included. In all cases 
when non – linear relations between Papp and apical concentrations were 
described, Papp values considered were collected in the saturation zone. 
Experimental values were obtained in pH values ranging from 6.8 to 7.4, with low 
to median passage numbers (28 to 46) and typically at a cell age close to 21 days.  
  
Table 2.1 – In vitro LogPapp (cm/s) CACO-2 values collected in the 
literature. Drugs were randomly divided between a Train (TR), test (TE) and 
external validation (VA) group Mean values after normalization with 
common drugs with the work from (Yazdanian et al., 1998) are presented 
in the observed column. Predicted values and residuals between observed 
and predicted values, using the 12-6-3-3-1 network, are also presented. 
Data Set Drug Observed Predicted Residue 
Tr (2E)-N-I-E-D -3.59 -4.18 0.59 
Tr (2E)-N-M-E-D -4.02 -4.13 0.12 
Tr (2E,4E)-N-I-D -5.24 -4.18 -1.07 
Tr (2E,4E,8Z)-N-I-T -4.46 -4.11 -0.35 
Tr (2E,4Z)-N-I-D-D -3.32 -4.05 0.73 
Tr (2E,4Z)-N-m-D-D -3.92 -4.02 0.10 
Tr (2E,4Z,8Z)-N-I-T-Y -3.80 -4.00 0.20 
Tr (2E,4Z,8Z,10Z)-N-I-T -3.67 -4.06 0.40 
Tr (2E,7Z)-N-I-D-D -4.84 -4.18 -0.66 
Tr (2E,9Z)-N-I-D-D -4.96 -4.32 -0.64 
Tr (2E,9Z)-N-M-D-D -4.21 -4.29 0.08 
Tr 5 - Aminolevulinic acid -5.34 -5.36 0.02 
Tr Acetaminophen -4.44 -4.83 0.39 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Tr Alanine -5.63 -5.39 -0.24 
Tr alfa-Methyldopa -6.63 -6.42 -0.22 
Tr Alfentanil -4.26 -4.55 0.29 
Tr Amoxicillin -6.31 -6.25 -0.06 
Tr Ampicillin -5.70 -6.06 0.36 
Tr Antipyrine -4.47 -4.77 0.30 
Tr Artemisinin -4.52 -4.19 -0.33 
Tr Artesunate -5.40 -5.71 0.31 
Tr Atenolol -6.34 -5.80 -0.54 
Tr Azithromycin -6.37 -6.46 0.09 
Tr Benzoic acid -4.15 -3.72 -0.43 
Tr Betaxolol ester -4.58 -5.47 0.89 
Tr Bosentan -6.19 -6.21 0.02 
Tr Bremazocine -4.82 -4.78 -0.03 
Tr Bromocriptine -5.91 -5.72 -0.18 
Tr Budesonide -4.89 -4.79 -0.10 
Tr Camptothecin -4.11 -4.52 0.41 
Tr Carbamazepine -4.37 -4.70 0.32 
Tr Catechin -6.82 -5.98 -0.84 
Tr Ceftriaxone -6.65 -6.72 0.07 
Tr Cefuroxime -6.79 -6.96 0.17 
Tr Cephalexin -6.42 -6.33 -0.09 
Tr Cephradine -5.69 -6.39 0.70 
Tr Chlorpromazine -4.70 -4.38 -0.32 
Tr Cimetidine -5.90 -5.43 -0.46 
Tr Ciprofloxacin -5.90 -5.24 -0.66 
Tr Clozapine -4.51 -4.59 0.08 
Tr Coumarin -4.25 -4.14 -0.11 
Tr Cromolina -6.89 -6.88 0.00 
Tr Cymarin -5.70 -5.74 0.04 
Tr Desipramine -4.97 -5.25 0.28 
Tr Dexamethasone -4.91 -5.24 0.33 
Tr D-glucose -4.67 -5.82 1.15 
Tr Diazepam -4.45 -4.75 0.30 
Tr Diclofenac -4.75 -5.81 1.06 
Tr Diltiazem -4.53 -4.76 0.23 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Tr Dmp 581 -5.48 -5.70 0.22 
Tr Dmp 811 -7.82 -6.03 -1.79 
Tr Dmxaa-g -6.52 -6.23 -0.29 
Tr Dopamine -5.03 -5.15 0.12 
Tr Dup 167 -5.11 -5.53 0.42 
Tr Dup 532 -8.20 -6.74 -1.46 
Tr Dup 996 -4.62 -4.34 -0.28 
Tr Elarofiban -6.21 -6.08 -0.13 
Tr Enalapril -6.21 -6.60 0.39 
Tr Enalaprilat -6.59 -6.60 0.01 
Tr Ephedrine -4.97 -4.69 -0.28 
Tr Epicatechin -6.82 -6.15 -0.67 
Tr Epicatechin-3-gallate -6.84 -6.60 -0.24 
Tr Epinephrine -6.23 -5.51 -0.71 
Tr Erythritol -6.16 -6.15 0.00 
Tr Erythromycin -5.78 -6.59 0.80 
Tr Estradiol -4.69 -4.27 -0.42 
Tr Etoposide -5.81 -6.24 0.43 
Tr Exp3174 -6.74 -6.70 -0.05 
Tr Felodipine -4.64 -4.77 0.13 
Tr Formoterol -5.63 -5.80 0.17 
Tr Foscarnet -7.47 -6.72 -0.75 
Tr Furosemide -6.62 -6.78 0.16 
Tr Glycine -4.36 -5.32 0.95 
Tr Glycine-Valine acyclovir -5.28 -5.66 0.38 
Tr Gly-pro -5.12 -5.59 0.47 
Tr Glysar -5.62 -5.72 0.09 
Tr Griseofulvin -4.36 -4.51 0.15 
Tr Guanoxan -4.87 -5.60 0.73 
Tr H216/44 -6.88 -6.91 0.03 
Tr H244/45 -5.77 -5.54 -0.23 
Tr H95/71 -6.00 -5.58 -0.42 
Tr Harmaline -6.07 -6.18 0.11 
Tr Harmane -6.13 -6.43 0.29 
Tr Harmine -6.13 -6.15 0.02 
Tr Harmol -6.37 -5.80 -0.56 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Tr Hydralazine -5.17 -4.55 -0.63 
Tr Hydrochlorothiazide -6.06 -5.79 -0.27 
Tr Ibuprofen -4.58 -5.15 0.57 
Tr Imipramine -5.17 -5.21 0.04 
Tr Indomethacin -4.89 -4.41 -0.48 
Tr Inuline -6.25 -5.92 -0.33 
Tr Ketoconazole -4.93 -4.59 -0.33 
Tr Ketoprofen -4.48 -5.24 0.76 
Tr Labetalol -4.82 -6.12 1.30 
Tr Lactic acid -6.19 -5.18 -1.01 
Tr Lactulose -6.81 -6.70 -0.11 
Tr Lamotrigine -4.39 -4.82 0.43 
Tr Lef553 -7.76 -6.96 -0.80 
Tr Lisinopril -7.39 -7.11 -0.27 
Tr L-phenylalanine -5.00 -5.04 0.03 
Tr Ly122772 -3.87 -4.16 0.30 
Tr Ly341904 -4.33 -4.51 0.18 
Tr Ly341908 -4.14 -4.50 0.37 
Tr Ly353462 -4.17 -4.66 0.48 
Tr Ly354030 -4.06 -4.60 0.54 
Tr Ly354400 -4.46 -4.56 0.10 
Tr Ly357822 -4.21 -4.41 0.20 
Tr Ly362546 -4.19 -4.45 0.25 
Tr Ly366347 -4.14 -4.42 0.28 
Tr Ly366349 -4.48 -4.59 0.11 
Tr Ly366659 -4.20 -4.53 0.33 
Tr Ly366799 -4.54 -4.55 0.02 
Tr Ly366856 -4.33 -4.55 0.22 
Tr Ly368177 -5.15 -4.41 -0.74 
Tr Mannitol -6.48 -6.90 0.41 
Tr Metformin -6.20 -5.60 -0.60 
Tr Methanol -4.40 -4.55 0.14 
Tr Methotrexate -6.10 -6.65 0.56 
Tr Methylprednisolone -4.93 -4.61 -0.32 
Tr Methylscopolamine -6.23 -5.44 -0.79 
Tr Metoprolol -4.60 -5.35 0.75 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Tr Naloxone -4.67 -4.91 0.24 
Tr Naringenin -4.41 -5.34 0.92 
Tr Naringin -6.82 -6.22 -0.60 
Tr N-desmethylclozapine -4.68 -4.72 0.04 
Tr Netivudine -6.84 -6.18 -0.66 
Tr Nevirapine -4.52 -4.67 0.15 
Tr Nicotine -4.71 -4.61 -0.10 
Tr Nitrendipine -4.93 -4.90 -0.04 
Tr Nordazepan -4.20 -4.57 0.38 
Tr Norfloxacin -6.70 -5.24 -1.46 
Tr Octyl gallate -6.82 -5.90 -0.92 
Tr Olsalazine -7.80 -6.80 -1.00 
Tr Ondansetron -4.34 -5.00 0.66 
Tr Ouabain -7.23 -7.92 0.69 
Tr Oxacillin -5.58 -5.87 0.30 
Tr Oxprenolol -4.76 -5.20 0.44 
Tr Oxprenolol ester -4.57 -5.14 0.57 
Tr Peg 282 -5.84 -6.14 0.30 
Tr Peg 326 -6.35 -6.24 -0.11 
Tr Peg 370 -6.68 -6.35 -0.33 
Tr Peg900 -6.26 -6.38 0.12 
Tr Penicillin V -7.51 -6.23 -1.28 
Tr Pindolol -4.71 -5.47 0.76 
Tr Piroxicam -4.33 -5.36 1.03 
Tr Pnu200603 -6.47 -5.54 -0.93 
Tr Pravastatin -5.84 -6.63 0.79 
Tr Prazosin -5.26 -4.95 -0.31 
Tr Prednisolone -4.72 -4.71 -0.01 
Tr Progesterone -4.64 -4.19 -0.45 
Tr Propofol -4.77 -4.37 -0.40 
Tr Propranolol ester -4.54 -4.97 0.43 
Tr Propylthiouracil -4.46 -4.55 0.09 
Tr Proscillaridin -6.41 -5.83 -0.58 
Tr Quercetin -6.82 -6.35 -0.47 
Tr Quinidine -4.94 -4.44 -0.49 
Tr Rapamycin -4.96 -4.62 -0.34 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Tr Roxithromycin -6.91 -6.87 -0.05 
Tr Saquinavir -6.48 -6.36 -0.12 
Tr Sb209670 -5.23 -4.19 -1.04 
Tr Scopolamine -4.93 -5.03 0.10 
Tr Sdz-rad -4.63 -4.99 0.36 
Tr Serotonin -4.86 -5.17 0.30 
Tr Sulfadiazine -4.75 -5.50 0.74 
Tr Sulfamethoxazole -4.88 -5.78 0.90 
Tr Sulfanilamide -5.26 -5.23 -0.02 
Tr Sulpiride -6.65 -5.69 -0.96 
Tr Sumatriptan -5.80 -4.91 -0.89 
Tr Talinolol -6.11 -5.46 -0.65 
Tr Tapp -7.73 -6.51 -1.22 
Tr Tarpp -6.12 -7.34 1.22 
Tr Tartaric acid -6.65 -6.75 0.10 
Tr Taurocholic acid -4.75 -5.28 0.53 
Tr Telithromycin -6.65 -6.38 -0.27 
Tr Telmisartan -4.82 -5.05 0.23 
Tr Terbutaline -6.16 -5.38 -0.79 
Tr Tetracycline -5.70 -6.62 0.92 
Tr Timolol -4.92 -4.94 0.02 
Tr Tiotidine -5.88 -5.95 0.07 
Tr Topiramate -4.54 -3.94 -0.59 
Tr Tranexamic acid -6.28 -5.55 -0.72 
Tr Trimethoprim -4.50 -4.70 0.19 
Tr Urea -5.34 -5.71 0.37 
Tr Valacyclovir -5.20 -5.18 -0.01 
Tr Valproic acid -4.60 -4.61 0.01 
Tr Vinblastine -5.48 -5.64 0.16 
Tr Xm970 -5.30 -5.92 0.62 
Tr Zidovudine -5.06 -5.35 0.29 
Tr Ziprasidone -5.23 -5.08 -0.15 
Tr Zomepirac -5.61 -5.66 0.05 
Te (2e,4z)-n-i-d-d -3.57 -4.00 0.43 
Te Acyclovir -6.07 -5.51 -0.57 
Te Alprenolol -4.57 -5.01 0.44 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Te Alprenolol ester -4.52 -4.98 0.45 
Te Amiloride -6.46 -6.52 0.06 
Te Amisulpride -5.66 -5.62 -0.03 
Te Betaxolol -4.91 -5.38 0.46 
Te Caffeine -4.48 -4.52 0.04 
Te Caftaric acid -5.41 -7.60 2.19 
Te Cefazolin -6.23 -6.66 0.43 
Te Cefcapene -6.94 -6.89 -0.04 
Te Cefcapene pivoxil -5.11 -5.65 0.54 
Te Cephalexin acetylated -6.63 -6.28 -0.36 
Te Chlorothiazide -6.72 -5.37 -1.35 
Te Cichoric acid -5.13 -7.66 2.54 
Te Cinnamic acid -3.64 -3.80 0.16 
Te Corticosterone -4.50 -4.43 -0.07 
Te Creatinine -5.95 -4.75 -1.20 
Te Digoxin -5.58 -7.63 2.05 
Te Dmxaa -4.60 -5.06 0.46 
Te Echinacoside -6.65 -6.60 -0.05 
Te Famotidine -6.16 -6.68 0.52 
Te Fleroxacin -4.98 -5.17 0.19 
Te Fluconazole -4.82 -4.93 0.10 
Te Gabapentin -8.16 -5.90 -2.25 
Te Harmalol -6.37 -5.80 -0.56 
Te Isoxicam -5.61 -5.71 0.10 
Te Lidocaine -4.36 -4.53 0.17 
Te Ly153186 -4.36 -4.50 0.14 
Te Ly355081 -4.26 -4.41 0.15 
Te Ly357132 -4.20 -4.35 0.15 
Te Ly362683 -4.43 -4.55 0.12 
Te Ly366572 -4.24 -4.51 0.27 
Te Ly366853 -5.30 -4.72 -0.58 
Te Ly368766 -4.07 -4.29 0.23 
Te Metaprotenol -6.42 -5.45 -0.97 
Te Morphine -5.45 -4.74 -0.71 
Te Naproxen -4.66 -4.74 0.08 
Te Paclitaxel -7.30 -7.18 -0.12 
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Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Te Phenytoin -4.49 -5.15 0.66 
Te Pirenzepine -6.36 -4.94 -1.42 
Te Pivampicillin -4.49 -5.36 0.86 
Te Propranolol -4.63 -5.09 0.46 
Te Raffinose -7.62 -7.61 0.00 
Te Ranitidine -6.31 -5.58 -0.73 
Te Remikiren -6.34 -5.97 -0.38 
Te Sb217242 -4.46 -4.24 -0.21 
Te Sildenafil -4.51 -4.12 -0.39 
Te Sotalol -5.76 -5.35 -0.41 
Te Sucrose -5.77 -7.29 1.52 
Te Sulfasalazine -6.89 -6.91 0.03 
Te Tenidap -4.57 -4.20 -0.37 
Te Testosterone -4.43 -4.28 -0.15 
Te Tiacrilast -5.07 -4.93 -0.14 
Te Timolol ester -4.67 -4.71 0.04 
Te Trovafloxacin -4.81 -5.27 0.45 
Te Uracil -5.37 -4.58 -0.79 
Te Verapamil -4.81 -4.70 -0.11 
Te Warfarin -4.63 -5.50 0.87 
Va Acebutolol -6.10 -5.71 -0.38 
Va Acebutolol ester -4.68 -5.46 0.77 
Va Acetylsalicylic acid -5.62 -4.81 -0.81 
Va Acrivastine -6.35 -6.03 -0.32 
Va Aminopyrine -4.44 -5.00 0.56 
Va Benzyl penicillin -6.08 -6.04 -0.04 
Va Bupropion -4.24 -4.54 0.30 
Va Chloramphenicol -4.96 -5.35 0.39 
Va Clonidine -4.58 -4.82 0.24 
Va Cortisona -4.69 -4.29 -0.40 
Va Danazol -4.84 -4.39 -0.45 
Va Dexamethasone-β-D-glucoronide -6.38 -5.84 -0.54 
Va Dexamethasone-β-D-glucoside -6.83 -7.76 0.93 
Va Dmp 728 -6.58 -6.84 0.26 
Va Doxorubicin -6.48 -6.25 -0.24 
Va Doxycycline -4.95 -6.60 1.65 
Chapter 2. Prediction of the In Vitro Permeability Determined 
in CACO-2 Cells by Using Artificial Neural Networks 
Paulo J. P. A. Paixão, 2010 39 
 
Table 2.1 – (Continued) 
Data Set Drug Observed Predicted Residue 
Va E3174 -7.30 -6.61 -0.69 
Va Fexofenadine -6.51 -6.25 -0.26 
Va Fluparoxan -4.10 -4.90 0.80 
Va Ganciclovir -6.37 -5.70 -0.68 
Va Glipizide -5.97 -5.68 -0.28 
Va Guanabenz -4.97 -4.89 -0.08 
Va Hydrocortisone -4.82 -4.63 -0.19 
Va L-DOPA -6.05 -6.25 0.20 
Va Loracarbef -7.34 -6.34 -1.00 
Va Losartan -6.05 -6.11 0.06 
Va Ly366092 -4.03 -4.42 0.39 
Va Ly366094 -5.22 -4.64 -0.58 
Va Ly368227 -4.36 -4.51 0.15 
Va Ly368228 -4.37 -4.56 0.20 
Va Meloxicam -4.71 -5.59 0.88 
Va Methyl gallate -5.39 -5.61 0.21 
Va Metolazone -5.21 -5.30 0.09 
Va Nadolol -6.14 -5.89 -0.25 
Va Oxazepam -4.22 -4.74 0.52 
Va Peg 194 -5.28 -6.02 0.74 
Va Peg 400 -6.98 -6.43 -0.54 
Va Phencyclidine -4.61 -5.04 0.43 
Va Practolol -6.02 -5.56 -0.45 
Va Propyl gallate -6.82 -5.78 -1.04 
Va Salicylic acid -4.82 -4.18 -0.64 
Va Sulfapyridine -5.00 -5.35 0.35 
Va Sulfisoxazole -4.92 -5.84 0.92 
Va Theophylline -4.61 -4.20 -0.41 
Va Tolbutamide -4.28 -5.47 1.19 
Data values were obtained from references (Alt et al., 2004; Anand et al., 2003; Artursson et al., 1993; Behrens and 
Kissel, 2003; Bhardwaj et al., 2005; Caldwell et al., 1998; Cavet et al., 1997; Crowe, 2002; Crowe and Lemaire, 1998; Da 
Violante et al., 2004; Ekins et al., 2001; Ertl et al., 2000; Fujiwara et al., 2002; Fukada et al., 2002; Furfine et al., 2004; 
Hartter et al., 2003; He et al., 2004; Hilgendorf et al., 2000; Hu and Borchardt, 1990; Hunter et al., 1993; Irvine et al., 
1999; Karlsson et al., 1999; Kerns et al., 2004; Khan et al., 2004; Lalloo et al., 2004; Lee et al., 2005; Marino et al., 2005; 
Markowska et al., 2001; Martel et al., 2003; Masungi et al., 2004; Matthias et al., 2004; Neuhoff et al., 2003; Nishimura et 
al., 2004; Nordqvist et al., 2004; Oka et al., 2002; Pachot et al., 2003; Pade and Stavchansky, 1998; Polli and Ginski, 
1998; Saitoh et al., 2004; Soldner et al., 2000; Stenberg et al., 2001; Sun et al., 2003; Tammela et al., 2004; Tannergren, 
2004; Tronde, 2002; Vaidyanathan and Walle, 2003; Watson et al., 2001; Wong et al., 2002; Yang and Wang, 2003; 
Zhou et al., 2004; Camenisch et al., 1998; Gan et al., 1993; Hou et al., 2004; Laitinen et al., 2003; Miret et al., 2004; 
Raoof et al., 1996; Ribadeneira et al., 1996; Yazdanian et al., 1998) 
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In Silico Calculation of the Molecular Descriptors 
 
The following methodology was used for the in silico descriptors: SMILES 
notation of each molecule was obtained using the on-line PubChem Compound 
database (http://www.ncbi.nlm.nih.gov). Ionization descriptors (pkaacid; pkabase), 
and lipophilicity (Log P) were obtained using the on-line ALOGPS 2.1 program 
(Tetko and Bruneau, 2004). For drugs without an acid ionisable group, a value of 
15 was attributed to pKaacid. For drugs without a basic ionisable group, a value of -
1 was attributed to pKabase. The remaining descriptors, related to size, 
compactness, lipophilicity and others, were obtained from the on-line E-Dragon 1.0 
software using CORINA to convert the SMILES notation to the 3D representation 
of the molecule (Tetko et al., 2005). A total of 246 molecular descriptors were 
calculated, consisting of 8 molecular properties, 48 constitutional descriptors, 73 
topological descriptors, 26 geometrical descriptors, 47 information indices and 44 
WHIM descriptors.  
 
ANN Model building 
 
The Artificial Neural Network (ANN) non-linear regression was performed 
using the backpropagation neural modelling system QNet for Windows v.2000 
build 751 (Vesta Services inc., USA) and an in-house developed Microsoft Excel® 
VBA routine for process automation. Papp values were log transformed and 
randomly divided between a train (TR group with 65% of the total data), a test (TE 
group with 20% of the total data) and an external validation group (VAL group with 
15% of the total data). All networks were built using normalised variables both in 
the input and output, and a sigmoid transfer function was used in all connections. 
Early stopping based on the degradation of the normalised data root mean square 
error (RMS) of the test group was used to avoid over fitting. Each network was 
started 15 times with random initial values to avoid convergence to local minima.  
Network optimization was performed in a two step process. The first step 
consisted of the reduction of the molecular descriptors space. This was initially 
done by removing highly correlated (r > 0.90) descriptors, allowing the removal of 
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molecular descriptors with information contained within another descriptor, and 
repetitive descriptors (90% equal values) removing descriptors with non-
discriminatory characteristics. The remaining descriptors were randomly divided in 
4 groups and tested in an ANN with a network architecture of 2 hidden layers with 
3 hidden neurons in the first layer and 2 hidden neurons in the second layer 
(n-3-2-1 network). These ANN were optimized for each of the molecular 
descriptors groups, and the relevance of each descriptor within each group of 
molecular descriptors was tested against the percent contribution for the final 
output of a random input variable, allowing the removal of molecular descriptors 
that were uncorrelated with the output variable. Finally a pruning procedure was 
undertaken, using the same network architecture and including all the remaining 
molecular descriptors. At the end of the first optimisation, the percent contribution 
for the final output was calculated to all descriptors and these were organised by 
quartiles of relative importance. Four new networks were built based on this 
organisation, and the quartile with the lowest test RMS was kept. Then the 
descriptor presenting the worst percent contribution value was removed and a new 
network was build. This procedure was repeated until a significant degradation of 
the RMS with a descriptor removal was observed. 
The second step consisted of the optimisation of the network architecture 
for the most relevant molecular descriptors. Several networks were built varying 
the number of hidden layers (1 to 3) and the number of hidden neurons (1 to 10) 
but maintaining the ratio between the number of patterns to the number of 
connections above 1. 
External validation was made by comparing the ANN predicted values to 
the observed in vitro values with the drugs in the validation group, not previously 
used in the training and optimization process. 
 
Statistical analysis 
 
Correlation between the predicted and observed values was determined by 
means of the Pearson correlation coefficient (r) for the train, test and validation 
groups for the log(Papp) data. In order to assess the precision and bias of the 
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network, root mean squared error (RMSE) and mean error (ME) were also 
estimated by using the following equations. 
 
( )
N
PP
RMSE obs
apppredapp∑ −= 2       (2.1) 
 ( )
N
PP
ME obs
apppredapp∑ −=        (2.2) 
 
Percentage of correct values within a 10-fold error (difference of log predicted to 
log observed values outside the interval -1 to 1) was also determined in order to 
assess the qualitative ability of the network. 
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Results  
 
Optimisation of the ANN model was made as described under methods. 
Regarding the reduction of the molecular descriptors space, the removal of 
correlated and non-discriminatory descriptors reduced the number of descriptors 
to 79. The next two procedures were performed using an ANN with an architecture 
of n-3-2-1, n being the number of molecular descriptors. This ANN structure was 
chosen as a compromise between simplicity, in order to avoid memorisation, and 
complexity to allow an adequate learning ability of the network. To escape local 
minima each network was run multiple times with random initial values. To avoid 
memorisation of data and loss of predictive ability, the learning process was early-
stopped based on the degradation of test RMS error. In the end of each descriptor 
set optimisation step, the network with the lower average test RMS error was kept, 
and the relative contribution of each input on the log(Papp) prediction was 
established using the “input node interrogator” option in QNet. In this option, 
individual input contribution is determined by cycling each input for all training 
patterns and computing the effect on the network’s output response. By 
comparison with a random input descriptor it was concluded that out of the 79 
descriptors randomly distributed in 4 groups, 22 were considered non relevant and 
were removed, since their input contribution was equal or inferior to the random 
input. Finally, by the pruning procedure described under methods, it was 
considered that 12 molecular descriptors were needed to characterise the output 
response, as a degradation of either the train and test RMS error was observed 
when further removals were undertaken (Figure 2.1). The final model was 
constructed with the 12 molecular descriptors presented in table 2.2.  
Based on these descriptors, a network architecture optimisation was 
pursued using a brute force approach. In order to maintain a practical 
computational time, the network architectural space was swept between 1 to 3 
hidden layers. The number of hidden neurons by layer was variable taking into 
consideration the ratio between the number of patterns to the number of 
connections. This ratio was maintained above 1 in order to reduce the ability of the 
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network to memorise the data and avoid overfitting (So and Richards, 1992; 
Turner et al., 2004). 
 
Table 2.2 – Summary of the 12 molecular descriptors used in the ANN 
model 
Molecular 
Descriptor Description  
Molecular 
Descriptor Description 
LogP Octanol:Water partition coefficient  Te 
T total size index weighted 
by atomic Sanderson 
electronegativities 
nR09 Number of 9-membered rings  Jhetv 
Balaban-type index from van 
der Waals weighted distance 
matrix 
Hy Hydrophilic Index  FDI Folding Degree Index 
MAXDP Maximal electrotopological positive variation  SPH Spherosity 
TPSA(tot) Topological Polar Surface Area for O, N and S   RBF Rotable Bond Fraction 
nO Number of Oxygen atoms in the molecule  pKa(acid) 
pKa of the strongest acidic 
group 
 
Detailed information of the presented molecular descriptors may be obtained in (Todeschini and 
Consonni, 2000). 
 
At the end of the optimization process the networks with the best statistical 
characteristics in terms of the train correlation, test correlation and test 1-log value 
tolerance were kept and their performance is presented in table 2.3. The 3 
networks show identical performances, with similar values for precision and bias in 
the predicted values for the TR and TE groups of data. The network 12-6-4-1 
presented the best behaviour in terms of the TR group of data but is the less 
competent in terms of the TE group of data. This is an indication on the dangers of 
using the train statistics for network selection, even when early-stopping is made. 
On the contrary, network 12-6-3-3-1, although the most complex of the 3 
architectures considered, presented the lowest difference between the statistics of 
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the TR and TE groups of data, indicating that overfitting was not significant and 
that probably this network has better prediction characteristics.  
 
 
Figure 2.1 – Plot of the performance of the pruning procedure in reducing the molecular 
descriptors number both in the train (TR) and in the test (TE) groups normalized data root 
mean square error (RMS).  
 
 
The ability of the selected networks to predict the LogPapp of new drugs was 
tested in the 45 drugs presented in the validation group and not previously used in 
the train process. As can be seen (Table 2.3 and figure 2.2) the network 12-6-3-3-
1 presented the best predictions with 91% of drugs well predicted within the ± 1-
log tolerance value. It also presented the lower RMSE of the 3 networks 
considered and an insignificant bias in the 3 groups of data.  
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Figure 2.2 – Plot of the in vitro observed vs in silico predicted LogPapp values for the 12-6-
3-3-1 ANN model. Solid line represents the line of unity and the dashed lines the ±1 log 
tolerance value. Closed circles are indicative of drugs in the Train group and open circles 
represent drugs in the Test group. Grey marks are relative to the external validation 
group.  
 
 
Table 2.3 – Statistical evaluation of the performance of the best 3 ANN 
archichectures to predict LogPapp values based on the molecular descriptors for 
the train, test and external validation data sets. 
    TR  TE  VAL 
Network   Corr Tol RMSE ME  Corr Tol RMSE ME  Corr Tol RMSE ME 
12-3-3-1   0.893 95.8 0.458 0.000  0.709 81.4 0.766 -0.064  0.717 88.9 0.679 0.060 
12-6-4-1   0.919 97.9 0.400 0.003  0.675 78.0 0.809 -0.042  0.763 88.9 0.636 -0.068 
12-6-3-3-1   0.843 92.2 0.546 0.001  0.702 86.4 0.791 -0.058  0.774 91.1 0.601 -0.043 
Corr – correlation coefficient 
Tol - % of correct values within ± 1 log value 
RMSE – Root Mean Squared Error  
ME – Mean error 
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Discussion  
 
Model Data 
 
Drug absorption in the GIT is a complex process. Various physical, 
chemical and biological processes are known to be involved in the overall oral 
bioavailability of drugs that may condition the movement of compounds from the 
intestinal lumen to the blood circulation. Permeation in the epithelium lining is, 
however, one of the major factors governing the drug bioavailability, and the in 
vitro CACO-2 cell system has been shown to be a suitable model for studies on 
intestinal drug absorption (Artursson and Karlsson, 1991; Rubas et al., 1993; Yee, 
1997). 
We collected a large database of drug and drug like Papp CACO-2 values 
described in the literature. Examples of drugs absorbed by all mechanisms of 
membrane movement were included. However, when concentration dependent 
Papp values were described, data was collected in the saturation zone in order to 
primarily consider the passive diffusion process of drug absorption. Various 
studies have enlightened the fact that variability within and between laboratories 
may condition the creation of large databases of Papp values from CACO-2 cells 
(Sun et al., 2002; Volpe, 2007). Reasons for this variability may be related to 
differences in the experimental conditions and with heterogeneity of the cell lines. 
The effect of pH in the permeability of drugs, as expected by the Brodie theory 
(Jollow and Brodie, 1972), was experimentally described  in CACO-2 cells by 
Neuhoff and co-workers (Neuhoff et al., 2003). It is also demonstrated that ideal 
passage numbers would be inside the interval of 28 – 65 with significant 
differences in TEER in higher passages (Briske-Anderson et al., 1997). Cell 
culture time also influences the morphology, formation of tight junctions and 
membrane proteins expression, being that the maturation of CACO-2 cells is 
described to be achieved after 21 days in culture (Behrens and Kissel, 2003). 
Some authors have previously dealt with the question of variability between 
different laboratories in their QSAR works. Yamashita et al (Yamashita et al., 
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2002a) proposed the “latent membrane permeability” concept, assuming that all 
CACO-2 permeability data sets share a hidden, common relationship between 
their membrane permeability and physicochemical properties. In practice, the 
authors made an iterative normalisation between the original data sources in order 
to reduce variability and concluded for their applicability in QSAR analysis. 
Fujiwara et al. (Fujiwara et al., 2002) made an analysis of variance for the residual 
sum of squares between before and after taking each sub-dataset in their QSAR 
model, and concluded that none of the sub-dataset were significantly different from 
the rest of the entire dataset. The authors did not indicate any particular rationale 
in their data collection. In our case, by including drugs from studies with similar 
experimental protocols, as described under methods, part of the described 
variability is expected to be reduced. Additionally, normalisation by common drugs 
of the different sources of data from the data source with the largest number of 
coumponds, the experimental RMSE was reduced from 0.427 to 0.367. 
 
Model building and Validation 
 
We used a multilayer feedforward backpropagation neural modelling system 
in order to build a QSAR model to relate molecular descriptors to Papp values as 
this type of modelling approach have shown its superiority over other multivariate 
methods in QSAR when nonlinear relations exist (Sutherland et al., 2004; Winkler, 
2004). However, like other regression methods, neural networks are prone to 
overfitting and validation problems. To overcome this, a train group of data with 
192 drugs was used to provide information to the network, and a test group with 
59 drugs to indicate where overfitting begins, finalising the training process. In 
order to validate the model, we used an external validation data set with 45 drugs. 
As a primary approach to overcome overfitting, early stop was used in order to 
reduce the effective size of each parameter. Early stop has shown to be an 
effective procedure to decrease the generalisation error when the number of train 
cases is not much bigger than the number of modified parameters (Amari et al., 
1997). The results obtained seem to confirm that overfitting did not occur, as the 
statistics of the train and test group of data for the 3 best ANN architectures are 
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not different (Table 2.3). We also tried to minimise overfitting by reducing the 
number of dimensions of the parameter space, using a sensitivity based pruning 
procedure. As can be seen in figure 2.1 and as described by others (Tetko et al., 
1996), reducing the number of descriptors resulted in a better prediction ability of 
the ANN as judged by the RMS of the test group of data. However, by removing 
more than 12 descriptors, an evident loss of both training and prediction ability 
was observed.  
Although the data in the test group was not used to train the network, if 
used to test the predictive performance of the method, like a “leave-n-out” 
approach, a weak form of validation would be obtained and ideally an external 
group of data should be used (Ekins, 2003) . Evaluation of the external validation 
group statistics for the ANN 12-6-3-3-1 (Table 2.3) clearly shows that this model 
contains good prediction properties with a RMSE value less than twice of the 
experimental error (0.367 vs 0.601), an acceptable performance for a QSAR 
method (Dearden and Worth, 2007).  
 
Comparison with other approaches 
 
Since the initial efforts of Palm et al. (Palm et al., 1996), various authors 
have proposed in silico models to predict the in vitro CACO-2 permeability of 
drugs. Yamashita et al. (Yamashita et al., 2002b)  used a genetic-algorithm based 
partial least squares based on logPapp values of 73 drugs resulting in a model with 
r = 0.886 and standard deviation (SE) = 0.389. Validation was made by a “leave-
some-out” procedure with an r = 0.825 and SE = 0.474. Hou et al. (Hou et al., 
2004) used multiple linear regression with 100 diverse drugs resulting in an 
r = 0.85 and SE = 0.41 in the train group of 77 drugs and r = 0.78 and SE = 0.49 in 
the validation group of 23 drugs. Guangli and Yiyu (Guangli and Yiyu, 2006) with 
the same data set but using a support vector machine method obtained an r = 0.88 
and RMSE = 0.361 for the train and r = 0.85 and RMSE = 0.518 for the validation 
group of data. Close inspection of the data revealed, however, that the validation 
data was overpredicted with a mean error of 0.11, especially at the lower end of 
permeability values. Again with the same data set but using atom-based stochastic 
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and non-stochastic linear indices as molecular descriptors, Castillo-Garit et al. 
(Castillo-Garit et al., 2008) used multiple linear regression resulting in an r = 0.85 
and SE = 0.43 in the train group of data, after the removal of 2 outliers. Validation 
group, with only 19 drugs, presented an r = 0.71 and SE = 0.51. Fujiwara and 
co-workers (Fujiwara et al., 2002) used an ANN to correlate five molecular 
descriptors to LogPapp values in 87 drugs. They reported a correlation coefficient of 
0.79 for the whole data set and a RMSE of 0.435 and 0.507 for the entire data set 
and for the leave-one-out cross-validation. The authors also concluded for superior 
results with their ANN model when comparing with a multiple linear regression 
analysis in the same data set. In another study, Degim (Degim, 2005) also used 
an ANN to correlate four molecular descriptors to LogPapp values in 50 drugs. The 
author reported an r = 0.976 and a SE = 0.188 in the train group. ANN 
performance in a validation group of 7 drugs was not so effective with an r = 0.856 
and a SE = 0.457, indicating a possible situation of overfitting in the model. Finally, 
Di Fenza and co-workers (Di Fenza et al., 2007) used an ANN coupled with a 
genetic algorithm search to optimize and correlate Volsurf descriptors to Papp 
values in two proprietary set of 106 NK-2 receptors antagonists and 101 
compounds with anti-tumour activity. Authors reported an r = 0.75 in a “leave-14%-
out” test for their best model, but due to a strong structure similarity in the train 
data, the model only provided an r = 0.61 in an external data set.  
Direct comparison between our proposed approach with these previous 
models is difficult as an independent external validation group of data would be 
required. However, it is visible that our model presents similar statistical 
performance to the formers with a significantly larger data set of drugs. Moreover, 
the fact that an external validation was made in our ANN model is an additional 
indication that it bears good predictive abilities. 
 
Model Interpretation 
 
When considering the relevant molecular descriptors (Table 2.2), they can 
be grouped in terms of lipophilicity, hydrophilicity, electronegativity, size, shape 
and flexibility characteristics of the molecules, and are in agreement with the 
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expected physical forces involved in drug absorption (Stenberg et al., 2002). LogP 
is a measure of lipophilicity and has been used in various studies regarding drug 
absorption (Egan et al., 2000; Lipinski et al., 2001; Winiwarter et al., 1998). nR09 
is the number of cyclic structures containing 9 carbon atoms in a molecule, and 
besides its simple structural characterization, it may also be a measure of either 
size or lipophilicity. Hy is a simple empirical index related to hydrophilicity of 
compounds based on count descriptors (Todeschini and Consonni, 2000). 
MAXDP, which represents the maximum positive intrinsic state difference and can 
be related to the electrophilicity of the molecule (Gramatica et al., 2000), is directly 
related with the electronegativity and water solubility of the molecule.  TPSA(tot) is 
defined as the part of the surface area of the molecule associated with O, N, S and 
the H bonded to any of these atoms, and is related to the hydrogen bonding ability 
of the molecule. nO is a count descriptor that indicates the number of O atoms in a 
molecule. Solubility (Martini et al., 1999), PSA and simple atom counts related to 
the H-bonding capacity were extensively used to predict drug absorption in various 
studies (Hou et al., 2004; Kelder et al., 1999; Palm et al., 1997; Winiwarter et al., 
2003; Winiwarter et al., 1998). Te is a WHIM descriptor and Jhetv is a Balaban 
type index both related with the molecular size. FDI and SPH are both shape 
descriptors indicating respectively if a molecule is folded or linear and flat or 
spherical. RBF indicates the number of bonds which allow free rotation around 
themselves weighted by the total number of bonds, and is a measure of molecular 
flexibility (Todeschini and Consonni, 2000). Both size and flexibility have also been 
correlated with drug absorption previously (Hou et al., 2004; Lipinski et al., 2001). 
pKa(acid) is the pKa of the strongest acid group in the molecule.  
Interpretation of the individual descriptors in an ANN, due to the “black-box” 
nature of this approach, is frequently described as difficult. One possible approach 
to overcome this issue is to find how input trends interact with output predictions. 
This was done by varying some selected inputs at a time, considering all the 
others constant with the median value.  
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Figure 2.3 – ANN interaction trends between the A) LogP and Hy, B) FDI and SPH, C) 
TPSA(tot) and nO and D) Te and pKaacid, in the logPapp prediction, maintaining all other 
descriptors constant as median values. 
Chapter 2. Prediction of the In Vitro Permeability Determined 
in CACO-2 Cells by Using Artificial Neural Networks 
54 Paulo J. P. A. Paixão, 2010 
 
 
Figure 2.3-A) presents the relationship between LogP and Hy. LogP relates 
positively with LogPapp as various authors have shown (Egan et al., 2000; Hou et 
al., 2004; Norinder and Osterberg, 2001), but at values for LogP > 5 the effect 
reaches a plateau, which is in accordance with the “Lipinsky’s rule of five” (Lipinski 
et al., 2001). Hy relates negatively with LogPapp, as the more hydrophilic the 
molecule, the lower the permeability value. Figure 2.3-B) shows the relationship 
between the FDI and SPH descriptors and may be an indication of the molecular 
behaviour in the paracellular route of absorption. As seen, when neither folded 
(FDI close to 1) nor spherical (SPH close to 0), the molecule presents a lower 
LogPapp value. Figure 2.3-C) presents the relationship between TPSA(tot) and nO 
and, as visible, LogPapp values decrease with both the increase in TPSA(tot) and 
nO. It has been suggested that PSA in some way describes the desolvation of a 
compound as it moves from an aqueous to a lipid environment (van de 
Waterbeemd et al., 1998) and it has been described that drugs with less than 10% 
absorption had PSA values above 140 Å (Palm et al., 1997). nO is a simple 
descriptor that may also be related to the H-bonding ability of the molecule, and its 
increased size, like the increase of the sum of H-bond donors and acceptors, 
relates negatively with LogPapp (Winiwarter et al., 1998). Figure 2.3-D) shows the 
relationship between the Te and pKa(acid) descriptors. Te is a molecular 
descriptor closely related to the molecular weight and its increase, as reported 
early (Fagerholm et al., 1999; Lipinski et al., 2001), resulted in a lower LogPapp 
value. pKa(acid) indicates that acids with pKa values below 7 are generally badly 
absorbed. This may not be completely related with the “pH’s partitioning 
hypotheses” as the pKa(basic) did not seemed to be an important descriptor for 
LogPapp. Martin (Martin, 2005) also reported a difference in absorption between 
anions and the remaining classes of molecules that resulted in different absorption 
rules. One possible explanation for this effect may be related to the electrostatic 
repulsion between a negatively charged molecule and the also negatively charged 
enterocyte. 
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Conclusions 
 
In conclusion, we presented an ANN methodology based in a pruning 
procedure to reduce the descriptors space, and using an early-stop approach that 
produced a robust and logical model with good predictive abilities. Comparison of 
our model with the previously reported ANN models also stresses its 
characteristics. It was build with more drugs than the method of Fujiwara and 
co-workers (Fujiwara et al., 2002), with an external validation with similar statistics 
of the authors own “leave-one-out” cross-validation. Additionally, It was not 
overfitted as the model of Degim (Degim, 2005) appears to be and it provides a 
larger chemical space than the model developed by Di Fenza and co-workers (Di 
Fenza et al., 2007). The presented methodology also provides some advantages 
over these same reports. Early stop provided an efficient training procedure to 
reduce the overfitting problem of the ANN. Pruning of the molecular inputs, in 
order to reduce the molecular space, resulted in a low computational intensive 
approach still capable to select molecular descriptors that are known to be related 
with the drug absorption process. Overall, this approach may be a useful 
prediction tool in the initial screening of compounds. 
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Blood-to-plasma concentration ratio (Rb defined as CB/Cp) is a measure of 
the drug distribution within the blood. Drugs, when reaching the blood stream, can 
bind to plasma proteins and/or to blood cells. If a drug binding in plasma exceeds 
that in blood cells Rb values are below 1 (Cp > CB). When drug binding in blood 
cells is larger than plasma binding of the drug (CB > Cp), Rb values are above 1.  
Rb is an important parameter to correctly characterise the pharmacokinetics 
of a drug, as it is related either to the volume of distribution (Vd) and to the 
clearance (CL) of the drug (Bachmann et al., 2003; McGinnity et al., 2004; Poulin 
and Theil, 2000; 2002a; b; Yamamoto et al., 2005). If in the Vd case, the 
importance of Rb can be overcome by considering blood cells distribution as a 
tissue distribution, the same cannot be done in terms of CL. In this case, if Cp > CB 
then AUCB < AUCp and consequently ClB > Clp, meaning that Clp will 
underestimate the ClB. The inverse will happen when CB > Cp, and Clp can 
substantially overestimate ClB (Gibaldi and Perrier, 1982). This can be easily 
overcame, as the experimental determination of Rb is a relatively simple procedure 
(Karanam et al., 1998). Unfortunately, Rb data is lacking in most pharmacokinetic 
studies. Furthermore, the majority of pharmacokinetic studies are made 
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considering plasma data, as drugs are usually and easily quantified in this 
medium.  
Physiologically Based pharmacokinetic models (PBPK) are a useful tool to 
simulate and predict the pharmacokinetic behaviour of xenobiotics. It had been 
extensively used in toxicology (Jarnberg and Johanson, 1999; Levitt, 2002) and, 
more recently, in the development of new drugs (Parrott et al., 2005; Theil et al., 
2003). In this type of models, drug distribution and elimination are related to blood 
flow rate to the different organs and assumptions are made that only the free 
fraction of the drug can distribute to the tissues. Rb is, by these means, an 
extremely important parameter that needs to be known but is often underrated. If 
this parameter is not experimentally estimated, a simple approximation was 
proposed stating that if the drug is an acid a value of Rb of 0.55 should be 
considered, or a value of Rb of 1 if the drug is basic or neutral (Riley et al., 2005). 
This approach is problematic as Rb for either basic or acid drugs with no specific 
binding in blood cells may range from 0.55 to values, a great degree, above 1. 
Additionally, comparison of simulated data to in vivo data may be biased as the 
ratio of plasma clearance to blood clearance is equal to Rb. 
The aim of this work was to establish mechanistic and regression models to 
predict the Rb for different classes of drugs, using mainly in silico molecular 
descriptors. Molecular descriptors are obtained through a mathematical or 
experimental procedure that transforms the chemical information encoded in the 
molecular representation of the chemical entity into numerical data (Todeschini 
and Consonni, 2000). The use of molecular descriptors is a fundamental tool in the 
development of new drugs. When determined in silico, they can be used to the 
early screening of hypothetically new therapeutic entities previous to the physical 
existence of the molecule itself. In order to relate these multiple molecular 
descriptors to the Rb value of a specific drug, different types of approaches were 
pursued. A mechanistic one based on a previous model for prediction of drug 
tissue distribution (Rodgers and Rowland, 2006), a linear regression QSAR using 
partial least squares and a non-linear regression QSAR using feed-forward back 
propagation neural networks.  
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Materials and Methods 
 
Data collection 
 
The Rb values were collected from the literature and are summarized in 
Table 3.1. Some drugs interact with specific binding sites in proteins of the blood 
cells and may present a concentration dependent blood distribution at therapeutic 
concentrations that are difficult to model. For this reason, only electrostatic and 
lipophilicity binding to blood cells were considered and drugs like 
hydroxychloroquine (French et al., 1987) or tacrolimus (Karanam et al., 1998; 
Zahir et al., 2004), were removed from the dataset. Unbound drug in plasma (fu) 
values were also collected from the literature, and fu was the only molecular 
descriptor used in model building not determined in silico.  
 
Table 3.1 – Blood-to-plasma concentration ratio for the 93 drugs. 
Drugs are also classified as Base, Acid, Neutral or Zwitterionic. 
Drug Class Rb Reference 
Alfentanilb B 0.63 (Goodman et al., 1996) 
Alprazolama,b B 0.78 (Obach, 1999) 
Amiodaronac B 0.73 (Goodman et al., 1996) 
Amitriptylineb B 0.86 (Goodman et al., 1996) 
Amodiaquineb Z 1.7 (Winstanley et al., 1987) 
Ascorbic acida,c A 0.82 (Poulin and Theil, 2002a) 
Atenololc B 1.07 (Goodman et al., 1996) 
Bepridilb B 0.67 (Pritchard et al., 1985) 
Betamethasonea,b N 1.1 (Goodman et al., 1996) 
Bupivacainec B 0.73 (Goodman et al., 1996) 
Caffeinea,b N 0.8 (Poulin and Theil, 2002a) 
Carvedilolb B 0.7 (Goodman et al., 1996) 
Chlorothiazidea,b A 1.5 (Goodman et al., 1996) 
Chlorpheniramineb B 1.34 (Poulin and Theil, 2002a) 
Chlorpromazineb B 0.78 (Obach, 1999) 
Chlorthalidonea,b A 0.725 (Goodman et al., 1996) 
Cimetidinec B 0.97 (Goodman et al., 1996) 
Chapter 3. Prediction of drug distribution within blood 
72 Paulo J. P. A. Paixão, 2010 
 
Table 3.1 – (Continued) 
Drug Class Rb Reference 
Clarithromycinb B 0.64 (Goodman et al., 1996) 
Cocaineb B 1 (Goodman et al., 1996) 
Dapsonea,b B 1.04 (Edstein et al., 1990) 
Desipramineb B 0.96 (Goodman et al., 1996) 
Desmethylselegilined B 0.55 (Goodman et al., 1996) 
Diazepama,b B 0.58 (Poulin and Theil, 2002a) 
Diclofenaca,b A 0.55 (Obach, 1999) 
Diltiazemb B 1 (Goodman et al., 1996) 
Diphenhydramineb B 0.65 (Obach, 1999) 
Doxazosina,b B 1.6 (Goodman et al., 1996) 
Epiroprimb B 1 (Poulin and Theil, 2002a) 
Etodolaca,b A 0.6 (Goodman et al., 1996) 
Famciclovira,b B 1 (Goodman et al., 1996) 
Felodipinea,b B 1.45 (Goodman et al., 1996) 
Fentanylc B 0.97 (Goodman et al., 1996) 
Flumazenila,c B 1 (Goodman et al., 1996) 
Hydralazineb B 1.65 (Goodman et al., 1996) 
Hydrochlorothiazidea,c A 1.7 (Goodman et al., 1996) 
Ibuprofena,b A 0.55 (Obach, 1999) 
Imipramineb B 1.1 (Goodman et al., 1996) 
Isradipinea,b B 0.55 (Goodman et al., 1996) 
Ketaserinb Z 0.7 (Meuldermans et al., 1988) 
Ketorolaca,c A 0.55 (Goodman et al., 1996) 
Labetalolb Z 1.4 (Goodman et al., 1996) 
Levocetirizined Z 0.59 (Benedetti et al., 2001) 
Lidocaineb B 0.84 (Shibata et al., 2002) 
Lomefloxacinb Z 1.4 (Goodman et al., 1996) 
Lorcainideb B 0.7 (Goodman et al., 1996) 
Mefloquineb B 1 (Goodman et al., 1996) 
Melphalanb Z 0.96 (Goodman et al., 1996) 
Meperidineb B 0.87 (La Rosa et al., 1984) 
Methadoneb B 0.75 (Goodman et al., 1996) 
Metoprololb B 1 (Goodman et al., 1996) 
Midazolama,b B 0.8 (Bjorkman et al., 2001) 
Monoacetyldapsoned B 0.69 (Edstein et al., 1990) 
Naloxoneb Z 1.22 (Shibata et al., 2002) 
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Table 3.1 – (Continued) 
Drug Class Rb Reference 
Nicardipineb B 0.71 (Goodman et al., 1996) 
Nitrazepama,b B 1 (Poulin and Theil, 2002a) 
Nitrofurantoina,b A 0.76 (Goodman et al., 1996) 
Nortriptilineb B 1.5 (Rollins et al., 1980) 
Octreotideb B 0.56 (Goodman et al., 1996) 
Omeprazolea,b Z 0.58 (Goodman et al., 1996) 
Ondansetronc B 0.83 (Goodman et al., 1996) 
Oxcarbazepinea,b N 1.25 (Theisohn and Heimann, 1982) 
Palonosetronb B 1.2 (Stoltz et al., 2004) 
Pentazocineb Z 1.06 (Poulin and Theil, 2002a) 
Phenacetina,b N 1.01 (Shibata et al., 2002) 
Phencyclidineb B 0.94 (Owens et al., 1983) 
Phenobarbitala,c A 0.861 (Poulin and Theil, 2002a) 
Pindololb B 0.69 (Goodman et al., 1996) 
Piperacillina,b A 0.65 (Goodman et al., 1996) 
Pravastatina,b A 0.59 (Goodman et al., 1996) 
Prazosina,b B 0.7 (Poulin and Theil, 2002a) 
Primaquined B 0.81 (Mihaly et al., 1985) 
Primidonea,c N 0.97 (Goodman et al., 1996) 
Propafenoneb B 0.7 (Goodman et al., 1996) 
Propofola,c N 1.25 (Poulin and Theil, 2002a) 
Propranololb B 0.89 (Goodman et al., 1996) 
Pyrimethaminec B 0.98 (Goodman et al., 1996) 
Quinidineb B 0.92 (Obach, 1999) 
Remoxiprideb B 0.7 (Poulin and Theil, 2002a) 
Rifabutinb Z 0.59 (Goodman et al., 1996) 
Risperidoneb B 0.67 (Mannens et al., 1994) 
Selegilineb B 1.7 (Goodman et al., 1996) 
Sematilided Z 1.09 (Poulin and Theil, 2002a) 
Sertralineb B 0.7 (Goodman et al., 1996) 
Sufentanilb B 0.74 (Goodman et al., 1996) 
Sulfadoxined Z 0.72 (Hellgren et al., 1990) 
Sulpirideb Z 1 (Poulin and Theil, 2002a) 
Tamsulosinb Z 0.55 (Matsushima et al., 1998) 
Tenoxicama,c Z 0.67 (Obach, 1999) 
Terbinafinea,b B 0.7 (Yeganeh and McLachlan, 2002) 
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Table 3.1 – (Continued) 
Drug Class Rb Reference 
Tetrahydrocannabinola,b A 0.55 (Poulin and Theil, 2002a) 
Thiopentala,b A 1 (Poulin and Theil, 2002a) 
Tolbutamidea,b A 0.55 (Obach, 1999) 
Triamterenea,b B 1.03 (Goodman et al., 1996) 
Triazolama,b B 0.62 (Obach, 1999) 
Valproic acida,b A 0.64 (Goodman et al., 1996) 
Verapamilc B 0.77 (Obach, 1999) 
Vinpocetined B 0.57 (Szakacs et al., 2001) 
Warfarina,c A 0.55 (Obach, 1999) 
Zileutona,c N 0.66 (Machinist et al., 1995) 
Zolpidema,c B 0.76 (Obach, 1999) 
 
a – Compound used in the Mechanistic model 
b – Compound included in the train set for the PLS and ANN regressions 
c – Compound included in the test set for the PLS and ANN regressions 
d – Compound included in the validation set for the PLS and ANN regressions 
 
The following methodology was used for the in silico descriptors: SMILES 
notation of each molecule was obtained using the on-line PubChem Compound 
database (http://www.ncbi.nlm.nih.gov). Ionization descriptors (pkaacid; pkabase), 
lipophilicity (Log P) and water solubility (Log S) were obtained using the on-line 
ALOGPS 2.1 program (Tetko and Bruneau, 2004). For drugs without an acid 
ionisable group, a value of 15 was attributed to pKaacid. For drugs without a basic 
ionisable group, a value of -1 was attributed to pKabase. Different fractions of drug 
at pH 7.4 and 7.2 (ionised acid, ionised base, neutral and zwitterion) were 
calculated by the Henderson-Hasselbalch equations using the in silico pKa values. 
In silico fu values were obtained using the on-line ADME Boxes 
(http://www.pharma-algorithms.com/webboxes). The remaining descriptors, 
related to size, compactness, lipophilicity and others, were obtained from the on-
line E-Dragon 1.0 software using CORINA to convert the SMILES notation to the 
3D representation of the molecule (Tetko et al., 2005). A summary of the 
molecular descriptors used and their description is presented in table 3.2.  
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Table 3.2 – Summary of the 30 molecular descriptors used in the 
different modelling approaches 
Molecular 
Descriptor Description 
Molecular 
Descriptor Description 
pKabase 
pKa of the strongest basic 
group ASP Asphericity 
pKaacid 
pKa of the strongest acid 
group AROM Aromaticity index 
fi_B_74 
Fraction of ionised base at 
pH 7.4 based on pKa and 
Henderson-Hasselbach 
equation 
nHDon Number of donor atoms for H-bonds  
fi_A_74 
Fraction of ionised acid at 
pH 7.4 based on pKa and 
Henderson-Hasselbach 
equation 
nHAcc Number of acceptor atoms for H-bonds  
fn_74 
Fraction of unionised drug at 
pH 7.4 based on pKa and 
Henderson-Hasselbach 
equation 
Ui Unsaturation index 
fz_74 
Fraction of zwitterionic drug 
at pH 7.4 based on pKa and 
Henderson-Hasselbach 
equation 
TPSA_NO Topologic polar surface area acconting to N and O
Tot_fn_74 Sum of fn_74 and fz_74 Log S Calculated solubility 
Var_fn Subtraction of Tot_fn_74 with Tot_fn_722 Log P 
Calculated octanol-water 
partition coefficient 
fu 
Unbound fraction of drug in 
plasma Log D 
Tot_fn_74 multiplied to 
Log P 
MW Molecular weight IAC Total information index of atomic composition 
Sv Sum of atomic van der Waals volumes AAC 
Mean information index 
on atomic composition 
ARR Aromatic ratio IDE Mean information content on the distance equality 
W3D 3D-Wiener índex IDM Mean information content on the distance magnitude
RGyr Radius of gyration IDDE 
Mean information content 
on the distance degree 
equality 
SPH Spherosity IVDE 
Mean information content 
on the vertex degree 
equality 
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Data Handling 
 
Since the Rb values in Table 3.1 varied between 0.55 and 1.7, they were 
normalised by transforming them to the logarithm of drug concentration in blood 
cells to plasma ratio (CBC/Cp) using the equation 3.1  
 
( )⎟⎠
⎞⎜⎝
⎛ −−=⎟⎟⎠
⎞
⎜⎜⎝
⎛
Htc
HtcR
C
C b
p
BC 1loglog       (3.1) 
 
being Htc the typical hematocrit value of 0.45. When Rb = 0.55, CBC/Cp = 0 
resulting in an undefined value after logarithmic transformation. In these cases a 
value of 0.01 was attributed to CBC/Cp prior to the logarithmic transformation.  
 
Mechanistic approach 
 
Rodgers and Rowland (Rodgers and Rowland, 2006) developed a 
mechanistic equation for predicting tissue affinity for acids, neutrals, weak bases 
(pKabase < 7) and Zwitterions (pKabase < 7). This equation assumes that drug 
binding to extracellular proteins, dissolution in tissue water and the partitioning of 
unbound unionised drug into neutral lipids and neutral phospholipids are the major 
interactions involved in tissue distribution for these types of drugs. The same 
equation can be used to predict the affinity of the drug to the erythrocytes in the 
blood, assuming that these have no extracellular space and contain no albumin or 
lipoproteins, resulting in,  
 
 ⎥⎦
⎤⎢⎣
⎡ ⋅+⋅+⋅+⋅⋅=
Y
fPfP
Y
fX
CC RBCNPRBCNLRBCIWURBC
,,, )7.03.0(  (3.2) 
 
where CRBC is the drug concentration in erythrocytes, Cu is the unbound drug 
concentration in plasma, f is the fractional tissue volume, subscripts  IW, NL and 
NP refer to intracellular water, neutral lipid and neutral phospholipid and P is the 
n-octanol:water partition coefficient for the unionised drug. X and Y are as follows: 
for weak monoprotic bases X = 1 + 10pKa-7.22 and Y = 1 + 10pKa-7.4; for monoprotic 
acids X = 1 + 107.22-pKa and Y = 1 + 107.4-pKa; for neutral drugs X and Y equal 1; and 
for zwitterions X=1+10pKabase-7.22 + 107.22-pKaacid and Y=1+10pKabase-7.4 + 107.4-pKaacid.  
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Since puu CfC ⋅= , equation 3.2 can be rearranged to 
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This equation requires two types of input. Variables fIW, fNL and fNP are 
physiologic based with values of 0.914, 0.0017 and 0.0029 in man respectively 
(Rodgers et al., 2005b). Variables fu, pKaacid, pKabase and P are drug specific 
inputs and were obtained as described under Data Collection. 
 
QSAR by PLS regression 
 
Distribution of drug between plasma and blood cells is a process where 
various types of interactions are expected to be involved. Drugs can bind to 
plasma proteins, and this can be quantified by the unbound drug in plasma (fu) 
values. In order to reduce variability in the model output, due to variability in this 
parameter, only drugs with fu values obtained experimentally were used to build 
the model. Regarding the blood cells, two types of interactions are feasible, 
namely an affinity to the cell lipid fraction, and an electrostatic interaction between 
the negative global charge of the cells and a positive charge for basic drugs. 
Permeability of the cell membrane to drugs is also dependent on lipophilicity, size 
and shape of the molecules. The molecular descriptors were chosen considering 
these facts. Since the number of molecular descriptors was considerable (n = 43), 
a PLS regression was undertaken in order to relate them to the log(CBC/Cp) values 
for the different drugs, using the software Statgraphics Centurion XV version 
15.1.02 (StatPoint inc, USA). Although PLS regression can analyze data with 
strongly collinear X-variables, the number of molecular descriptors was in the first 
place reduced to 30 by removing highly correlated (r > 0.95) descriptors (Table 
3.2). Data was randomly divided between a train set (n = 74) and a test set 
(n = 19) used to test the predictive ability of the models (Table 3.1). An additional 
set of 7 drugs with fu values obtained in silico was used as an external validation 
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set. Input and output variables were normalised by auto-scaling (Wold et al., 
2001). Initially, the number of significant components was studied, based on the 
response balance between the train and the test sets. The minimum number of 
components was considered based on the average Prediction r2 (Q2) calculated 
based in the PRESS residuals in the test set. High leverage points and outliers, as 
well as unimportant molecular descriptors based on regression coefficients were 
also investigated. 
 
QSAR by ANN 
   
The same previously used molecular descriptors, train, test and validation 
sets were considered for the ANN non-linear regression (Table 3.1). The Neural 
network approach was performed using QNet for Windows v.2000 build 751 
(Vesta Services inc., USA) and an in-house developed Microsoft Excel® VBA 
routines for process automation. Both the input and output variables were 
normalised, and a sigmoid transfer function was used in all connections. Early 
stopping based on the degradation of the normalized data root mean square 
(RMS) error of the test set was used to avoid overfitting. Each network was started 
10 times with random initial values to avoid convergence to local minima. Network 
optimization was performed in a two step process. In the first step, the number of 
molecular descriptors was reduced by removing highly correlated (r > 0.95) 
descriptors. Then a pruning procedure was undertaken, using a network 
architecture of 2 hidden layers with 3 and 2 neurons in the first and second layer, 
and removing a descriptor at a time based on the lowest average percent 
contribution for the final output. A significant degradation of the RMS with a 
descriptor removal was the criterion for stopping the descriptors reduction 
procedure. The second step consisted in the optimization of the network 
architecture for the most relevant molecular descriptors. Several networks were 
made varying the number of hidden layers (1 to 3) and the number of hidden 
neurons (1 to 6). 
 
Chapter 3. Prediction of drug distribution within blood 
Paulo J. P. A. Paixão, 2010 79 
 
Statistical analysis 
 
Correlation between the predicted and observed values was determined by 
means of the determination coefficient (r2) for the train and test sets for the 
log(CBC/Cp) data. In order to assess the precision and bias of the different 
approaches, root mean squared prediction error (RMSE) and average fold error 
(afe) were estimated to the back calculated Rb values by using the following 
equations. 
( )
N
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RMSE is a measure of precision, since it is representative of the size of the typical 
random error and afe is a measure of bias with equal values for under and 
overpredictions (Ito and Houston, 2004). Additionally, percentage of correct values 
within a 1.25 fold error (log ratio of predicted to observed Rb values outside the 
interval -0.1 to 0.1) was also determined. 
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Results  
 
Statistical analysis of the different methodologies is presented in table 3.3. 
Graphical representation of the performance of each approach in adjusting and 
predicting log(CBC/Cp) data is also presented in figure 3.1. 
 
Table 3.3 – Statistical results for the different 
modelling strategies. 
Statistics Set Mechanistic PLS ANN 
Train - 0.543 0.927 
r2 
Test 0.342 0.644 0.871 
Train - 0.29 0.17 
RMSE 
Test 0.51 0.36 0.20 
Train - 1.01 1.01 
afe 
Test 1.17 1.06 1.02 
Train - 28 14 % outside 1.25-
fold error Test 46 37 16 
 
Mechanistic approach 
 
Incorporation of the in silico descriptors pKabase, pKaacid and Log P, as well 
as the in vitro descriptor fu, into the mechanistic approach (equation 3.3) presented 
a statistically significant correlation with the in vivo log(CBC/Cp) values although the 
regression line of the observed vs predicted values did not match to a 1:1 
relationship (Figure 3.1-A). Data was generally underpredicted and only 54% of 
cases presented a predicted error below the 1.25 fold error when the data was 
transformed to Rb (Table 3.3). Basic drugs with log(CBC/Cp) > -1 presented high 
residuals, and are generally not well predicted by this approach. 
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Figure 3.1 – Plot of the observed vs predicted log(CBC/Cp) values for the A) mechanistic 
equation, B) PLS model and C) ANN model. Dashed line represents the line of unity and 
the solid line the regression line between the experimental and calculated values of 
log(CBC/Cp). Open marks represent drugs that were included in the train set. Closed marks 
are indicative of drugs in the test set. Drugs are also represented as Acid (♦), Base (■), 
Neutral (▲) and Zwitterionic (●).  
 
QSAR by PLS regression 
 
A PLS regression was made using all the molecular descriptors described 
in table 3.1. Simplification was undertaken based on the standard coefficients of 
the descriptors in the model, removing the less influential ones. Ten descriptors 
were removed and the final model comprised 20 descriptors. A number of 4 
components, explaining 60.8% of variance in the input variables, presented the 
best Q2. Three drugs (clarithromycin, octreotide and rifabutin) were identified as 
high leverage observations, that also seemed to be a different subpopulation in the 
data (Figure 3.2).  
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Figure 3.2 – PLS factor scores plot between the 2 first components indicating the 
existence of 3 drugs substantially different in the independent variable space from the 
remaining data set. 
 
This type of data should be interpreted with some caution, and a balance 
between information and relevance in the model should be pursued before 
removal. Since none of these were proven by the PLS model to be outliers, and 
the model did not seem to be distorted by them, these molecules were considered 
“good leverage” chemicals that allow the extrapolation of the model to their input 
space (Gramatica et al., 2007). The PLS model presented a significant correlation 
with a Q2 of 0.614 for the test set of data, lower bias in Rb and a better amount of 
predicted values within a 1.25 fold error when compared to the mechanistic 
approach (Table 3.3, Figure 3.1-B).  In order to assess the feasibility of using in 
silico estimated fu values, the model output was compared to the output obtained 
by using the in vitro values. A correlation of r2=0.900, a slope statistically not 
different from 1 and 74% (training set) and 53% (test set) of Rb correct values 
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within a 1.25 fold error were obtained.  The Rb prediction ability of the PLS model 
was also tested using the validation set of data (Table 3.4) and three of the seven 
drugs were correctly predicted within the 1.25 fold error. 
 
Table 3.4 – Evaluation of the prediction ability of the ANN and 
PLS models in the external validation set using in silico 
estimated fu values. 
    ANN PLS 
Drug Obs Rb  Pred Rb fold error  Pred Rb fold error 
Desmethylselegiline 0.55 1 1.81 0.95 1.73 
Levocetirizine 0.59 0.55 1.07 0.59 1 
Monoacetyldapsone 0.69 0.75 1.08 0.79 1.15 
Primaquine 0.81 0.93 1.15 1.1 1.35 
Sematilide 1.09 1.05 1.04 2.22 2.04 
Sulfadoxine 0.72 0.59 1.22 0.57 1.25 
Vinpocetine 0.57 0.55 1.03 0.73 1.28 
 
Observed (Obs Rb) and Predicted (Pred Rb) Rb values 
 
Examination of the PLS standardized coefficient plot (Figure 3.3) reveals 
that the main molecular descriptors that directly influence the response function 
are pKaacid, pKabase, fu and Var_fn whereas fi_acid and AROM are descriptors that 
inversely influence the response function as well as the molecular size related 
descriptors, namely W3D and Sv. Interestingly, lipophilicity as measured by Log P 
and Log D does not seem to be an important feature in describing the blood 
distribution of drugs in this model.  
  
QSAR by ANN 
 
Optimization of the ANN model was made as described under methods. 
The initial model was constructed with the 30 molecular descriptors presented in 
table 3.2. A 2 hidden layers ANN with 3 and 2 hidden neurons in the first and 
second layer was used. This ANN structure was chosen as a compromise 
between simplicity, in order to avoid over parameterization and memorization, and 
complexity to allow an adequate learning ability of the network. To escape local 
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minima each network was run 10 times with random initial values and learning was 
early-stopped based on the degradation of test RMS error to avoid memorization. 
 
 
Figure 3.3 – Studentized coefficient plot for the PLS model using 4 components. 
 
 After 10 runs, the network with the lower average test RMS error was kept, 
and the relative contribution of each input on the log(CBC/Cp) prediction was 
established using the “input node interrogator” option in QNet. In this option, inputs 
contribution are determined by cycling each input for all training patterns and 
computing the effect on the network’s output response. Based on the obtained 
values, the least relevant input was removed, and the network trained again with 
n-1 inputs. This procedure was carried on until a significant degradation on the test 
RMS was observed. It was considered that 11 molecular descriptors were needed 
to characterise the output response, as a degradation of 24% on the test RMS was 
observed when reducing the number of inputs to 10 molecular descriptors. The 
apparent 11 most relevant inputs were pKabase, pKaacid, Var_fn, fu, Sv, W3D, IAC, 
AAC, IDE, IDM and IDDE. Based on these descriptors, a network architecture 
optimization was pursued using a brute force approach. In order to maintain a 
practical computational time, the network architectural space was swept between 
1 to 3 hidden layers and 1 to 6 hidden neurons by layer. The best neural network 
presented an architecture of 11-4-4-1 and its performance is presented in table 3.3 
and figure 3.1-C. The regression line of the observed vs predicted values almost 
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coincide with a 1:1 relationship and the model showed the best general prediction 
quality, with no bias and the best percentage of predicted values within a 1.25 fold 
error in the back transformed to Rb data of the three models.  
Statistical comparison of both the RMSE (precision of the predicted values), 
afe (bias in the predicted values) and r2 did not show a significantly better 
performance using the training set than those from using the test set, revealing 
that no overfitting did occur. In order to assess the feasibility of using in silico 
estimated fu values, the model output was compared to the output obtained by 
using the in vitro values. A correlation of r2=0.649 and 65% (training set) and 79% 
(test set) of Rb correct values within a 1.25 fold error were obtained. A slope 
statistically (p<0.05) lower than 1 (slope±CI95%=0.830±0.127) was observed. 
Further investigation revealed that this inaccuracy was due to the in silico 
underestimation of fu values for some drugs with high binding to proteins (fu>0.95). 
Nevertheless, the Rb prediction ability of the ANN model when tested using the 
validation set of data (Table 3.4) presented six out of seven drugs correctly 
predicted within the 1.25 fold error.  
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Discussion  
 
To our knowledge, this is the first systematic attempt to model the drug 
distribution within the blood. After reaching systemic circulation, drugs bind to 
blood constituents and a balance between different bound and free forms is 
established. In plasma, drugs may bind to different proteins. Albumin is considered 
the main transport protein for drugs, especially if they present an acidic behaviour 
(Kratochwil et al., 2004). Bases are usually bound to α1-acid glycoprotein, but can 
bind to albumin as well (Saiakhov et al., 2000). Lipoproteins are also known to 
transport drugs with high lipophilicity (Brocks et al., 2006; Colussi et al., 1999). 
Overall, this was quantified by the in vivo molecular descriptor fu. The amount of 
drug that is unbound in plasma may distribute to the cell fraction of the blood. 
Affinity to blood cells may be based on the drug lipophilicity, size and hydrogen 
bond capacity, as these are relevant parameters for cellular uptake by passive 
diffusion (Fujikawa et al., 2007). Drug charge is another important parameter as 
the cells present an overall negative charge. In order to describe these 
characteristics in the drugs, various types of molecular descriptors were 
considered. Some, namely Log P, Log S and pKa are physical properties 
estimated in silico. Ideally these data should have been determined in vitro, but the 
in silico models for these parameters all presented good prediction characteristics 
with errors close to the in vitro variability (Mannhold et al., 2008; Meloun et al., 
2007; Tetko et al., 2001). On the contrary, fu is a biological property and the in 
silico models did not present an optimal performance (Petrauskas et al., 2006). 
Therefore, in order to reduce variability and/or bias introduced by this parameter, 
only in vitro fu values were used in the regression process.    
In this work we used a drug dataset assembled from various published 
papers and textbooks. All compounds are drugs or drug-like organic molecules 
from different chemical series and the dataset includes acid, base, neutral and 
zwitterionic molecules. Molecules that are known to present a concentration 
dependent blood-to-plasma ratio, or that information on plasma binding was not 
available, were not included in the dataset. 
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Initially, we tried to model the blood-to-plasma ratio using a previously 
developed mechanistic approach (Rodgers and Rowland, 2006). This approach 
was reported to correctly predict 84% of the tissue-to-plasma water partition 
coefficients within a factor of 3. Assumptions were made that only plasma protein 
binding, dissolution in tissue water and partitioning of unbound unionised drug into 
neutral lipids and neutral phospholipids were the major interactions involved in 
tissue distribution. For this reason, drugs that presented a basic group with pKa 
values above 7 were not considered, as a significant proportion of the drug would 
be in an ionised cationic form at physiologic pH. In these cases an additional, but 
difficult to quantify, electrostatic interaction with the blood cells acidic 
phospholipids must be considered to improve prediction accuracy (Rodgers et al., 
2005a). Evaluation of the predictive ability of the model was in accordance with the 
previously published results for the tissue-to-plasma water partition coefficients. As 
in the original work, no significant bias was observed, but the relationship between 
observed and predicted values was not coincident to the line of unity revealing 
some underpredictability. This may indicate that the model underrates the drug 
distribution to the blood cells, but the use of experimentally determined pKa and 
Log P showed a slight improvement of predictability in the original work, and the 
same behaviour is expected to happen with our data.  
Since the mechanistic model was limited in the drug space and additional 
descriptors may be necessary to describe the drug distribution to the blood cells, 
we tried to develop a PLS regression using the complete dataset and all the 
molecular descriptors. The PLS regression is able to reduce dimensionality, 
especially important in situations where a large number of independent variables 
are involved. It is also a regression approach easily interpretable, allowing the 
identification of the most relevant parameters and the relationship between them 
(Wold et al., 2001). Evaluation of the observed vs predicted plot reveals that the 
PLS model overpredicts the lower log(CBC/Cp) values, but performs reasonably 
well with the remaining data. This is not too problematic as back transformation to 
Rb for these compounds results in predicted values ranging from 1.02 to 1.18 fold 
errors, within the previously accepted value of 1.25 fold error. The most relevant 
molecular descriptors are related to compound ionization and free drug in plasma. 
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As expected, fu is directly related to log(CBC/Cp) as more free drug will be available 
to distribute to the blood cells. Other relevant molecular descriptors directly related 
to log(CBC/Cp) are fi_B_74, fz_74, Var_fn, pKaacid and pKabase. These descriptors 
confirm some of the assumptions of the mechanistic model. Increase of the 
cationic, the zwitterionic and the neutral form are directly related to log(CBC/Cp). On 
the contrary, increase of the anionic form is inversely related to log(CBC/Cp) values. 
Aromaticity and size related descriptors are also inversely related to log(CBC/Cp). 
This suggests that the existence of rigid planar ring systems and increased size 
may constrain drug entry into the blood cells. Aromatic molecules are also less 
soluble and need to be solubilised in plasma by binding to plasma proteins 
(Votano et al., 2004), resulting in fewer molecules to be available to distribute to 
blood cells. The proposed ANN model provided better statistical results as 
compared to the PLS and mechanistic models (Table 3.3, Figure 3.1-C) which is in 
accordance to various QSAR studies where ANN models shown superiority over 
various other approaches (Sutherland et al., 2004).  Due to the “black-box” nature 
of this approach, interpretation of an ANN is frequently described as difficult, but 
one possible approach to overcome this issue is to find how input trends interact 
with output predictions. This was done by varying two inputs at a time, considering 
all the others constant with the median value for the corresponding descriptor.  
Figure 3.4-A presents the effect of pKaacid and pKabase on the ANN. In 
general, acids (pKabase = -1) present lower log(CBC/Cp) values than bases 
(pKaacid = 15), zwitterions and neutrals (pKaacid = -1 and pKabase = 15). Log(CBC/Cp) 
increases with increasing pKaacid, which seems to indicate that increasing the 
ionised fraction of the acid results in higher drug concentration in plasma. The 
value of log(CBC/Cp) also increases with increasing pKabase indicating that the 
ionised base, with positive charge, can bind to the blood cells. This is consistent 
with the negative charge attributed to blood cells. 
Figure 3.4-B presents the relationship between fu and Sv. As expected, 
increasing the unbound drug in plasma results in increasing log(CBC/Cp). This 
effect is partially reduced by the size of the molecule, as can be seen in the Sv 
axis.  
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Figure 3.4 – ANN interaction trends between the A) pKabase and pKaacid, B) fu and Sv, C) 
pKabase and Var_fn for basic molecules, and pKaacid and Var_fn for acidic molecules, in the 
log(CBC/Cp) prediction, maintaining all other descriptors constant as median values. 
 
Another easily interpretable parameter, Var_fn, was studied in bases 
(pKaacid = 15) and acids (pKabase = -1) separately. Since Var_fn is directly related 
to the pKa of the molecule, only molecules with pKa values within 6 to 9 will suffer 
the influence of the Var_fn parameter. Var_fn is not a significant parameter for 
bases (Figure 3.4-C), in agreement with the fact that the ionised base can bind by 
itself to the blood cells. For acids (Figure 3.4-C), on the contrary, Var_fn presents 
an influential effect, much in line with the pH partitioning hypothesis. The lower the 
Var_fn value, the more ionised drug will be outside the blood cells, and lower will 
be the log(CBC/Cp) value.  
The other molecular descriptors considered relevant by the ANN are 
topologic information indexes that can be considered as a quantitative measure of 
the lack of structural homogeneity or the diversity of a graph (Todeschini and 
Consonni, 2000). Although non empirical and difficult to interpret, these 
descriptors had shown to be able of effectively estimating the cerebrovascular 
penetration for a set of twenty-eight compounds (Basak et al., 1996). 
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To evaluate the prediction ability of the proposed methodologies an external 
validation was also performed with a set of seven drugs not used in the regression 
process. These drugs were not initially included since no in vitro values of fu were 
available. Although the use of in silico fu values clearly increases variability and 
degrades the prediction ability, the ANN was able to correctly predict the Rb value 
of six out of the seven validation drugs within a 1.25 fold error. 
In conclusion, models based on mechanistic equations, partial least 
squares, and artificial neural network methods were developed to predict the 
blood-to-plasma concentration ratio of drugs based in selected molecular 
descriptors. Statistical analysis of the training data set clearly indicates the 
superiority of the ANN model over the PLS regression. Comparison of the 
predictive ability on the test and validation set confirms this superiority. The use of 
this model may be an important tool in early drug discovery by providing a relevant 
pharmacokinetic parameter. This may help understanding whether the plasma 
pharmacokinetics are representative of the blood pharmacokinetics or not. 
Additionally, it may help to better characterise the in vitro / in vivo extrapolation of 
intrinsic clearances to in vivo hepatic clearances in PBPK modelling. 
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Introduction 
 
Undesirable pharmacokinetic properties are still one of the major reasons 
for drug failures and the low success rate of drug discovery programs (Singh, 
2006). Due to lack of reliable predictive models in early development phases, new 
drug entities are subjected to a large number of in vitro and animal in vivo tests 
before they are ultimately administered in man. During phase 1 clinical studies, 
development is frequently discontinued after a large number of data has already 
been produced. Due to cost, time and ethical reasons, the use of in silico methods 
based on this data to predict fundamental ADME (Absorption, distribution, 
metabolism and elimination) properties is increasing, and already plays a role in 
the early drug candidate selection (Richon, 2008). 
Hepatic clearance (CLH) is a major pharmacokinetic parameter, as it is 
related both to the drug elimination and to the drug oral bioavailability. Due to 
those two facts, and since it influences the dose and dose regime in man, it is a 
major factor for drug selection in the development phase of new drug candidates. 
Several methods exist to predict CLH in humans, namely interspecies extrapolation 
(Wajima et al., 2002), allometric scaling (Hu and Hayton, 2001), in vitro-in vivo 
Chapter 4. Prediction of the In Vitro Intrinsic Clearance 
Determined in Suspensions of Human Hepatocytes by Using 
Artificial Neural Networks 
100 Paulo J. P. A. Paixão, 2010 
 
correlations (Naritomi et al., 2003), physiologically-based in vitro-in vivo prediction 
(Ito and Houston, 2004) and in silico methods (Ekins et al., 2000). A recent review 
(Fagerholm, 2007) recommended that, of these, physiologically-based in vitro-in 
vivo prediction using hepatocytes intrinsic clearances (CLint), should be applied 
and improved. In this type of approach, the CLint value determined in human 
hepatocytes suspensions is used to predict the CLH in human after inclusion on a 
mathematical liver model with physiological parameters. The “well-stirred” model 
(Rowland et al., 1973) is one of the most used, due to its simplicity and reasonable 
results (Ito and Houston, 2004). In its original form, the “well-stirred” model 
emphasizes the relationship between the blood perfusion (Q), metabolic activity 
(Clint) and drug binding in blood (fu,B) in the hepatic clearance of drugs. However, 
inclusion of fu,B for all drugs often results in poor predictions mainly for basic, 
neutral and zwitterionic drugs and various authors proposed extrapolations without 
the inclusion of this parameter (Jacobson et al., 2007; Lau et al., 2002; McGinnity 
et al., 2004; Reddy et al., 2005).  
Some in silico methods are already being published with variable success 
(Chang et al., 2008; Ekins, 2003; Ekins and Obach, 2000; Jolivette and Ward, 
2005; Lee et al., 2007; Li et al., 2008; Schneider et al., 1999; Turner et al., 2004; 
Wajima et al., 2002; Zuegge et al., 2001). These could be divided into methods 
employing only in silico derived parameters or combining in vitro and in vivo data. 
The first class is extremely useful, as it would provide clearance prediction before 
the drug actually exists. Moreover, since in silico methods are, by nature, only the 
first line of drug selection, the type of parameter predicted should also play a role 
when developing an in silico method. For example, various methods exist that 
directly predict human CLH. Since estimation of the in vivo CLH is frequently made 
by considering that the CLH is equal to the in vivo non-renal clearance in man, this 
results in an overestimation of the CLH value. Another drawback in these types of 
modelling approaches is that prediction confirmation is only possible when the 
drug is administered to humans, leaving no room for “fine-tuning” during the 
development phase. 
In this study, a new in silico model was developed based on the CLint of 89 
drugs determined in vitro with suspensions of human hepatocytes by the substrate 
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depletion method in absence of added serum. Only in silico derived parameters 
were used, and an artificial neural network was optimized to relate these molecular 
descriptors to the in vitro data. The model applicability was tested, in a 
physiologically-based in silico-in vivo approach, with another 112 drugs from which 
a reliable estimation of the human in vivo CLH and the in vivo CLint determined by 
“well-stirred” model was possible. With this ANN model it is possible to provide 
estimates of CLint, which could be early validated in the pipeline process of new 
drug development and that, by using physiologically-based in silico-in vivo 
prediction, could be used to estimate the CLH itself. 
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Materials and Methods 
 
Data collection 
 
In vitro CLint values (Table 4.1) were obtained from published studies of 
drug metabolism in human hepatocytes using the substrate depletion method in 
absence of added serum. Drugs were randomly divided between a train (n = 71) 
and a test group (n = 18) used in the ANN optimization Process. An external 
validation group (n = 5) of data was also considered based on drugs not included 
in the train and test group from the study of Jacobson et al. (Jacobson et al., 
2007). In this study, although 2.5% of BSA was included in the incubation medium, 
no differences in CLint were described by the authors when BSA was not added to 
the incubation medium.  
 
Table 4.1 – In vitro CLint values collected in the literature. Values were determined 
in human hepatocytes suspensions using the substrate depletion method without 
the addition of serum in the incubation medium. 
Log In vitro CLint   
(µL/min/106 cells)  
Compounds Data A B C D E F G H I Ja) In silico  predicted
7-Hydroxycoumarin Train - - - - - - - - - 1.4 - - 1.37 
Acebutolol Train - - - - - - 0.26 - - - - - 0.2 
Acetaminophen Train -0.11 - - - - - - - - - - - -0.13 
Antipyrine Train - -0.33 - - - - - - - - - - -0.36 
Atenolol Train - - - - - - -1.00 - - - - - -0.95 
Benzydamine Train - - - 1.31 - - - - - - - - 1.13 
Bepridil Train - - - - - - 0.30 - - - - - 0.45 
Betaxolol Train - - - - - - 0.40 - - - - - 0.37 
Bisoprolol Test - - - - - - 0.20 - - - - - 0.01 
Bosentan Train - - - - - 0.18 - - - - - - 0.13 
Bromocriptine Train - - - - - - 1.57 - - - - - 1.8 
Bufuralol Train - - - - - - - - - 0.85 - - 1.09 
Caffeine Train - 0.15 - - - - 0.52 - - - - - 0.46 
Carbamazepine Train - - - - -0.10 - 0.30 - - - - - 0.18 
Carvedilol Train - - - - - - 1.54 - - - - - 1.37 
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Table 4.1 – (Continued) 
Log In vitro CLint   
(µL/min/106 cells)  
Compounds Data A B C D E F G H I Ja) In silico  predicted
Cerivastatin Val - - - - - - - - - - - 0.23 0.7 
Cetirizine Train - - - - - - -1.00 - - - - - -0.95 
Chlorpheniramine Train - - - - - - 0.45 - - - - - 0.95 
Chlorpromazine Test - 1.04 - - - - - - - - 0.71 - 1.36 
Chlorprothixene Train - 1.15 - - - - - - - - - - 1.43 
Cimetidine Train - - - - - - 0.08 - - - - - 0.15 
Clozapine Test - - - - - - 0.78 - - - - - 1.06 
Codeine Train - - - - - - 1.36 - - - - - 1.46 
Desipramine Train - 1.04 - - - - 0.48 - - - - - 0.92 
Dextromethorphan Test - - - - - - 0.88 1.20 1.18 - - - 1.03 
Diazepam Train 0.13 0.15 - - - - -0.52 -0.05 -0.05 0.30 - - -0.02 
Diclofenac Test - - - - - - - 1.67 1.64 0.90 - - 0.42 
Diltiazem Train 1.37 0.67 - - - - 0.95 1.11 1.11 - - - 1.07 
Diphenhydramine Train - - - - - - 0.78 - - - - - 0.7 
Doxepin Train - - - - - - 1.11 - - - - - 0.78 
Ethinylestradiol Test - - - - - - 0.85 0.85 0.70 - - - 0.29 
Famotidine Train - - - - - - -1.00 - - - - - -1.03 
FK079 Train 1.11 - - - - - - - - - - - 0.98 
FK1052 Train 0.41 - - - - - - - - - - - 0.38 
FK480 Train 0.51 - - - - - - - - - - - 0.64 
Fluoxetine Train - - - - - - 0.00 - - - - - -0.11 
Furosemide Test - -2.00 - - - - - - - - - - -1.37 
Gemfibrozil Train - - - - - - - 1.38 1.30 - - - 1.3 
Granisetron Train - - - - - - 0.95 - - - - - 0.41 
Ibuprofen Train - 0.62 - - - - - - - - - - 0.67 
Imipramine Train - 0.91 - - - - 0.90 - 0.85 - - - 1.15 
Irbesartan Val - - - - - - - - - - - 0.81 -0.28 
Isradipine Train - - - - - - 1.26 - - - - - 0.79 
Ketoprofen Test - - - - - - - 0.60 0.00 - - - -0.23 
Lidocaine Train - - - - - - - - - - 1.13 - 0.88 
Lorazepam Test - -0.57 - - - - 0.00 - - - - - 0.04 
Mephenytion Val - - - - - - - - - - - 0.32 -0.56 
Methylprednisolone Train - 0.99 - - - - - - - - - - 1.14 
Methylumbelliferone Val - - - - - - - - - - - 1.51 1.14 
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Table 4.1 – (Continued) 
Log In vitro CLint   
(µL/min/106 cells)  
Compounds Data A B C D E F G H I Ja) In silico  predicted
Metoprolol Train - - - - - - 0.85 0.85 1.00 - 0.81 - 0.76 
Midazolam Train - 0.85 - - - 1.10 1.15 1.15 1.04 0.90 - - 0.80 
Morphine Train - - - - - - 1.38 - - - - - 1.38 
Nadolol Test - - - - - - -1.00 - - - - - -0.88 
Naloxone Test - 1.45 - - - 1.90 2.33 - - - - - 1.52 
Naproxen Train - - - - - - - 0.70 0.48 - - - 0.98 
Nifedipine Train - 0.89 - - - - 0.75 - - - - - 0.93 
Nitrendipine Test - - - - - - 0.87 - - - - - 1.03 
Nortriptyline Train - - - - - - - - - - 0.44 - 0.46 
Omeprazole Train - - - - - - 0.23 - - - - - 0.24 
Ondansetron Train - - - - - - 0.15 - - - - - 0.70 
Oxazepam Train - 0.30 - - - - - - - - - - 0.19 
Oxyprenolol Val - - - - - - - - - - - 0.34 1.03 
Phenacetin Train - - - - - - - - - 0.88 - - 1.02 
Phenytoin Train - - - - 0.47 - - - - - - - 0.57 
Pindolol Test - - - - - - 0.45 - - - - - 0.58 
Pirenzepine Train - - - - - - -1.00 - - - - - -0.94 
Prazosin Train - - - - - - 0.36 - - - - - 0.58 
Prednisone Train - 0.99 - - - - - - - - - - 0.88 
Procainamide Train - - - - 0.11 - - - - - - - 0.09 
Propafenone Test - - - - - - - - - - 1.76 - 0.54 
Propofol Train - - - - - - 2.03 2.03 1.96 - - - 1.52 
Propranolol Test - 1.00 - - - - 1.00 1.18 1.28 - 1.11 - 0.98 
Quinidine Train - - - - 0.74 - - - - - - - 0.51 
Quinotolast Train -2.00 - - - - - - - - - - - -1.92 
Ranitidine Train - - - - - - 0.00 - - - - - 0.02 
Ritonavir Train - - - - - - 0.32 - - - - - 0.31 
Scopolamine Train - - - - - - 0.85 - - - - - 1.02 
Sildenafil Train - 0.72 - - - - - - - - - - 1.03 
Sulpiride Train - -2.00 - - - - - - - - - - -1.83 
Temazepam Test - - - - - - 0.30 - - - - - -0.14 
Tenoxicam Train - 0.41 - - - - - - - - - - 0.18 
Terbutaline Train - -2.00 - - - - - - - - - - -2.00 
Theophylline Test - -0.28 - - -0.32 - - - - - - - -0.56 
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Table 4.1 – (Continued) 
Log In vitro CLint   
(µL/min/106 cells)  
Compounds Data A B C D E F G H I Ja) In silico  predicted
Tolbutamide Train - 0.20 - - - - - - - - -0.25 - -0.07 
Triazolam Train - - - - - - 0.00 - - - 0.34 - 0.17 
Triprolidine Train - - - - - - 0.63 - - - - - 0.42 
Troglitazone Train 1.32 - - - - - - - - - - - 1.40 
Valproic acid Test - - - - -0.31 - - - - - - - 0.67 
Verapamil Train - 1.20 - - - - 1.26 1.62 1.63 - - - 1.54 
Vinpocetine Train - - 2.41 - - - - - - - - - 1.76 
Warfarin Train - 0.04 - - - - - - - - - - 0.09 
Zidovudine Train 0.51 - - - - - - - - - - - 0.41 
Zileuton Train - - - - - - 0.32 - - - - - 0.45 
Zolpidem Train - - - - - - - - - - 0.56 - 0.62 
 
a) 2.5% of BSA in the incubation medium. 
Data set A-J were obtained from references, (Naritomi et al., 2003), (Lau et al., 2002), (Szakacs et al., 2001), 
(Fisher et al., 2002), (Bachmann et al., 2003), (Blanchard et al., 2005), (McGinnity et al., 2004), (Floby et al., 
2004), (Reddy et al., 2005) and (Jacobson et al., 2007) respectively. 
 
 In order to test the ability of the in silico model to predict in vivo intrinsic 
clearances, two additional data sets were also obtained (table 4.2 and table 4.3).  
 
Table 4.2 – In vivo pharmacokinetic data for the drugs included in the ANN 
model building and used to evaluate the ability of the in vitro hepatocytes 
suspensions in estimating the in vivo Clint and CLH by the “well-stirred” 
model. P indicates data determined in plasma; Bl data determined in blood; F 
is the drug oral bioavailability; Frenal is the percentage of parent drug 
eliminated in urine; Rb is the blood to plasma concentration ratio of the drug; 
Fp is the percentage of drug bound to plasma proteins; A acid, B basic, N 
neutral and Z zwitterionic drug and pH 7.4. 
 CL F  (%) 
Frenal 
(%) 
Fp  
(%) 
CLtotal  
(ml.min-1.kg-1) Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1)  
CLH  
(ml.min-1.kg-1) 
Acetaminophen P 88 30 20 5 1.04 B 4.8 2.40e 
Atenolol P 58 94 5 2.4 1.07d B 2.24 0.13 
Carvedilol P 25 2 95 8.7 0.72 B 12.12 11.88 
Cimetidine P 60 62 19 8.3 0.97d B 8.56 3.25 
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Table 4.2 – (Continued) 
 CL F  (%) 
Frenal 
(%) 
Fp  
(%)  
CLtotal  
(ml.min-1.kg-1)  Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1)  
CLH  
(ml.min-1.kg-1)  
Clozapine P 55 1 95 6.1 1.13 B 5.41 5.36 
Diazepam P 100 1 98.7 0.38 0.58d N 0.66 0.65 
Diclofenac P 54 1 99.5 4.2 0.56 A 7.54 7.46 
Diltiazem P 38 4 78 11.8 1.00d B 11.8 11.33 
Diphenhydramine P 72 1.9 78 6.2 0.65d B 9.54 5.60e 
Furosemide P 61 66 98.6 2 0.55 A 3.61 1.23 
Gemfibrozil P 95 1 97 1.7 0.55 A 3.08 1.00e 
Granisetron P 60 16 65 11 0.86 B 12.81 8.00e 
Lidocaine P 0.35 2 70 9.2 0.84d B 10.95 10.73 
Lorazepam P 93 1 91 1.1 1.05 N 1.05 1.04 
Methylprednisolone P 82 4.9 78 6.2 0.78 N 7.94 3.60e 
Metoprolol P 38 10 11 15 1.00d B 15 13.5 
Midazolam P 44 1 98 6.6 0.80d N 8.25 8.17 
Morphine P 24 4 35 24 0.95 B 25.22 15.20e 
Naloxone P 2 0 30c 22 1.22d B 18.03 18.03 
Nifedipine P 50 0 96 7 1.63 N 4.28 4.28 
Nortriptyline P 51 2 92 7.2 1.50d B 4.8 4.7 
Ondansetron P 62 5 73 5.9 0.83d B 7.11 6.75 
Prazosin P 68 4 95 3 0.70d N 4.29 4.11 
Propranolol Bl 26 0.5 87 16 0.89d B 16 14.80e 
Quinidine P 80 18 87 4.7 0.88 B 5.31 4.36 
Ranitidine P 52 69 15 10.4 1.03 B 10.11 3.14 
Sildenafil P 38 0 96 6 0.99 N 6.04 6.04 
Valproic Acid P 100 1.8 93 0.14 0.64d A 0.22 0.21 
Zidovudine P 63 18 25 26 1.06 N 24.5 7.40e 
Zolpidem P 72 1 92 4.5 0.76d N 5.92 5.86 
 
Values were collected in (Goodman et al., 2006) except a) (Ritschel, 2000) b) (Rowell et al., 1980) c) 
(Garrett et al., 1985) and d) were in vitro value from (Paixao et al., 2008). For data in e) CLH was 
determined according to equation 4.2. Values in f) were limited to 19.5 ml.min-1.kg-1. 
 
These consisted of drugs with human intravenous in vivo pharmacokinetic 
data that were available (Goodman et al., 2006). In these cases, data on 
intravenous total plasma Clearance, free fraction in plasma, fraction of drug 
eliminated by the kidneys, as well as oral bioavailability were collected. 
Experimentally determined values of the drug blood-to-plasma concentration ratio 
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(Rb) were used whenever available, or calculated according to Paixão et. al. 
(Paixao et al., 2008). This model provided predictions of Rb with a percentage of 
correct values within a 1.25-fold error of 86%, 84% and 87% in the train, test and 
validation data set respectively. 
 
Table 4.3 – In vivo pharmacokinetic data for the drugs not included in the train 
process and used to evaluate the ANN model applicability in estimating the in vivo 
Clint and CLH by the “well-stirred” model. P indicates data determined in plasma; Bl 
data determined in blood; F is the drug oral bioavailability; Frenal is the percentage of 
parent drug eliminated in urine; Rb is the blood to plasma concentration ratio of the 
drug; Fp is the percentage of drug bound to plasma proteins; A acid, B basic, N 
neutral and Z zwitterionic drug and pH 7.4. 
 CL F (%) 
Frenal 
(%)  
Fp  
(%)  
CLtotal  
(ml.min-1.kg-1) Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1)  
CLH  
(ml.min-1.kg-1)  
In Silico 
Pred LogCLint 
(µL/min/106 cells)
Acyclovir P 30 75 15 6.19 1.08 N 5.75 1.44 0.53 
Alendronate P 7 45 78 1.11 1.70 Z 0.65 0.36 -2.54 
Alfentanil P - 1 92 6.7 0.63d) N 10.63 10.53 -0.14 
Allopurinol P 53 12 2a) 9.9 1.09 N 9.11 8.02 -0.49 
Alprazolam P 88 20 71 0.74 0.78d) N 0.95 0.76 0.49 
Amikacin P - 98 4 1.3 0.97 B 1.34 0.03 -2.93 
Amiodarona P 46 0 99.9 1.9 0.73d) B 2.6 2.6 1.08 
Amitriptyline B 48 2 95 11.5 0.86d) B 11.5 10.40e) 0.93 
Amlodipine P 74 10 93 5.9 1.20 B 4.91 4.42 -0.09 
Amoxicillin P 93 86 18 2.6 1.04 A 2.51 0.35 -0.06 
Aprepitant P 65 0 95 1.29 0.6 N 2.14 2.14 1.11 
Atropine P - 57 18 8 0.99 B 8.12 3.49 0.16 
Azathioprine P 60 2 30a) 57 1.05 N 54.23 8.00e) 1.07 
Bupivacaine Bl - 2 95 7.1 0.73d) B 7.1 6.96 0.25 
Buprenorphine P - 0 96 13.3 1.00 B 13.3 13.3 2.04 
Buspirone P 3.9 0 95 28.3 0.62 B 45.99 19.22e) 0.35 
Butorphanol P 17 1.9 80 40 1.90 B 21.03 16.60e) -1.12 
Calcitriol P 61 10 99.9 0.43 0.55 N 0.78 0.7 -0.02 
Candesartan P 42 52 99.8 0.37 0.55 A 0.67 0.32 0.53 
Cefazolin P 90 80 89 0.95 0.56 A 1.7 0.34 0.44 
Cefepime P - 80 18 1.8 0.74 A 2.43 0.49 -2.19 
Cefixime P 47 41 67 1.3 0.62 A 2.11 1.25 -2.22 
Ceftazidime P - 84 21 1.92 0.72 A 2.68 0.43 -1.54 
Celecoxib P - 3 97 6.6 0.57 N 11.61 11.26 -0.44 
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Table 4.3 – (Continued) 
 CL F (%) 
Frenal 
(%)  
Fp  
(%)  
CLtotal  
(ml.min-1.kg-1) Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1) 
CLH  
(ml.min-1.kg-1)  
In Silico 
Pred LogCLint 
(µL/min/106 cells)
Cephalexin P 90 91 14 4.3 1.02 A 4.21 0.38 0.27 
Chlorthalidone Bl 64 65 75 0.04 0.73d) N 0.04 0.01 -0.42 
Cinacalcet P 20 0 95 18 0.64 B 28.28 16.00e) 0.18 
Ciprofloxacin P 60 50 40 7.6 1.07 Z 7.09 3.55 -0.37 
Clindamycin P 87 13 93.6 4.7 0.76 B 6.15 2.60e) 1.11 
Clonidine P 95 62 20 3.1 1.04 B 2.97 1.13 1.33 
Cyclophosphamide P 74 6.5 13 1.3 1.06 N 1.22 1.14 -0.1 
Dapsone P 93 15 73 0.6 1.04d) N 0.58 0.49 -2.85 
Dicloxacillin P 50 60 95.8 1.6 0.55 A 2.89 1.16 1.66 
Didanosine P 38 36 5 16 1.08 N 14.85 9.5 0.14 
Docetaxel P - 2.1 94 22.6 0.55 N 40.93 19.50f) 2.12 
Dofetilide P 96 52 64 5.23 0.72 B 7.3 3.5 -0.11 
Doxycycline P 93 41 88 0.53 1.70 Z 0.31 0.18 -2.43 
Entacapone P 42 0 98 10.3 0.55 A 18.66 11.60e) 0.87 
Ethambutol P 77 79 18 8.6 0.96 B 8.98 1.89 0.31 
Etoposide P 52 35 96 0.68 0.55 N 1.23 0.8 1.57 
Fentanyl P - 8 84 13 0.97d) B 13.4 12.33 0.59 
Finasteride P 63 1 90 2.3 0.56 N 4.12 4.08 0.91 
Flecainide P 70 43 61 5.6 0.89 B 6.3 3.59 -0.23 
Fluconazole P 90 75 11 0.27 1.06 N 0.26 0.06 -1.06 
Flumazenil P 16 0.2 40 9.9 1.00d) N 9.9 9.88 1 
Fluorouracil P 28 10 10 16 1.09d) N 14.62 13.16 1.51 
Fluphenazine P 2.7 0 92b) 10 0.69 B 14.55 14.55 0.66 
Foscarnet P 9 95 15 1.6 1.27 A 1.26 0.06 -2.91 
Fulvestrant P - 1 99 9.3 1 N 9.3 9.21 0.64 
Gabapentin P 60 66 3 1.6 1.1 Z 1.46 0.49 -0.36 
Galantamine P 95 2 18 5.7 1.04 B 5.48 1.00e) -0.68 
Ganciclovir P 4 91 1 3.4 1.08 N 3.16 0.28 -0.98 
Gentamicin P - 90 10 1.52 1 B 1.52 0.15 -2.93 
Glimepiride P 100 0.5 99.5 0.62 0.55 A 1.12 1.11 0.92 
Glyburide P 90 0 99.8 1.3 0.56 A 2.34 2.34 0.65 
Hydrochlorothiazide P 71 95 58 4.9 1.70d) N 2.88 0.14 0.17 
Hydromorphone P 42 6 7.1 14.6 1.07 B 13.62 12.8 1.18 
Imatinib P 98 5 95 3.3 0.64 B 5.17 0.40e) 1.19 
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Table 4.3 – (Continued) 
 CL F (%) 
Frenal 
(%)  
Fp  
(%)  
CLtotal  
(ml.min-1.kg-1) Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1)  
CLH  
(ml.min-1.kg-1)  
In Silico 
Pred LogCLint 
(µL/min/106 cells)
Indomethacin P 100 15 90 1.4 0.56 A 2.51 2.14 1.36 
Irbesartan P 70 2.2 90 2.12 0.64 Z 3.34 3.26 -0.28 
Isosorbide Dinitrate P 22 1 28 46 1 N 46.06 15.60e) 0.99 
Isosorbide-5-
Mononitrate P 93 5 0 1.8 1.08 N 1.67 1.59 -1.01 
Lamivudine P 86 50 36 4.95 1.06 N 4.67 2.33 0.41 
Lansoprazole P 81 1 97 6.23 0.56 N 11.17 3.80e) -0.03 
Letrozole P 99.9 3.9 60 0.58 0.92 N 0.63 0.61 0.12 
Levetiracetam P 100 66 10 0.96 1.07 N 0.89 0.3 -0.63 
Levofloxacin P 99 70 30 2.52 1.05 Z 2.41 0.72 1.36 
Linezolid P 100 35 31 2.1 0.73 A 2.86 1.86 0.01 
Losartan P 35.8 12 98.7 8.1 0.55 A 14.68 12.92 0.6 
Meloxicam P 97 1 99.4 0.15 1.22 A 0.12 0.12 -0.3 
Melphalan P 71 12 90 5.2 0.96d) Z 5.42 4.77 0.96 
Meperidine P 52 5 58 17 0.87d) B 19.54 9.60e) 0.79 
Mercaptopurine P 12 22 19 11 1.2 N 9.2 7.18 -2.71 
Metformin P 52 99.9 0 7.62 1.04 B 7.33 0.01 -2.91 
Methadone P 92 24 89 1.7 0.75d) B 2.27 1.60e) 0.85 
Methotrexate P 70 81 46 2.1 0.71 A 2.94 0.56 -2.92 
Metoclopramide P 76 20 40 6.2 0.96 B 6.44 4.80e) 0.96 
Metronidazole P 99 10 11 1.3 1.07 N 1.21 1.09 0.75 
Montelukast P 62 0 99 0.7 0.55 A 1.27 1.27 1.48 
Moxifloxacin P 86 21.9 39.4 2.27 1.05 Z 2.16 1.69 0.76 
Nalmefene P 40 9.6 34 15 1.11 B 13.54 12.24 0.99 
Neostigmine P - 50 0a) 16.7 1.07 N 15.6 7.8 -1.14 
Nitrofurantoin P 90 47 62 9.9 0.76d) A 13.03 2.00e) 1.22 
Oxycodone P 42 19 45 12.4 1.03 B 12.04 9.75 1.59 
Pancuronium P - 67 7 1.8 1.02 N 1.77 0.58 1.56 
Phenobarbital P 100 24 51 0.06 0.86d) N 0.07 0.05 -0.55 
Pravastatin P 18 47 45 13.5 0.55d) A 24.55 13.01 -1.02 
Quetiapine P 9 1 83 19 0.9 B 21.11 18.20e) 1.14 
Quinine P 76 16 90 0.9 0.91 B 0.99 0.83 0.49 
Repaglinide P 56 1 97.4 9.3 0.55 A 16.85 8.80e) 0.8 
Riluzole P 64 1 98 5.5 1.7 N 3.24 3.2 1.74 
Risedronate P 1 87 24 1.5 1.07 A 1.4 0.18 -2.91 
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Table 4.3 – (Continued) 
 CL F (%) 
Frenal 
(%)  
Fp  
(%)  
CLtotal  
(ml.min-1.kg-1) Rb 
Drug 
Class
CLblood 
(ml.min-1.kg-1) 
CLH  
(ml.min-1.kg-1)  
In Silico 
Pred LogCLint 
(µL/min/106 cells)
Risperidone P 66 3 89 5.4 0.67d) B 8.06 7.82 1.2 
Rizatriptan P 47 28 14 12.3 1.04 B 11.85 8.53 0.24 
Rocuronium P - 17 25 4.25 1 N 4.26 3.54 1.46 
Ropivacaine P - 1 92 6.3 0.93 B 6.81 6.74 0.49 
Sulfamethoxazole P 100 14 53 0.31 0.79 A 0.39 0.34 -0.96 
Sumatriptan P 14 22 17.5 22 1.03 B 21.37 16.67 0.29 
Tamsulosin P 100 12.7 99 0.62 0.55d) B 1.13 0.98 0.87 
Tegaserod P 11 0 98 18 0.72 B 25.04 17.80e) -0.97 
Tenofovir P 25 82 1 2.6 1.05 A 2.47 0.44 -2.75 
Terazosin P 82 12.5 92 1.15 0.84 N 1.37 1.2 0.43 
Tetracycline P 77 58 65 1.67 1.7 Z 0.98 0.41 -2.29 
Timolol P 61 8 10 7.7 0.87 B 8.88 7.80e) 0.11 
Tramadol P 70 20 20 8 1.03 B 7.75 6.2 0.34 
Trazodone P 81 1 93 2.1 0.81 N 2.61 2.58 -0.24 
Trimethoprim P 63 63 37 1.9 1.03 N 1.84 0.68 0.47 
Valsartan P 23 29 95 0.49 0.55 A 0.89 0.63 0.42 
Vecuronium P - 20 69 6.4 0.97 N 6.6 5.28 1.37 
Vinorelbine P 27 11 87 21 0.58 B 36.34 14.60e) 2.11 
Zaleplon P 31 1 60 15.7 0.99 N 15.84 13.80e) 0.55 
Ziprasidone P 59 1 99.9 11.7 0.81 B 14.52 8.20e) 1.27 
 
Values were collected in (Goodman et al., 2006) except a) (Ritschel, 2000) b) (Rowell et al., 1980) c) (Garrett et 
al., 1985) and d) were in vitro value from (Paixao et al., 2008). For data in e) CLH was determined according to 
equation 4.2. Values in f) were limited to 19.5 ml.min-1.kg-1. 
 
In Silico Calculation of the Molecular Descriptors 
 
The following methodology was used for the in silico descriptors: SMILES 
notation of each molecule was obtained using the on-line PubChem Compound 
database (http://www.ncbi.nlm.nih.gov). Ionization descriptors (pkaacid; pkabase), 
lipophilicity (Log P) and water solubility (Log S) were obtained using the on-line 
ALOGPS 2.1 program (Tetko and Bruneau, 2004). For drugs without an acid 
ionisable group, a value of 15 was attributed to pKaacid. For drugs without a basic 
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ionisable group, a value of -1 was attributed to pKabase. The remaining descriptors, 
related to size, compactness, lipophilicity and others, were obtained from the on-
line E-Dragon 1.0 software using CORINA to convert the SMILES notation to the 
3D representation of the molecule (Tetko et al., 2005). A total of 233 molecular 
descriptors were calculated, consisting of 10 molecular properties, 48 
constitutional descriptors, 73 topological descriptors, 22 geometrical descriptors, 
47 information indices and 33 WHIM descriptors.  
 
ANN Model building 
 
The Artificial Neural Network (ANN) non-linear regression was performed 
using the backpropagation neural modelling system QNet for Windows v.2000 
build 751 (Vesta Services inc., USA) and an in-house developed Microsoft Excel® 
VBA routines for process automation. CLint values were log transformed and 
randomly divided between a train (n = 71) and a test group (n = 18). More than 
one CLint experimental value was available for some drugs. In these cases, all 
values were considered but with a weighting factor of 1/n being n the number of 
independent determinations of CLint for the individual drug. Both the Input and 
output variables were normalised, and a sigmoid transfer function was used in all 
connections. Early stopping based on the degradation of the root mean square 
error (RMS) of the normalised data in the test group was used to avoid over fitting. 
Each network was started 20 times with random initial values to circumvent 
convergence to local minima.  
Network optimization was performed in a two step process. The first step 
consisted of the reduction of the molecular descriptors space. This was initially 
done by removing highly correlated (r > 0.90) descriptors, allowing the removal of 
molecular descriptors with information contained within another descriptor. Then, 
an ANN with a network architecture of 1 hidden layer with 3 hidden neurons was 
optimized for each of the molecular descriptors class, and the relevance of each 
descriptor within each class of molecular descriptors was tested against the 
percent contribution for the final output of a random input variable, allowing the 
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removal of molecular descriptors that were uncorrelated with the output variable. 
Finally a pruning procedure was undertaken, using also a network architecture of 1 
hidden layer with 3 hidden neurons and including all the remaining molecular 
descriptors. At the end of each optimisation, the percent contribution for the final 
output was calculated to all descriptors and the descriptor presenting the worst 
value was removed. This procedure was repeated until a significant degradation of 
the RMS with a descriptor removal was observed.  
The second step consisted of the optimisation of the network architecture 
for the most relevant molecular descriptors. Several networks were made varying 
the number of hidden layers (1 to 3) and the number of hidden neurons (1 to 5). 
 
Model applicability 
 
Typically, in vitro CLint data determined in human hepatocytes suspensions 
is used to predict the in vivo CLH as this is a major parameter in order to 
characterize the drug elimination and bioavailability in man. For that purpose, in 
vitro CLint data is introduced in a mathematical liver model, such as the “well-
stirred” model, and used to predict the human CLH value. With the same purpose, 
we tested the ability of the ANN model to predict both the in vivo CLint and the in 
vivo CLH using the drugs from table 4.2 and table 4.3. Since predictive errors by 
both the in vitro data and the “well-stirred” model were expected, drugs from table 
4.2 that were present in the training and test data sets of table 4.1 were used to 
test the ability of the in vitro data to predict the in vivo CLint and the in vivo CLH by 
using the “well-stirred” model. The 112 drugs from table 4.3 were effectively used 
to test the ANN model performance in the same situation. 
The in vivo CLH values from table 4.2 and 4.3 drugs were determined by 
using equation 4.1 (Naritomi et al., 2003),  
 
( )renal
b
plasma
total
H fR
CLCL −⋅= 1        (4.1) 
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This equation assumes that total blood clearance, determined by the ratio 
between the described total plasma clearance ( plasmatotalCL ) to the drug blood-to-
plasma concentration ratio (Rb), is the sum of Hepatic and Renal Clearance the 
last being determined by using the fraction of drug eliminated by the kidneys 
( renalf ). 
Some drugs may have other non renal elimination routes besides the 
hepatic one. In these cases, it is expected that CLH determined by equation 4.1 
would be overpredicted. To minimise this, in vivo CLH was also determined by 
equation 4.2 (Iwatsubo et al., 1997), 
 
( )oralHH FQCL −⋅= 1         (4.2) 
 
This equation assumes that oral bioavailability ( oralF ) is only a result of the 
first pass-effect in the liver, allowing the determination of the liver extraction ratio 
(EH) and the CLH by multiplying EH with the hepatic blood flow rate (QH) with a 
value of 20 ml.min-1.kg-1. Although equation 4.2 could also provide overpredicted 
values for CLH, in theory these would be the maximum possible values for this 
parameter. For this reason, when comparing CLH determined by equation 4.1 to 
the value obtained with equation 4.2, if the first is bigger the latter prevails. 
The in vivo CLint values were determined by using the “well-stirred” liver 
model rearranged in equation 4.3, 
 
( )HHBu
HH
ClQf
ClQCL −⋅
⋅=
,
int        (4.3) 
 
with the previously determined in vivo CLH and the free fraction of drug in blood 
(fu,B) determined by the ratio between the free fraction of drug in plasma (fu) by the 
drug blood-to-plasma concentration ratio (Rb). Hepatocellularity was considered to 
be 107 × 106 cell/g liver (Wilson et al., 2003) and it was also assumed that liver 
weighed 20 g/kg of body weight in order to scale the in silico CLint values from 
unities of µL/min/106 cells to ml.min-1.kg-1. 
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Statistical analysis 
 
Correlation between the predicted and observed values was determined by 
means of the Pearson correlation coefficient (r) for the train and test groups for the 
log(CLint) data. In order to assess the precision and bias of the network, root mean 
squared prediction error (RMSE) and mean error (ME) were also estimated by 
using the following equations. 
 
( )
N
ClCl
RMSE obspred∑ −= 2intint       (4.4) 
 
( )
N
ClCl
ME obspred∑ −= intint        (4.5) 
 
Percentage of correct values within a 2-fold error (difference of log predicted to log 
observed values outside the interval -0.3 to 0.3) was determined in order to assess 
the quantitative ability of the network. Additionally, percentage of correct values 
within a 10-fold error (difference of log predicted to log observed values outside 
the interval -1 to 1) was also determined in order to assess the qualitative ability of 
the network. 
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Results  
 
ANN Model building 
 
Optimisation of the ANN model was made as described under methods. 
Regarding the reduction of the molecular descriptors space, the removal of 
correlated descriptors reduced the number of descriptors to 92. The next two 
procedures were preformed using an ANN with 3 hidden neurons in 1 hidden 
layer. This ANN structure was chosen as a compromise between simplicity, in 
order to avoid over parameterization and memorization, and complexity to allow an 
adequate learning ability of the network. To escape local minima each network 
was run 20 times with random initial values and learning was early-stopped based 
on the degradation of test RMS error to avoid memorisation. After 20 runs, the 
network with the lower average test RMS error was kept, and the relative 
contribution of each input on the log(CLint) prediction was established using the 
“input node interrogator” option in QNet. In this option, inputs contribution are 
determined by cycling each input for all training patterns and computing the effect 
on the network’s output response. Of the 92 non correlated descriptors, 43 were 
considered non relevant, since their input contribution was equal or inferior to a 
random input and were also removed. Finally, by the pruning procedure described 
under methods, it was considered that 21 molecular descriptors were needed to 
characterise the output response, as a degradation of the test RMS error was 
observed when further removals were undertaken. The final model was 
constructed with the 21 molecular descriptors presented in table 4.4. Based on 
these descriptors, a network architecture optimisation was pursued using a brute 
force approach. In order to maintain a practical computational time, the network 
architectural space was swept between 1 to 3 hidden layers and 1 to 5 hidden 
neurons by layer. Additionally, the ratio between the number of patterns to the 
number of connections was maintained above 1 in order to reduce the ability of the 
network to memorise the data and avoid overfitting (So and Richards, 1992; 
Turner et al., 2004). 
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Table 4.4 – Summary of the 21 molecular descriptors used in the ANN 
model 
Molecular 
Descriptor Description  
Molecular 
Descriptor Description 
AMW Average Molecular Weight  PJI2 2D Petitjean Shape Index 
BAC Balaban Centric Index  PW3 Randic Shape Index Path/Walk 3 
Gm 
G Total Symmetry Index  
Weighted By Atomic 
Masses 
 PW5 Randic Shape Index Path/Walk 3 
HNar Narumi Harmonic Topological Index  Ram Ramification Index 
Hy Hydrophilic Factor  RBN Number Of Rotable Bonds
IC4 
Information Content Index 
(Neighborhood Symmetry 
Of 4-Order) 
 SIC2 
Structural Information 
Content (Neighborhood 
Symmetry Of 2-Order) 
LogP Oil:Water Partitioning Coefficient  SPI Superpendentic Index 
Me 
Mean Atomic Sanderson 
Electronegativity (Scaled 
On Carbon Atom) 
 TI1 Second Mohar Index 
Ms Mean Electrotopological State  Tot_Fn Fraction Of Neutral Drug 
MSD Mean Square Distance Index   TPSA(NO) 
Topological Polar Surface 
Area (No) 
nCIR Number Of Circuits    
 
Detailed information of the presented molecular descriptors may be obtained in (Todeschini and 
Consonni, 2000). 
 
The best neural network presented an architecture of 21-3-2-2-1 and its 
performance is presented in figure 4.1 and table 4.5. The model produced good 
correlations both in the training and test groups. Additional statistical comparison 
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of the ANN for the training and test groups revealed a similar behaviour, either in 
RMSE (precision of the predicted values) and ME (bias in the predicted values), 
indicating that overfitting was not significant. Similar values were also obtained 
when considering the quantitative and qualitative ability of the network. An Y-
scrambling analysis was also performed, by randomly permuting the output values 
in the training data set, and no statistically significant models were achieved 
(Figure 4.2), indicating that the occurrence of chance correlations was not present. 
 
 
Figure 4.1 – Plot of the in vitro observed vs in silico predicted log(CLint) values for the 
ANN model. Solid line represents the line of unity and the dashed lines the ±1 log 
tolerance value. Closed marks represent drugs that were included in the train set. Open 
marks are indicative of drugs in the test set. Cross marks represent drugs in the external 
validation group. 
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Table 4.5 – Statistical evaluation of the performance of the ANN model 
to predict in vitro CLint values based on the molecular descriptors for 
the train and test data. 
  RMSE ME Correlation 
% within 10-fold 
difference 
% within 2-fold 
difference 
Train 0.236 -0.001 0.953 100 79 
Test 0.544 -0.173 0.804 91 53 
Validation 0.747 -0.233 0.315 80 0 
 
 
Figure 4.2 – Evaluation of the occurrence of chance correlations by a y-randomization 
test. Open mark indicates the real data performance. Close marks indicates the model 
performance when the in vitro CLint values in the train data set were randomly permuted in 
their position. 
 
Evaluation of the ANN performance in the external validation group of 5 
drugs provided similar RMSE and ME when compared to the test group of data 
(Table 4.5). Correlation was not so evident but, considering the data range of the 
external validation group (0.23 – 1.51 logCLinf values) and the RMSE, the obtained 
value is still acceptable. None of the drugs were predicted within the 2-fold 
difference, but only marginally in the case of 4-methylumbelliferone. When 
considering the within 10-fold difference acceptance interval, 4 of the drugs were 
correctly predicted. In the original work (Jacobson et al., 2007), the CLint value for 
irbesartan was not able to predict CLH within a reasonable limit. Because of this, 
we removed this drug from the external validation group and found that it 
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significantly improved the group statistics to a RMSE = 0.635, ME = -0.020, 
r = 0.467 and 100% drugs within the 10-fold error difference. 
 
Model applicability 
 
Pharmacokinetics for a total of 290 drug molecules is described in 
Goodman and Gilman (Goodman et al., 2006). In order to include only drugs with 
reliable in vivo intrinsic clearances, all drugs with the following characteristics were 
removed prior to analysis: CL/F determination, CL with high variability, liposomal 
formulations, isomers with different pharmacokinetics, known metabolisation by 
multiple organs, CL data obtained in cancer patients, non-linear elimination 
pharmacokinetics, pro-drug data, re-conversion of the metabolite, endogenous 
substances, unreliable pharmacokinetic data or due to impossibility to calculate all 
the required molecular descriptors. This was done because these facts would 
impair the correct quantification of in vivo CLint. The remaining 142 drugs included 
30 drugs (Table 4.2) presented in the ANN optimisation process, used to establish 
the ability of the in vitro hepatocytes suspension to predict the in vivo CLint 
determined by “well-stirred” model and the human in vivo CLH values. This was 
done by comparing the in vitro values in this group to the in vivo determined 
values. The remaining 112 drugs (Table 4.3), for which only in silico predictions 
were available, were used to evaluate the prediction ability of the ANN model by 
itself.  
The in vivo CLint values used in the validation process were calculated by 
equation 4.3 as described in methods. Since some authors pointed out a better 
correlation when drug binding is considered only in acidic drugs at pH 7.4, the in 
vivo values were also calculated by considering fu,B equal to 1 for the remaining 
classes of drugs. Statistical performance of these two approaches is presented in 
table 4.6 and figure 4.3.  
When considering drug binding (figure 4.3a), a significant correlation is 
obtained, but both the in vitro and in silico values resulted in underpredictions. A 
low precision is observed, with only 19% of the in silico estimations and 16% of the 
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in vitro estimations within a 2-fold difference of the in vivo observed value, 
indicating a poor ability to quantitatively estimate this parameter.  
 
 
Figure 4.3 – Plot of the in vivo observed vs in vitro and in silico predicted log(CLint) values 
for the ANN model in unities of ml.min-1.kg-1. Solid line represents the line of unity and the 
dashed lines the ±1 log tolerance value. Open marks are indicative of drugs from table 4.2 
with in vitro CLint data. Closed marks represent drugs from table 4.3 with in silico CLint 
data. The in vivo observed values were determined by the “well-stirred” model based on 
the in vivo CLH and including fu,B in all drugs (A) or considering fu,B only in acid drugs (B). 
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Table 4.6 – Statistical comparison between the use of in vitro data and 
the ANN model to predict in vivo CLint values. In vivo CLint values were 
determined by using the “well-stirred” model either considering blood 
binding for all drug classes or just to acid drugs. Group A consisted of 
30 drugs from table 4.2, with in vitro CLint data, that were used in the 
training process of the ANN model. Group B includes the 112 drugs from 
table 4.3 for which only in silico CLint were used. 
 Data Set RMSE ME Correlation 
% within 10-fold 
difference 
% within 2-fold 
difference 
fu,B in all drugs      
Group A (In Vitro) 1.042 -0.838 0.636 57 16 
Group B (In Silico) 1.450 -0.748 0.527 56 19 
      
fu,B in acids      
Group A (In Vitro) 0.643 -0.073 0.579 93 52 
Group B (In Silico) 1.197 -0.249 0.508 63 16 
 
In the situation that drug binding is neglected for basic, neutral and 
zwitterionic drugs (figure 4.3b), a significant correlation is also obtained. A smaller 
underprediction is observed but again only 16% of the in silico determined drugs in 
the group B are predicted within a 2-fold difference of the in vivo observed value. 
For the in vitro data, however, a significant improvement in prediction was 
observed with 52% of the predictions within a 2-fold difference of the in vivo 
observed value. 
When considering a 10-fold difference, the prediction ability is considerably 
increased in all situations, indicating that the ANN model may be used to 
qualitatively predict the in vivo CLH. In order to test this hypothesis, both the in vitro 
and the in silico CLint values were used to predict the in vivo CLH by using the 
“well-stirred” model of the liver (figure 4.4).  
Again, drug binding was either considered to all drugs or just to acidic drugs 
as previously. A successful match was considered when the predicted value is not 
different from the observed one within a ± 4 ml.min-1.kg-1, assuming also a 50% 
error in the in silico CLint value. When drug binding is considered, 67% of the in 
vitro based predictions and 69% of the in silico based prediction are correctly 
predicted (figure 4.4a). When drug binding is applied to acidic drugs only, 97% of 
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the in vitro based predictions and 72% of the in silico based prediction are within 
the acceptance limits (figure 4.4b). 
 
 
Figure 4.4 – Plot of the in vitro and in silico predicted log(CLint) vs in vivo observed CLH 
values for the ANN model. Solid line represents the predicted CLH values based in the 
introduction of the in vitro and in silico CLint values in the “well-stirred” model considering 
fu,B in all drugs (A) or only in acid drugs (B). The dashed lines represent the tolerance 
interval. In vivo observed CLH are represented by open circles for the table 4.2 drugs were 
in vitro CLint data was used. Closed circles are used for table 4.3 drugs  were in silico CLint 
data was used. The closer a mark is to the solid line the better the prediction. 
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Discussion  
 
Model development 
 
To our knowledge, this is the first attempt to model in silico the CLint 
obtained in suspensions of human hepatocytes. Previous in silico works were 
done based on in vitro microssomes (Chang et al., 2008; Ekins, 2003; Ekins and 
Obach, 2000; Lee et al., 2007; Li et al., 2008), combining in vitro and in vivo data 
(Schneider et al., 1999; Zuegge et al., 2001), in vitro and in silico data (Jolivette 
and Ward, 2005; Wajima et al., 2002) and relating in silico with human in vivo 
pharmacokinetics (Li et al., 2008; Turner et al., 2004). 
CLint as determined by using suspensions of isolated hepatocytes presents 
advantages over other in vitro methods. Hepatocytes are intact cells with a 
complete set of phase I and II metabolizing enzymes that mimic the in vivo 
metabolisation of drugs (Gomez-Lechon et al., 2003). With the optimization of the 
cryopreservation protocols, an increased pool of liver sources is now available, 
with a minimal loss of metabolic activity (Blanchard et al., 2005; Griffin and 
Houston, 2004; McGinnity et al., 2004; Naritomi et al., 2003). Due to these facts, it 
appears to be the most promising tool to predict CLH in the development phase of 
new drug entities (Fagerholm, 2007) making it also an ideal target for QSAR 
models. 
This ANN model was trained based in a dataset of 71 different drugs, with 
data from different laboratories. Although similar experimental conditions were 
considered, some intra – drug variability was observed between laboratories, as 
observed previously (Nagilla et al., 2006). This variability may have a physiologic 
meaning (Shibata et al., 2002), and was introduced in the model by including all 
individual determinations with a weighting related to the number of different 
determinations per drug. ANN models are prone to overfitting problems. In order to 
reduce this possibility, we used an early stop procedure, a frequently used 
approach to minimize data memorisation (Cataltepe et al., 1999), with a test group 
of 18 drugs. Additionally, the ratio between the number of patterns to the number 
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of connections was maintained above 1 as this could also reduce the ability of the 
model to memorise the data (Turner et al., 2004). Comparison of the model 
performance in the train and test groups resulted in similar statistics which 
indicates that network training was stopped before overfitting did occur. Evaluation 
of the model performance in the external validation group of data is also indicative 
of the model’s predictive abilities, and an indication that it may be used to predict 
the CLint value in new drugs. 
 
Model Inputs 
 
Interpretation of the relationships between the input and output variables 
are difficult to make when using ANN models. One possible approach is to 
evaluate the relevance of each input on the final output by cycling each input for all 
training patterns and computing the effect on the network’s output response. The 
percent contribution of the input descriptors for the output response is presented in 
figure 4.5.  
 
 
Figure 4.5 – Relevance of each molecular descriptor in the prediction of CLint by the ANN, 
obtained by cycling each input for all training patterns and computing the effect on the 
network’s output response at a time. 
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As can be seen, the molecular descriptors encode information related to 
electronic (Ms, Me, Ram, TPSA(NO), RBN), physical-chemical properties (Hy, 
LogP, Tot_Fn), branching, compactness and symmetry (SPI, HNar, SIC2, BAC, 
Gm, IC4, MSD, TI1),  size and shape (AMW, PJI2, PW3, PW5) and aromaticity 
(nCIR) (Todeschini and Consonni, 2000). As can be seen, the molecular 
descriptors encode information related to electronic (Ms, Me, Ram, TPSA(NO), 
RBN), physical-chemical properties (Hy, LogP, Tot_Fn), branching, compactness 
and symmetry (SPI, HNar, SIC2, BAC, Gm, IC4, MSD, TI1),  size and shape 
(AMW, PJI2, PW3, PW5) and aromaticity (nCIR) (Todeschini and Consonni, 
2000).  
The top relevant descriptors also indicate the significance of structural 
considerations at an atomic and molecular level in determining the metabolic 
behaviour of a compound. Ram is a σ-electron descriptor and a measure of atom 
connectedness for acyclic graphs within the molecule (Araujo and De la Pena, 
1998). Hy is an empirical index related to the hydrophilicity of the compounds. 
TPSA(NO) is a descriptor related to the hydrogen-bonding ability of compounds 
and has been previously used to predict membrane permeability (Linnankoski et 
al., 2006; Zhao et al., 2007). SPI is a molecular descriptor derived from the H-
depleted molecular graph proposed to enhance the role of terminal vertices in 
QSAR studies and it has been used to predict the antiulcer activity in a set of 128 
molecules (Gupta et al., 1999). MSD and BAC are molecular descriptors known to 
be related to the branching in a structure (Caputo and Cook, 1989). nCIR counts 
the number of walks with non repeated paths in the graph representation of the 
molecule. It is a direct indication of cycle structures in the molecule. SIC2 is a 
topological information index representing a measure of the structural complexity. 
Ms is a measure of the average electronic accessibility of the atoms in the 
molecule and can be interpreted as a probability of interaction with another 
molecule. PW5 is a molecular shape descriptor and is related to transport 
phenomena and interaction capabilities between ligands and receptors 
(Todeschini and Consonni, 2000).  
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Model applicability  
 
The applicability of the proposed model was evaluated by testing the ability 
of the ANN model to predict the in vivo intrinsic clearance with the latter being 
estimated based on the pharmacokinetic values of the drugs. Different classes of 
drugs with a broad range of CLH values were included but, since extrahepatic CL 
is neglected, there is a possibility of overestimation when estimating the CLH. Use 
of known drugs with reliable intravenous data and comparison with the EH 
estimated by bioavailability may reduce this effect when extremely evident.  
The liver model may also influence the estimation of CLint, especially in high 
CL drugs (Houston and Carlile, 1997) and the “dispersion” and “parallel tube” 
models usually present the best results (Iwatsubo et al., 1997). However, due to its 
simplicity and minor differences in the prediction on in vivo CLH, the use of the 
“well-stirred” model is still often recommended (Ito and Houston, 2004). Use of fu,B 
is also a question of debate. Neglecting this parameter in basic, zwitterionic and 
neutral drugs seems to improve CLH estimations both when using microsomes 
(Obach, 1999) or hepatocytes suspensions (Jacobson et al., 2007; Lau et al., 
2002; McGinnity et al., 2004; Reddy et al., 2005).  
We tested the predictive ability of the ANN model either by using fu,B in all 
classes of drugs or just in acidic drugs using the “well-stirred” model. Similar 
correlations were observed when comparing both the in vitro and the in silico 
predictions with the in vivo CLint observed values either using fu,B to all drugs or 
just for acids, and comparable to previously observed values for in vitro – in vivo 
extrapolations (McGinnity et al., 2004). It has also been proposed to evaluate the 
performance of a method by determining the percentages of predicted values 
below a 2 – fold error (Obach et al., 1997). When applied to CLint data our results 
were unsatisfactory either using the in vitro or the in silico predicted values (Table 
4.6). These values were, however, in accordance with previously described values 
for in vitro – in vivo extrapolation with human hepatocytes (Naritomi et al., 2003; 
Riley et al., 2005) and reasons for this lack of prediction may be either lower 
activity of the hepatocytes after cryopreservation or inappropriate in vivo CLint 
estimation methods (Fagerholm, 2007). However, considering the described 
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inter-individual (Shibata et al., 2002) and inter-laboratory (Nagilla et al., 2006) 
variability of the in vitro CLint in various drugs, also visible in data from table 4.1, 
probably the 2-fold error is too restrict. When using a less strict limit of a 10-fold 
error, previously used in another in silico approach (Ekins and Obach, 2000), the 
final performance improved considerably particularly when including the fu,B term 
only in acids. 
Final evaluation of the method was made by establishing the ability to use 
the in silico CLint to predict the in vivo CLH by using the “well-stirred” model of the 
liver. As can be seen in figure 4.4, overall predictions are good with 69% (figure 
4.4A) and 72% (figure 4.4B) well predicted values within the accepted values. Low 
clearance drugs are generally well predicted either using fu,B for all drugs or just for 
acidic drugs.  
For high clearance drugs, however, neglecting fu,B for basic, neutral and 
zwitterionic drugs results in better predictions. To mimic the in vivo situation, it is 
assumed in the ”well-stirred” model that the distribution within the liver is perfusion 
rate limited with no diffusion barriers, only unbound drug crosses the cell 
membrane and occupies the enzyme site, and there is a homogenous distribution 
of metabolic enzymes in the liver (Houston and Carlile, 1997). Removal of fu,B 
could contradict the model assumptions and is was not recommended (Fagerholm, 
2007). These are, however, gross approximations of the complex physiology of the 
liver. Several active drug transporters are present in human hepatocytes, resulting 
that the unbound intracellular concentration may differ from that in the external 
medium (Hewitt et al., 2007; Pelkonen and Turpeinen, 2007). Non-specific binding 
inside the cell is expectably higher in neutral, basic and zwitterionic drugs, and this 
could cancel the effects of plasma protein binding (Obach, 1999). Lipoprotein 
uptake in hepatocytes may also promote the entry of basic and neutral 
hydrophobic drugs, as these are highly bound to these proteins (Ohnishi et al., 
2002). There is also evidences of albumin conformational changes when in 
contact with hepatocytes that may accelerate drug dissociation at the cells surface 
(Horie et al., 1988). All these facts are of considerable influence when 
extrapolating from CLint to CLH, especially in drugs with high CLH values, but are 
still prone to investigation. It is also visible that using fu,B in all drugs results in a 
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marked underprediction. This underprediction is  partially reduced when fu,B is 
considered only for acids. Other reasons for this underprediction may also be: (i) 
lower metabolic activity of the in vitro hepatocytes, (ii) the assumption that Vd in 
hepatocytes equals that of the physical volume of the cells and/or (iii) 
overestimation of the in vivo CLH (Fagerholm, 2007). 
When considering the use of in vitro CLint values to predict the in vivo CLH, 
similar performance to the in silico data was observed with 67% well predicted 
values within the accepted values (Figure 4.4A). Neglecting fu,B for basic, neutral 
and zwitterionic drugs resulted again in significative better predictions with 97% 
well predicted values within the accepted values (Figure 4.4B). In this case, the in 
vitro data presented better performance when compared to the in silico based CLint 
values. When evaluating the data chemical space by means of a principal 
component analysis (Figure 4.6) both train and test data sets, used in the ANN 
model optimization process, share the same descriptor space. Drugs used in the 
in silico model applicability (table 4.3), however, present some molecules that are 
outside the model molecular space and for which an increased uncertainty of the 
prediction is expected. 
 
 
Figure 4.6 – PCA scores t[1] and t[2] for the train (close marks) and test (open marks) 
drugs from table 4.1. Table 4.3 drugs, used to test the ANN model applicability, are 
represented as cross marks. The analysis resulted that the first 2 components explained 
50% of the descriptors variance. 
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Conclusions 
 
In conclusion, we present an in silico method to predict the in vitro CLint 
obtained in human hepatocytes suspensions, based only in calculated molecular 
descriptors. Model applicability in a large group of data not previously used in the 
model building procedure demonstrated a reasonable ability to predict human in 
vivo CLH from the in silico CLint for a wide range of drugs, only marginally inferior to 
the performance of the in vitro data from which the model was build, with similar 
correlations and less than the double RMSE. Nevertheless, for optimal use, the 
model predictive performance should be improved possibly by including more 
drugs, when available, in the ANN train process. This model may be a valuable 
tool in early drug discovery by providing a relevant pharmacokinetic parameter. 
Additionally, by estimating an in vitro determined parameter, it is also prone for 
easy confirmation which is fundamental in the drug development process in order 
to reduce costs and utilization of large animal data.  
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Evaluation of a physiologically based 
model to predict oral bioavailability 
using in vitro and in silico drug related 
parameters 
 
 
 
 
Introduction 
 
Oral administration, due to its ease and patient compliance, is the preferred 
route and a major goal in the development of new drug entities. It is also 
traditionally one of the reasons for either discontinuation or prolongation of the 
development of compounds (Singh, 2006). In this context, and as a consequence 
of the large output of molecular synthesis due to combinatorial chemistry, initial 
screening of hits in a number of thousands is done typically by using in silico 
approaches. In vitro tests are then used to reduce the number of compounds from 
hundreds to dozens and in vivo animal models to 1–5 finally potential drugs that 
go to clinical trials (Venkatesh and Lipper, 2000). In this process, a large amount 
of data is typically produced, many of which never results in a new drug entity. 
However, this information, far from being discarded, is currently used to build 
many in silico models that may help in the early screening of new drugs. 
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Another currently performed effort is the Integration of data from all these 
development phases for the lead selection (Saxena et al., 2009). In this regard, 
physiologically based pharmacokinetic (PBPK) models are one of the most 
promising tools (Nestorov, 2007; Rowland et al., 2004), and some examples of 
their application in the drug development are already available (Lupfert and 
Reichel, 2005; Norris et al., 2000; Parrott and Lave, 2008; Parrott et al., 2005; 
Poulin and Theil, 2000; Theil et al., 2003).  
Various physiological compartmental models of absorption are described in 
the literature (Agoram et al., 2001; Grass, 1997; Huang et al., 2009; Yu and 
Amidon, 1999; Yu et al., 1996b), but considering the basic structure and the 
importance of the gastrointestinal track (GIT) transit time, it is fair to say that they 
are all implementations and optimizations over the CAT model (Yu et al., 1996b). 
In its initial form, CAT model assumed passive absorption, instantaneous 
dissolution, linear transfer kinetics for each segment and minor absorption from 
the stomach and colon. Although simple assumptions were considered, this initial 
approach was able to predict in fair agreement the bioavailability of 10 passively 
diffused drugs (Yu and Amidon, 1999). By including Michaelis-Menten kinetics (Yu 
and Amidon, 1998), gastric emptying and dissolution (Yu, 1999) the model 
applicability was extended to other classes of drugs. Various subsequent 
optimizations were later made in commercial packages by including first-pass 
metabolism and colon absorption - GastroplusTM (Agoram et al., 2001), introducing 
direct physiologic meaning in the model compartments – iDEATM (Grass, 1997) 
and considering the physiologic heterogeneity of the GIT – SimCypTM (Di Fenza et 
al.). If the ability to simulate, within the model assumptions, the effect of changes 
in the fundamental drug related parameters and the implication of these changes 
in the pharmacokinetic profile of the drug is unquestionable, some efforts have 
also been made in order to quantify the predictive ability of these same models in 
a new drug scenario with promising results (Cai et al., 2006; De Buck et al., 
2007a; De Buck et al., 2007b; Parrott and Lave, 2002; Parrott et al., 2005). 
However, and specially when in silico drug parameters are required, due to the 
proprietary nature of these commercial packages and the use of internal training 
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sets for model parameters optimizations, it is difficult to effectively test the models 
with “true” external validation data. 
The purpose of this work was to build a physiologically based absorption 
model that described the fundamental steps involved in the human oral 
bioavailability. Its performance was tested using in vitro data from CACO-2 cells 
and suspensions of human hepatocytes. Replacement of these data sources with 
in silico derived ones was tested by considering only drugs that were not 
previously used in the internal training and testing processes of the QSAR model 
building strategies.  
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Materials and Methods 
 
Model structure 
 
The present model was built based on the CAT model (Yu and Amidon, 
1998; 1999) in its integrated form (Yu, 1999) in order to consider permeability, 
dissolution and solubility limited absorption. A parallel model was included to 
establish the water volume in the GIT. Additionally, a liver compartment was also 
included to quantify the first pass effect on absolute bioavailability (Rowland et al., 
1973). The final structure of the physiological based absorption model is presented 
in figure 5.1 and the model equations are despicted in annex 1. The GIT is divided 
in three segments with a series of multiple compartments connected by linear 
transfer kinetics from one to the next. The first segment is related to the stomach 
(subscript S) and consists of a single compartment, which is connected to the 
second segment, that define the small intestine, consisting in a sequence of seven 
compartments (subscripts 1–7). The final segment with only one compartment is 
related to the colon (subscript C). Drug, in an immediate release dosage form, is 
administered to the stomach with 250 ml of water where it may dissolve. Both solid 
(Mp) and soluble drug (Ms) will then suffer similar gastric emptying rates (ks) and 
move through the different intestinal segments with similar transit time 
characteristics (kt). Drug dissolution rate (kD) is define by the Noyes-Whitney 
equation without “sink conditions”. Due to this, and in order to determine the 
concentration of dissolved drug, the water content (V) of the GI track was also 
modelled. The same segment series were considered, with transfer kinetics 
between the compartments similar to the previously described. Water volume is 
considered dependent of the rate of salivary and gastric (R1), duodenal (R2) and 
intestinal mucous (R3) secretions as well as the intestinal water reabsorption (kH2O) 
process. Only dissolved drug is assumed to be absorbable in the small intestine at 
a rate defined by kA. All absorbed drug will pass by the liver where it will be 
metabolized according to the “well-stirred” model. By calculating the mass of solid 
drug reaching the colon, being absorbed and escaping the liver, bioavailability 
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limited by dissolution (Fd), absorption (Fabs) and metabolization (Fmet) may be 
determined as well as absolute bioavailability (Foral). The presented model is a 
typical case of an initial value problem of a system of differential equations and 
was numerically solved by the use of ADAPT II (D'Argenio and Schumitzky, 1979; 
D’Argenio and Schumitzky, 1997). 
 
 
Figure 5.1 – Structure of the physiologic-based pharmacokinetic model of absorption. 
 
Physiological Parameters 
 
Physiological parameters of the model used in the present study are 
presented in table 5.1. Gastric emptying is assumed to folow first-order kinetics 
with the residence time of 0.25h (Yu and Amidon, 1998). The small intestinal 
transit time was found to be 3.32h and the 7 compartment model has shown to be 
the best compartmental model to depict the small intestine transit time distribution 
(Yu et al., 1996a). Water model was optimized by considering a 24h secretion of 
1000 ml of saliva, 1500 ml of gastric secretions (joint in R1), 1000 ml of pancreatic 
secretions, 1200 ml of Bile secretion (joint in R2) and 1800 ml of intestinal mucus 
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secretion (equally divided in the 7 compartments and considered as R3). kH2O was 
determined by considering that 80% of the water in the small intestine is 
reabsorbed and only 1300 ml of water reach the colon every day. Stomach water 
volume (Vs) and individual small intestine water volumes (V1 to V7) are the water 
content at each compartment when the GIT secretions and water reabsorption 
reach equilibrium.  
 
Table 5.1 – Physiological parameters used 
in the pharmacokinetic model 
Transit rate constants 
kS = 4.00 h-1 
kT = 2.11 h-1 
Water model Parameters 
R1 = 104.2 mL/h 
R2 = 91.7 mL/h 
R3 = 10.7 mL/h 
Vs = 26.04 mL  
V1 = 73.47 mL  
V2 = 58.95 mL  
V3 = 48.05 mL  
V4 = 39.87 mL  
V5 = 33.73 mL  
V6 = 29.13 mL  
V7 = 25.67 mL  
KH2O = 0.7015 h-1 
Intestine radius  
r1 = 1.70 cm 
r2 = 1.58 cm 
r3 = 1.47 cm 
r4 = 1.37 cm 
r5 = 1.26 cm 
r6 = 1.16 cm 
r7 = 1.05 cm 
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Drug Related Parameters 
 
Specific parameters were introduced in order to describe the dissolution, 
absorption and metabolisation characteristics of the different drugs. Dissolution 
rate (RD) was mathematically described by the Noyes-Whitney equation, 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −⋅⋅⋅
⋅⋅=
i
iS
i
p
iP
D V
M
S
rh
MD
R ),(),(
3
ρ       (5.1) 
 
were D is the diffusion coefficient with a value of 5×10-6 cm2.s-1, ρ is the 
density of drug with a value of 1200 mg cm-3, h is the diffusion layer 
thickness that was set to be 30 µm and rp the radius of the particles, 
considered constant over time with a value of 50 µm (Yu, 1999).  
 
These values were kept constant in all simulations. Si is the solubility of the 
drug in the different compartments, taking into consideration the pH differences 
that the drug suffers when transiting across the GIT. It is assumed that in stomach 
pH = 1.5. Duodenum (compartment 1 of the small intestine) presents a pH = 4.6, 
jejunum (compartments 2 and 3) presents a pH = 6.5 and ileum (compartments 
4-7) presents a pH = 7.5. Bile salts are known to play an important role in the 
emulsification and solubilisation of drugs (Wiedmann and Kamel, 2002). Although 
the estimation of the in vivo solubility of drugs in bile salts is still difficult, A linear 
relationship was shown between LogP and the micelle/aqueous partition 
coefficient in vitro (Wiedmann et al., 2002). Based on this fact, it was considered 
that drugs with logP values above 2.5 would be 50 times more soluble in the 
duodenum than the drug aqueous solubility at pH 4.5. Additionally, it was assumed 
that, when due to pH changes the amount of drug dissolved enters a compartment 
with lower solubility, a supersaturated solution may be formed and no precipitation 
occurs. 
 Considering drug absorption in the model, the rate of absorption (RA) was 
calculated by, 
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were Peff is the drug effective human permeability, M(S,i) is the mass of 
dissolved drug in each of the 7 individual small intestine compartments and 
r is the radius of the small intestine which  is assumed to linearly decrease 
from 1.75 cm at the proximal to 1.0 cm at the distal end (Willmann et al., 
2004) 
 
The relative amount of drug metabolized in the liver (EH), and according to 
the “well-stirred” model, is defined as, 
 
int,
int,
ClfQ
Clf
E
BuH
Bu
H ⋅+
⋅=    (5.3) 
were QH is the liver blood flow with a physiological value of 81 L/h. fu,B is 
the fraction of unbound drug in blood. For acids, this parameter was 
determined by the ratio between the free fraction of drug in plasma (fu) and 
the drug blood-to-plasma concentration ratio (Rb). Rb values were 
calculated using an ANN model according to Paixão et. al. (Paixao et al., 
2009). For basic, neutral and zwitterionic drugs fu,B was considered equal 
to 1. Finally, CLint is the hepatic intrinsic clearance of the drug. 
 
Si, Papp and CLint datasets 
 
To test the model and its applicability in predicting human absolute 
bioavailability, we used a total of 164 drugs for which relevant pharmacokinetic 
properties were available, namely, absolute bioavailability, total plasma clearance, 
fraction of unchanged drug excreted in urine and plasma protein binding (Table 
5.2). Experimentally determined values of the Rb were collected whenever 
available, or calculated according to Paixão et. al. (Paixao et al., 2009). This 
model provided predictions of Rb with a percentage of correct values within a 
1.25-fold error of 86%, 84% and 87% in the train, test and validation data sets 
respectively. 
 
Table 5.2 – Pharmacokinetic data for the 164 drugs used to test the model 
applicability in predicting the human absolute bioavailability. 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Acebutolol 0.37 0.40 0.26 6.80 1.00 B 4.08 0.46 0.80 A) 
Acetaminophen 0.88 0.30 0.20 5.00 1.04 B 2.40 1.00 0.88 B) 
Acyclovir 0.30 0.75 0.15 6.19 1.08 N 1.44 0.32 0.93 B) 
Alendronate 0.02 0.45 0.78 1.11 1.70 Z 0.36 0.02 0.98 B) 
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Table 5.2 – (continued) 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Allopurinol 0.53 0.12 0.01 9.90 1.09 N 8.02 0.88 0.60 B) 
Alprazolam 0.88 0.20 0.71 0.74 0.78 N 0.76 0.91 0.96 B) 
Amiodarona 0.46 0.00 1.00 1.90 0.73 B 2.60 0.53 0.87 B) 
Amitriptyline 0.48 0.02 0.95 11.50 0.86 B 10.40 1.00 0.48 B) 
amlodipine 0.74 0.10 0.93 5.90 1.20 B 4.42 0.95 0.78 B) 
Amoxicillin 0.50 0.86 0.18 2.60 1.04 A 0.35 0.51 0.98 B) 
Antipyrine 1.00 0.95 0.10 1.52 1.00 N 0.08 1.00 1.00 C) D) 
Aprepitant 0.65 0.00 0.95 1.29 0.60 N 2.14 0.73 0.89 B) 
Atenolol 0.58 0.94 0.05 2.40 1.07 B 0.13 0.58 0.99 B) 
Benzydamine 0.87 0.55 0.20 2.28 1.00 B 1.03 0.92 0.95 E) F) G) 
Bepridil 0.60 0.01 0.99 5.30 0.67 B 7.83 0.99 0.61 A) 
Betaxolol 0.89 0.15 0.55 4.70 1.00 B 2.20 1.00 0.89 A) 
Bisoprolol 0.90 0.63 0.35 3.70 1.00 B 1.37 0.97 0.93 A) 
Bosentan 0.50 0.01 0.98 2.20 1.00 A 2.18 0.56 0.89 H) 
Bromocriptine 0.05 0.02 0.93 5.00 1.00 B 4.90 0.07 0.76 A) 
Bufuralol 0.46 0.00 0.85 6.20 1.00 B 6.20 0.67 0.69 I) 
Buspirone 0.04 0.00 0.95 28.30 0.62 B 19.22 1.00 0.04 B) 
Caffeine 1.00 0.01 0.36 1.40 0.80 N 0.00 1.00 1.00 A) 
Calcitriol 0.61 0.10 1.00 0.43 0.55 N 0.70 0.63 0.96 B) 
Candesartan 0.42 0.52 1.00 0.37 0.55 A 0.32 0.43 0.98 B) 
Carbamazepine 0.70 0.01 0.74 0.91 1.06 N 0.85 0.73 0.96 B) 
Carvedilol 0.25 0.02 0.95 8.70 0.72 B 11.88 0.62 0.41 B) 
cefixime 0.47 0.41 0.67 1.30 0.62 A 1.25 0.50 0.94 B) 
Cephalexin 0.90 0.91 0.14 4.30 1.02 A 0.38 0.92 0.98 B) 
Cetirizine 0.85 0.71 0.99 0.52 1.00 Z 0.15 0.86 0.99 B) 
Chlorpheniramine 0.59 0.10 0.70 1.70 1.34 B 1.14 0.63 0.94 B) 
Chlorpromazine 0.40 0.01 0.97 8.60 0.78 B 10.92 0.88 0.45 B) 
Chlorprothixene 0.41 0.00 0.99 12.40 0.81 B 11.80 1.00 0.41 J) 
Chlorthalidone 0.64 0.65 0.75 0.04 0.73 N 0.01 0.64 1.00 B) 
Cimetidine 0.60 0.62 0.19 8.30 0.97 B 3.25 0.72 0.84 B) 
Cinacalcet 0.20 0.00 0.95 18.00 0.64 B 16.00 1.00 0.20 B) 
ciprofloxacin 0.60 0.50 0.40 7.60 1.07 Z 3.55 0.73 0.82 B) 
Clindamycin 0.87 0.13 0.94 4.70 0.76 B 2.60 1.00 0.87 B) 
Clonidine 0.95 0.62 0.20 3.10 1.04 B 1.13 1.01 0.94 B) 
Clozapine 0.55 0.01 0.95 6.10 1.13 B 5.36 0.75 0.73 B) 
Cyclophosphamide 0.88 0.07 0.13 1.30 1.06 N 1.14 0.93 0.94 B) 
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Table 5.2 – (continued) 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Dapsone 0.93 0.15 0.73 0.60 1.04 N 0.49 0.95 0.98 B) 
Desipramine 0.38 0.02 0.82 10.00 0.96 B 10.21 0.78 0.49 A) 
Diazepam 1.00 0.01 0.99 0.38 0.58 N 0.65 1.03 0.97 B) 
Diclofenac 0.54 0.01 1.00 4.20 0.56 A 7.46 0.86 0.63 B) 
Dicloxacillin 0.50 0.60 0.96 1.60 0.55 A 1.16 0.53 0.94 B) 
didanosine 0.38 0.36 0.05 16.00 1.08 N 9.50 0.72 0.52 B) 
Diltiazem 0.38 0.04 0.78 11.80 1.00 B 11.33 0.88 0.43 B) 
Diphenhydramine 0.72 0.02 0.78 6.20 0.65 B 5.60 1.00 0.72 B) 
dofetilide 0.96 0.52 0.64 5.23 0.72 B 0.80 1.00 0.96 B) 
Doxycycline 0.93 0.41 0.88 0.53 1.70 Z 0.18 0.94 0.99 B) 
Entacapone 0.42 0.00 0.98 10.30 0.55 A 11.60 1.00 0.42 B) 
ethambutol 0.77 0.79 0.18 8.60 0.96 B 1.89 0.85 0.91 B) 
etoposide 0.52 0.35 0.96 0.68 0.55 N 0.80 0.54 0.96 B) 
Famotidine 0.45 0.67 0.17 7.10 1.00 N 2.34 0.51 0.88 A) 
Finasteride 0.63 0.01 0.90 2.30 0.56 N 4.08 0.79 0.80 B) 
Flecainide 0.74 0.43 0.61 5.60 0.89 B 3.59 0.90 0.82 B) 
Fluconazole 0.90 0.75 0.11 0.27 1.06 N 0.06 0.90 1.00 B) 
flumazenil 0.16 0.00 0.40 9.90 1.00 N 9.88 0.32 0.51 B) 
Fluorouracil 0.28 0.10 0.10 16.00 1.09 N 13.16 0.82 0.34 B) 
fluphenazine 0.03 0.00 0.92 10.00 0.69 B 14.55 0.10 0.27 B) 
Foscarnet 0.09 0.95 0.15 1.60 1.27 A 0.06 0.09 1.00 B) 
Furosemide 0.71 0.66 0.99 2.00 0.55 A 1.23 0.76 0.94 B) 
gabapentin 0.60 0.66 0.03 1.60 1.10 Z 0.49 0.62 0.98 B) 
galantamine 0.95 0.20 0.18 5.70 1.04 B 1.00 1.00 0.95 B) 
Ganciclovir 0.05 0.91 0.01 3.40 1.08 N 0.28 0.05 0.99 B) 
Gemfibrozil 0.95 0.01 0.97 1.70 0.55 A 1.00 1.00 0.95 B) 
Glimepiride 1.00 0.01 1.00 0.62 0.55 A 0.01 1.00 1.00 B) 
Glyburide 0.90 0.00 1.00 1.30 0.56 A 2.34 1.02 0.88 B) 
Granisetron 0.60 0.16 0.65 11.00 0.86 B 8.00 1.00 0.60 B) 
Hydrochlorothiazide 0.71 0.95 0.58 4.90 1.70 N 0.14 0.72 0.99 B) 
Hydromorphone 0.42 0.06 0.07 14.60 1.07 B 12.80 1.17 0.36 B) 
Ibuprofen 0.80 0.01 0.99 0.60 0.55 A 1.07 0.85 0.95 B) 
imatinib 0.98 0.05 0.95 3.30 0.64 B 0.40 1.00 0.98 B) 
Imipramine 0.42 0.02 0.90 15.00 1.10 B 11.60 1.00 0.42 B) 
Irbesartan 0.70 0.02 0.90 2.12 0.64 Z 3.26 0.84 0.84 B) 
Isosorbide Dinitrate 0.22 0.01 0.28 46.00 1.00 N 15.60 1.00 0.22 B) 
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Table 5.2 – (continued) 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Isosorbide-5-
mononitrate 0.93 0.05 0.00 1.80 1.08 N 1.59 1.01 0.92 
B) 
Isradipine 0.17 0.00 0.97 10.00 0.55 N 16.20 0.89 0.19 A) 
Ketoprofen 1.00 0.01 0.99 1.20 1.00 A 0.00 1.00 1.00 A) 
Lamivudine 0.86 0.50 0.36 4.95 1.06 N 2.33 0.97 0.88 B) 
Lansoprazole 0.81 0.01 0.97 6.23 0.56 N 3.80 1.00 0.81 B) 
Letrozole 1.00 0.04 0.60 0.58 0.92 N 0.02 1.00 1.00 B) 
Levetiracetam 1.00 0.66 0.10 0.96 1.07 N 0.30 1.02 0.98 B) 
Levofloxacin 0.99 0.70 0.30 2.52 1.05 Z 0.20 1.00 0.99 B) 
Lidocaine 0.37 0.02 0.70 9.20 0.84 B 10.73 0.80 0.46 B) 
Linezolid 1.00 0.35 0.31 2.10 0.73 N 0.01 1.00 1.00 B) 
Lorazepam 0.93 0.01 0.91 1.10 1.05 N 1.04 0.98 0.95 B) 
Losartan 0.36 0.12 0.99 8.10 0.55 A 12.92 1.01 0.35 B) 
Meloxicam 0.97 0.01 0.99 0.15 1.22 A 0.12 0.98 0.99 B) 
Melphalan 0.71 0.12 0.90 5.20 0.96 Z 4.77 0.93 0.76 B) 
Meperidine 0.52 0.05 0.58 17.00 0.87 B 9.60 1.00 0.52 B) 
mercaptopurine 0.12 0.22 0.19 11.00 1.20 N 7.18 0.19 0.64 B) 
metformin 0.52 1.00 0.00 7.62 1.04 B 0.01 0.52 1.00 B) 
Methadone 0.92 0.24 0.89 1.70 0.75 B 1.60 1.00 0.92 B) 
Methotrexate 0.70 0.81 0.46 2.10 0.71 A 0.56 0.72 0.97 B) 
Methylprednisolone 0.82 0.05 0.78 6.20 0.78 N 3.60 1.00 0.82 B) 
metoclopramide 0.76 0.20 0.40 6.20 0.96 B 4.80 1.00 0.76 B) 
Metoprolol 0.38 0.10 0.11 15.00 1.00 B 12.40 1.00 0.38 B) 
Metronidazole 0.99 0.10 0.11 1.30 1.07 N 0.20 1.00 0.99 B) 
Midazolam 0.44 0.01 0.98 6.60 0.80 N 8.17 0.74 0.59 B) 
Montelukast 0.62 0.00 0.99 0.70 0.55 A 1.27 0.66 0.94 B) 
Morphine 0.24 0.04 0.35 24.00 0.95 B 15.20 1.00 0.24 B) 
moxifloxacin 0.86 0.22 0.39 2.27 1.05 Z 1.69 0.94 0.92 B) 
Nadolol 0.34 0.73 0.20 2.90 1.00 B 0.78 0.35 0.96 A) 
Nalmefene 0.40 0.10 0.34 15.00 1.11 B 12.24 1.03 0.39 B) 
Naloxone 0.02 0.00 0.30 22.00 1.22 B 18.03 0.20 0.10 B) 
Naproxen 0.99 0.01 1.00 0.13 1.00 A 0.13 1.00 0.99 B) 
Nifedipine 0.50 0.00 0.96 7.00 1.63 N 4.28 0.64 0.79 B) 
Nitrendipine 0.23 0.01 0.98 21.00 0.70 N 15.48 1.00 0.23 A) 
Nitrofurantoin 0.90 0.47 0.62 9.90 0.76 A 2.00 1.00 0.90 B) 
Nortriptyline 0.51 0.02 0.92 7.20 1.50 B 4.70 0.67 0.76 B) 
Omeprazole 0.71 0.00 0.95 7.50 0.58 N 5.80 1.00 0.71 A) 
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Table 5.2 – (continued) 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Ondansetron 0.62 0.05 0.73 5.90 0.83 B 6.75 0.94 0.66 B) 
Oxazepam 0.97 0.01 0.99 1.05 0.66 N 0.60 1.00 0.97 A) 
Oxycodone 0.42 0.19 0.45 12.40 1.03 B 9.75 0.82 0.51 B) 
Phenacetin 0.28 0.40 0.33 20.00 1.01 N 11.88 0.68 0.41 K) 
Phenobarbital 1.00 0.24 0.51 0.06 0.86 N 0.05 1.00 1.00 B) 
Phenytoin 0.90 0.02 0.89 5.90 1.00 N 2.00 1.00 0.90 B) 
Pindolol 0.75 0.54 0.51 8.30 1.00 B 3.82 0.93 0.81 A) 
Pirenzepine 0.33 0.90 0.11 3.76 1.00 B 0.38 0.34 0.98 L) M) 
Pravastatin 0.18 0.47 0.45 13.50 0.55 A 13.01 0.51 0.35 B) 
Prazosin 0.68 0.04 0.95 3.00 0.70 N 4.11 0.86 0.79 B) 
Prednisone 0.80 0.03 0.75 3.60 1.00 N 3.49 0.97 0.83 B) 
Procainamide 0.83 0.67 0.16 1.70 1.00 B 0.56 0.85 0.97 B) 
Propafenone 0.05 0.01 0.95 17.00 0.70 B 14.00 0.17 0.30 A) 
Propofol 0.00 0.00 0.98 27.00 1.25 N 20.00 1.00 0.00 B) 
Propranolol 0.26 0.01 0.87 16.00 0.89 B 14.80 1.00 0.26 B) 
Quetiapine 0.09 0.01 0.83 19.00 0.90 B 18.20 1.00 0.09 B) 
Quinidine 0.75 0.18 0.87 4.70 0.88 B 4.36 0.96 0.78 B) 
Quinine 0.76 0.16 0.90 0.90 0.91 B 0.83 0.79 0.96 B) 
Ranitidine 0.52 0.69 0.15 10.40 1.03 B 3.14 0.62 0.84 B) 
Repaglinide 0.56 0.01 0.97 9.30 0.55 A 8.80 1.00 0.56 B) 
Riluzole 0.64 0.01 0.98 5.50 1.70 N 3.20 0.76 0.84 B) 
Risedronate 0.01 0.87 0.24 1.50 1.07 A 0.18 0.01 0.99 B) 
Risperidone 0.66 0.03 0.89 5.40 0.67 B 6.80 1.00 0.66 B) 
Rizatriptan 0.47 0.28 0.14 12.30 1.04 B 8.53 0.82 0.57 B) 
Scopolamine 0.29 0.06 0.10 15.50 1.00 B 14.20 1.00 0.29 N) 
Sildenafil 0.38 0.00 0.96 6.00 0.99 N 6.04 0.54 0.70 B) 
sulfamethoxazole 1.00 0.14 0.53 0.31 0.79 A 0.34 1.02 0.98 B) 
Sulpiride 0.27 0.74 0.00 5.90 1.00 B 1.53 0.29 0.92 O) 
Sumatriptan 0.14 0.22 0.18 22.00 1.03 B 16.67 0.84 0.17 B) 
Tamsulosin 1.00 0.13 0.99 0.62 0.55 B 0.98 1.05 0.95 B) 
Tegaserod 0.11 0.00 0.98 18.00 0.72 B 17.80 1.00 0.11 B) 
Tenoxicam 0.95 0.00 0.99 0.04 0.67 A 0.06 0.95 1.00 P) 
terazosin 0.82 0.13 0.92 1.15 0.84 N 1.20 0.87 0.94 B) 
Terbutaline 0.26 0.57 0.23 3.40 1.00 B 1.46 0.28 0.93 Q) R) 
Tetracycline 0.77 0.58 0.65 1.67 1.70 Z 0.41 0.79 0.98 B) 
Theophylline 0.96 0.18 0.56 0.65 1.33 N 0.40 0.98 0.98 B) 
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Table 5.2 – (continued) 
Drug Foral frenal fp CLplasm (ml.min-1.kg-1) Rb 
Drug
Class CLH Fabs Fmet  
Timolol 0.76 0.08 0.10 7.70 0.87 B 4.84 1.00 0.76 B) 
Tolbutamide 0.85 0.00 0.96 0.24 0.55 A 0.44 0.87 0.98 B) 
Tramadol 0.70 0.20 0.20 8.00 1.03 B 6.20 1.01 0.69 B) 
Trazodone 0.81 0.01 0.93 2.10 0.81 N 2.58 0.93 0.87 B) 
Triazolam 0.44 0.02 0.90 2.46 0.62 N 3.89 0.55 0.81 A) 
trimethoprim 0.63 0.63 0.37 1.90 1.03 N 0.68 0.65 0.97 B) 
Valproic acid 1.00 0.02 0.93 0.14 0.64 A 0.21 1.01 0.99 B) 
Valsartan 0.39 0.29 0.95 0.49 0.55 A 0.63 0.40 0.97 B) 
Verapamil 0.22 0.03 0.90 15.00 0.77 B 15.60 1.00 0.22 B) 
Vinorelbine 0.27 0.11 0.87 21.00 0.58 B 14.60 1.00 0.27 B) 
Vinpocetine 0.57 0.00 0.66 5.20 0.57 B 8.68 1.00 0.57 S) 
Warfarin 0.93 0.02 0.99 0.05 0.55 A 0.08 0.93 1.00 B) 
Zaleplon 0.31 0.01 0.60 15.70 0.99 N 13.80 1.00 0.31 B) 
Zidovudine 0.63 0.18 0.25 26.00 1.06 N 7.40 1.00 0.63 B) 
Ziprasidone 0.59 0.01 1.00 11.70 0.81 B 8.20 1.00 0.59 B) 
Zolpidem 0.72 0.01 0.92 4.50 0.76 N 5.60 1.00 0.72 B) 
 
References for the pharmacokinetic data are from A) (Goodman et al., 1996), B) (Goodman et al., 
2006), C) (Rimmer et al., 1986), D) (Atiba et al., 1987), E) (Koppel and Tenczer, 1985), F) 
(Chasseaud and Catanese, 1985), G) (Baldock et al., 1991), H) (Weber et al., 1999), I) (Balant et al., 
1980), J) (Raaflaub, 1975), K) (Raaflaub and Dubach, 1975), L) (Vergin et al., 1986), M) (Lee et al., 
1986), N) (Putcha et al., 1989), O) (Wiesel et al., 1980), P) (Heintz et al., 1984), Q) (Fagerstrom, 
1984), R) (Nyberg, 1984), S) (Vereczkey et al., 1979) 
 
Ideally, in vivo solubility, permeability and metabolic activity data would be 
used in equations 5.1, 5.2 and 5.3 in order to characterize the drug dependent part 
of oral bioavailability. In practice, and especially in early phases of the lead 
development, in vivo data is not available and extrapolations or allometric scaling 
approaches are typically used. In our study, we used both in silico and in vitro 
based estimations of permeability and metabolic activity, and only in silico 
estimations of solubility.  
  In silico estimated solubility values were obtained using the on-line ADME 
Boxes (http://www.pharma-algorithms.com/webboxes) considering the “In buffer 
solubility” option and the pH values of the stomach, duodenum, jejunum and ileum. 
In a recent paper testing the predictive performance of various in silico solubility 
models in a new data set of 122 drugs, ADME Boxes presented 59% of well 
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predicted drugs within ±0.5 log unit of measured value and a standard error of 
0.62 log values (Dearden, 2006). 
In order to estimate the effective permeability of the different drugs in the 
GIT, both in silico and in vitro apparent permeabilities values based on the 
CACO-2 cell system were used. In vitro values were collected in the literature, 
under similar experimental conditions, namely, experimental pH values ranging 
from 6.8 to 7.4, with low to median passage numbers (28 to 46) and typically at a 
cell age close to 21 days. For drugs without in vitro data available, an in silico ANN 
model was used (Paixao et al., 2010b). This model was based on calculated 
molecular descriptors for a total of 296 in vitro CACO-2 apparent permeability 
(Papp) drug values also collected in the literature. The model presented correlations 
of 0.843 and 0.702 and a Root Mean Square Error (RMSE) of 0.546 and 0.791 for 
the train (N = 192) and test (N = 59) group respectively. An external validation step 
was also performed with an additional group of 45 drugs resulting in a correlation 
of 0.774 and a RMSE of 0.601. Papp values were used to estimate the effective 
human permeability (Peff). multiple linear regression, based on 29 reference drugs 
with known human effective permeability, resulted in the equation 
Log(Peff)(cm/h) = 0.932 + 0.763 × Log(Papp)(cm/h) + 0.0324 × RBN, being  RBN the 
number of rotable bonds in the molecule, and presenting an r = 0.887 and 
RMSE = 0.301 (Figure 5.2). 
 
Figure 5.2 – Relationship between the predicted logarithm of the effective human jejunal 
permeability by the multiple linear regression and the in vivo observed values. 
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To estimate the in vivo hepatic intrinsic clearance both in silico and in vitro 
intrinsic clearance (CLint) values based on suspensions of human hepatocytes 
were used. In vitro CLint values were obtained from published studies of drug 
metabolism in human hepatocytes using the substrate depletion method in 
absence of added serum. For drugs without in vitro data available, an in silico ANN 
model was again used (Paixao et al., 2010a). The ANN model was built based 
only on calculated molecular descriptors and 89 in vitro CLint values. Data was 
divided into a train group of 71 drugs for network optimization and a test group of 
another 18 drugs for early-stop and internal validation resulting in correlations of 
0.953 and 0.804 for the train and test group respectively. The external validation 
was made with another 112 drugs by comparing the in silico predicted CLint with 
the in vivo CLint estimated by the “well-stirred” model based on the in vivo hepatic 
clearance (CLH). Acceptable correlations were observed with r values of 0.508 and 
63% of drugs predicted within a 10-fold difference when considering blood binding 
in acidic drugs only. In order to scale the in silico and in vitro CLint values to the in 
vivo CLint, hepatocellularity was considered to be 107 × 106 cell/g liver (Wilson et 
al., 2003) and it was also assumed that liver weighed 20 g/kg of body weight. 
To test the applicability of the PBPK based absorption model, data from 
table 5.2 was grouped in terms of Papp and CLint source. In vitro data for both Papp 
and CLint was available for 49 drugs (Table 5.3). In vitro data for CLint only was 
available for 25 drugs (Table 5.4). In vitro data for Papp only was available for 
another 22 drugs (Table 5.5). For the remaining 68 drugs, in silico based data was 
used (Table 5.6). 
 
Statistical analysis 
 
Since bioavailability is a measure ranging from 0% to 100%, correlation 
between the predicted and observed values was determined by means of the 
Spearman rank correlation coefficient (rs) for the four groups of data. In order to 
assess the precision and bias of the model, RMSE and mean error (ME), 
respectively, were also calculated by using the following equations. 
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( )21∑ −= obspred FFnRMSE       (5.4) 
 
( )∑ −= obspred FFnME 1        (5.5) 
 
Percentage of correct values within an absolute ±20% margin error was 
determined in order to test the quantitative ability of the model to predict absolute 
bioavailability. Additionally, percentage of correct values within a ±35% error was 
also determined to test the qualitative predictive ability of the model.  
For drugs presenting a prediction error outside the ±20% threshold value, 
an evaluation of the probable cause of failure was made based on the in vivo 
pharmacokinetic data. In this context, the in vivo CLH values from table 5.2 drugs 
were determined by using equation 5.6 (Naritomi et al., 2003),  
 
( )renal
b
plasma
total
H fR
CLCL −⋅= 1        (5.6) 
 
This equation assumes that total blood clearance, determined by the ratio 
between the described total plasma clearance ( plasmatotalCL ) to the drug blood-to-
plasma concentration ratio (Rb), is the sum of Hepatic and Renal Clearance, being 
the last determined by using the fraction of drug eliminated by the kidneys ( renalf ). 
Some drugs, however, may have other non renal elimination routes besides the 
hepatic one. In these cases, it is expected that CLH determined by equation 5.6 
would be overpredicted. To minimise this, in vivo CLH was also determined by 
equation 5.7 (Iwatsubo et al., 1997), 
 ( )oralHH FQCL −⋅= 1         (5.7) 
 
This equation assumes that oral bioavailability ( oralF ) is only a result of the 
first pass-effect in the liver, allowing the determination of the liver extraction ratio 
(EH) and the CLH by multiplying EH with the hepatic blood flow rate (QH) with a 
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value of 20 ml.min-1.Kg-1. Although equation 5.7 could also provide overpredicted 
values for CLH, in theory these would be the maximum possible values for this 
parameter. For this reason, when comparing CLH determined by equation 5.6 to 
the value obtained with equation 5.7, if the first is bigger the latter prevails. For 
these drugs, the relative amount of drug escaping the first-pass effect (Fmet) is 
equal to Foral resulting that the relative amount of drug absorbed (Fabs) presents a 
value of 1. For the remaining drugs, Fmet was determined by using equation 5.8, 
 ( )HHmet QClF /1−=         (5.8) 
 
And Fabs, including both the effect of in vivo solubility and in vivo 
permeability, was determined by using equation 5.9, 
 
metoralabs FFF /=         (5.9) 
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Results  
 
Prediction using in vitro data 
 
The first evaluation of the presented methodology was made based on 
absorption and biotransformation data obtained from in vitro experiments for the 
drugs on table 5.3.  
 
Table 5.3 – Drug parameters and predicted bioavailability by the 
pharmacokinetic model for the 49 drugs with In vitro data for both Papp and 
CLint. 
 Data parameters Obs. Predicted 
Drug 
In 
vitro 
CLint 
(L/h) 
In 
vitro 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml) 
Sol 
pH4.6  
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg)
Foral 
(%) Fd Fabs Fmet
Foral
(%) 
Acebutolol 16.18 0.21 106.40 106.40 106.40 21.23 200 37 1.00 0.62 0.83 51 
Acetaminophen 6.97 1.96 7.58 7.58 7.58 7.58 2000 88 1.00 1.00 0.92 92 
Antipyrine 4.22 1.87 19.71 14.95 14.95 14.95 600 100 1.00 1.00 0.95 95 
Atenolol 0.90 0.12 923.64 923.64 923.64 473.70 50 58 1.00 0.43 0.99 42 
Betaxolol 22.47 1.80 82.76 4138 82.76 15.77 40 89 1.00 1.00 0.78 78 
Bosentan 13.48 0.19 0.00 0.02 0.01 0.06 600 50 0.08 0.43 0.99 3 
Bromocriptine 332.56 0.20 17.22 860.98 17.22 2.17 5 5 1.00 0.61 0.20 12 
Caffeine 21.12 1.70 31.50 31.50 31.50 31.50 350 100 1.00 1.00 0.79 79 
Carbamazepine 12.58 2.03 0.04 0.04 0.04 0.04 200 70 0.62 0.94 0.86 51 
Chlorpromazine 72.49 1.55 3.50 174.83 2.78 0.36 100 40 1.00 0.99 0.53 52 
Cimetidine 10.79 0.24 390.91 390.91 390.91 310.51 400 60 1.00 0.66 0.88 58 
Clozapine 53.93 1.73 179.62 1055 0.29 0.06 150 55 1.00 1.00 0.60 60 
Desipramine 62.92 0.95 59.64 2982 59.64 40.32 50 38 1.00 0.97 0.56 55 
Diazepam 10.08 1.92 2.26 0.07 0.07 0.07 15 100 1.00 1.00 0.89 89 
Diclofenac 395.47 1.43 0.03 3.81 4.09 30.31 50 54 1.00 0.99 0.96 95 
Diltiazem 116.84 2.60 16.89 16.89 0.87 0.13 120 38 1.00 1.00 0.41 41 
Famotidine 0.90 0.15 1019 16.15 0.29 0.11 40 45 1.00 0.51 0.99 50 
Furosemide 0.09 0.06 0.29 3.98 194.77 630.27 40 71 1.00 0.24 1.00 24 
Ibuprofen 37.75 1.91 0.06 8.38 9.01 58.15 800 80 1.00 1.00 0.99 99 
Imipramine 71.90 0.68 28.05 1402 23.87 3.01 200 42 1.00 0.94 0.53 50 
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Table 5.3 – (Continued) 
 Data parameters Obs. Predicted 
Drug 
In 
vitro
CLint 
(L/h) 
In 
vitro 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml) 
Sol 
pH4.6  
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg)
Foral 
(%) Fd Fabs Fmet
Foral
(%) 
Ketoprofen 22.47 2.27 0.02 3.19 3.35 25.43 200 100 1.00 1.00 0.99 99 
Lidocaine 120.44 3.05 575.33 575.33 66.06 12.88 750 37 1.00 1.00 0.40 40 
Methylprednisolone 87.18 0.89 0.08 0.08 0.08 0.08 24 82 0.99 0.94 0.48 45 
Metoprolol 62.92 2.68 558.70 558.70 558.70 217.36 100 38 1.00 1.00 0.56 56 
Morphine 215.71 0.60 220.28 11014 87.69 13.27 700 24 1.00 0.92 0.27 25 
Nadolol 0.90 0.14 759.61 759.61 692.77 245.80 120 34 1.00 0.49 0.99 48 
Naloxone 714.55 1.41 568.97 568.97 45.20 7.85 20 2 1.00 0.99 0.10 10 
Naproxen 35.95 1.53 0.18 27.62 27.06 148.68 250 99 1.00 0.99 0.99 99 
Nitrendipine 66.51 1.28 0.27 0.09 0.09 0.09 20 23 1.00 0.98 0.55 54 
Ondansetron 12.58 2.52 40.50 2025 2.28 0.32 8 62 1.00 1.00 0.87 86 
Oxazepam 17.98 2.87 0.03 0.81 0.02 0.02 25 97 0.97 1.00 0.82 79 
Phenytoin 26.47 1.93 0.16 0.16 0.16 0.18 300 90 0.99 0.97 0.75 73 
Pindolol 25.17 1.76 2213 2213 1567 988.74 20 75 1.00 1.00 0.76 76 
Pirenzepine 0.90 0.07 1976 734.28 37.66 5.83 10 33 1.00 0.29 0.99 29 
Prazosin 20.67 0.58 541.64 171.28 4.40 1.84 5 68 1.00 0.91 0.80 72 
Propofol 961.72 1.18 0.21 10.47 0.21 0.21 1 0 1.00 0.98 0.08 8 
Propranolol 116.84 2.04 482.99 24149 482.99 175.36 80 26 1.00 1.00 0.41 41 
Quinidine 49.43 1.02 893.64 893.64 67.79 10.50 400 75 1.00 0.98 0.62 61 
Ranitidine 8.99 0.14 1505 703.99 38.69 5.59 150 52 1.00 0.49 0.90 44 
Scopolamine 62.92 1.11 1076 1076 152.06 35.65 0.5 29 1.00 0.98 0.56 55 
Sildenafil 46.74 2.70 2795 368.45 9.47 2.86 50 38 1.00 1.00 0.63 63 
Sulpiride 0.09 0.06 304.34 304.34 76.45 11.31 100 27 1.00 0.25 1.00 25 
Terbutaline 0.09 0.12 1006 1006 528.20 196.25 5 26 1.00 0.43 1.00 43 
Theophylline 4.49 1.34 17.61 17.61 18.02 18.02 400 96 1.00 0.99 0.95 94 
Tolbutamide 9.71 3.50 0.19 0.24 4.00 28.31 500 85 1.00 1.00 0.99 99 
Valproic acid 4.40 1.98 2.95 4.46 83.00 262.47 500 100 1.00 1.00 0.99 99 
Verapamil 269.64 2.49 8.66 433.18 3.45 0.44 120 22 1.00 1.00 0.23 23 
Warfarin 9.89 1.76 0.20 16.52 10.45 69.03 6 93 1.00 1.00 1.00 99 
Zidovudine 28.77 0.76 15.74 15.74 15.74 15.74 350 63 1.00 0.95 0.74 70 
 
Figure 5.3 presents the relationship between the predicted and the 
observed oral bioavailabilities for the 49 drugs in this data set.  
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Figure 5.3 – Plot of the in vivo observed bioavailability vs the model predictict 
bioavailability by the PBPK model of absorption using In vitro data for both Papp and CLint. 
Solid line represents the line of unity and the dashed line the ± 20% absolute tolerance 
value. Drugs outside the ± 35% absolute tolerance value are also labelled. 
 
A correlation of rs = 0.7945 was observed with a RMSE = 17.7% and a 
ME = 1.6%. The model was able to predict 82% of data within the accepted ±20% 
error interval and 92% of the data lies within the ±35% error interval, thus showing 
excellent qualitative and quantitative prediction capabilities. When evaluating the 
reasons for wrong prediction, solubility was responsible for one case (bosentan), 
Papp was responsible for 3 cases (furosemide, ondansetron and sildenafil) and 
CLint was responsible for the remaining 5 cases (caffeine, diclofenac, 
methylprednisolone, nitrendipine and scopolamine) of badly predicted drugs. 
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Prediction using in silico Papp CACO-2 values 
 
When considering drugs from table 5.4, for which only in vitro CLint data was 
available, the model was tested by including in silico predicted Papp values to 
characterize the drug absorption phase.  
 
Table 5.4 – Drug parameters and predicted bioavailability by the 
pharmacokinetic model for the 25 drugs with in vitro data for CLint only. 
 Data parameters Obs. Predicted 
Drug 
In 
Vitro 
CLint  
(L/h) 
In 
Silico 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml)
Sol 
pH4.6 
M 
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg)
Foral 
(%) Fd Fabs Fmet
Foral
(%) 
Benzydamine 184.40 0.92 269.52 13476 19.52 2.46 5 87 1.00 0.97 0.31 30 
Bepridil 17.98 1.87 220.90 11045 6.67 0.88 200 60 1.00 1.00 0.82 82 
Bisoprolol 14.38 0.87 527.90 527.90 527.90 178.88 10 90 1.00 0.96 0.85 82 
Bufuralol 62.92 2.37 75.39 3769 41.43 5.85 60 46 1.00 1.00 0.56 56 
Carvedilol 314.58 0.79 4.07 203.26 0.13 0.02 12.5 25 1.00 0.95 0.20 20 
Cetirizine 0.90 0.39 42.65 0.42 0.37 0.47 10 85 1.00 0.81 0.99 81 
Chlorpheniramine 25.17 1.39 1045 52242 315.54 73.97 4 59 1.00 0.99 0.76 76 
Chlorprothixene 125.83 2.27 3.02 150.84 1.20 0.15 100 41 1.00 1.00 0.39 39 
Diphenhydramine 53.93 1.56 286.55 14328 97.10 16.11 44 72 1.00 0.99 0.60 60 
Gemfibrozil 197.74 1.02 0.08 6.42 3.46 25.62 600 95 1.00 0.98 0.88 86 
Granisetron 80.89 1.45 1059 1059 431.31 110.86 1 60 1.00 0.99 0.50 50 
Isradipine 161.78 0.43 0.14 0.05 0.05 0.05 5 17 0.98 0.80 0.33 26 
Lorazepam 5.71 0.25 0.02 0.61 0.01 0.01 2 93 0.98 0.67 0.89 59 
Midazolam 106.28 0.97 17.10 4.38 0.00 0.00 10 44 1.00 0.97 0.43 42 
Nifedipine 59.77 1.58 0.62 0.21 0.21 0.21 10 50 1.00 0.99 0.58 57 
Nortriptyline 24.63 0.40 13.20 660.09 13.20 6.77 125 51 1.00 0.83 0.77 63 
Omeprazole 15.28 1.25 165.35 0.74 0.46 0.48 20 71 1.00 0.99 0.84 83 
Phenacetin 67.41 3.55 1.36 1.36 1.36 1.36 1000 27.5 1.00 1.00 0.46 46 
Prednisone 87.18 0.86 0.11 0.11 0.11 0.11 10 80 1.00 0.95 0.48 46 
Procainamide 11.68 1.95 1076 1076 438.28 135.44 1000 83 1.00 1.00 0.87 87 
Propafenone 517.71 1.04 121.17 6058 121.17 24.74 150 5 1.00 0.98 0.14 13 
Tenoxicam 23.37 0.94 0.49 0.51 8.67 58.64 20 95 1.00 0.97 1.00 97 
Triazolam 14.29 1.64 8.23 0.57 0.00 0.00 0.25 44 1.00 1.00 0.85 84 
Vinpocetine 2336.88 1.54 78.47 3923 11.61 1.57 20 56.6 1.00 0.99 0.03 3 
Zolpidem 32.27 1.00 172.88 1016 0.50 0.28 10 72 1.00 0.98 0.72 70 
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Figure 5.4 presents the relationship between the observed and the 
predicted oral bioavailabilities for the 25 drugs in this data set. A correlation of rs = 
0.6089 was observed with a RMSE = 22.2% and a ME = -2.9%.  The model was 
able to predict 76% of the data within the accepted ±20% error interval and 88% of 
data within the ±35% error interval, indicating again excellent qualitative and 
quantitative prediction capabilities. When evaluating the reasons for wrong 
prediction, none of the drugs presented solubility related estimation problems. In 
silico Papp was, however, responsible for 2 wrong cases (lorazepam and triazolam) 
and in vitro CLint was responsible for the remaining 4 cases (benzydamine, 
bepredil, prednisone and vinpocetine) of badly predicted drugs.  
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Figure 5.4 – Plot of the in vivo observed bioavailability vs the model predictict 
bioavailability by the PBPK model of absorption using In vitro data for CLint only. Solid line 
represents the line of unity and the dashed line the ± 20% absolute tolerance value. Drugs 
outside the ± 35% absolute tolerance value are also labelled. 
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Prediction using in silico CLint hepatocytes values 
 
For the drugs from table 5.5, only in vitro Papp data was available. In this 
case, the model was tested by including in silico predicted CLint values to 
characterise the drug metabolisation in the liver.  
 
Table 5.5 – Drug parameters and predicted bioavailability by the 
pharmacokinetic model for the 22 drugs with in vitro data for Papp only. 
 Data parameters Obs. Pred. 
Drug 
In 
Silico 
CLint  
(L/h) 
In 
Vitro 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml)
Sol 
pH4.6 
M 
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg) 
Foral 
(%) Fd Fabs Fmet
Foral
(%) 
Acyclovir 30.79 0.14 23.05 5.79 5.79 5.92 400 30 1.00 0.48 0.72 35 
Amoxicillin 7.77 0.09 2.65 0.30 0.34 6.65 3000 50 0.87 0.28 0.93 23 
Cephalexin 16.81 0.08 1.03 0.14 0.16 0.32 500 90 0.66 0.30 0.85 17 
ciprofloxacin 3.83 0.17 208.80 9.39 1.56 1.35 500 60 1.00 0.55 0.95 53 
Clonidine 191.67 1.51 148.57 7429 6.05 0.96 0.1 95 1.00 0.99 0.30 30 
Doxycycline 0.03 0.86 46.54 1.25 1.20 1.22 100 93 1.00 0.96 1.00 96 
etoposide 333.91 0.24 0.07 0.07 0.07 0.07 100 52 0.51 0.60 0.20 6 
Fluconazole 0.78 1.34 7.52 1.50 1.50 1.50 200 90 1.00 0.99 0.99 98 
Foscarnet 0.01 0.01 457.51 1414 1414 1414 560 9 1.00 0.05 1.00 5 
gabapentin 3.89 0.00 241.93 7.48 6.51 6.51 600 60 1.00 0.01 0.95 1 
Ganciclovir 0.94 0.09 26.12 9705 9705 9705 1000 5 1.00 0.35 0.99 34 
Hydrochlorothiazide 13.15 0.11 0.94 0.94 0.96 0.99 12.5 71 1.00 0.42 0.86 36 
Losartan 35.79 0.19 2.93 0.42 0.01 0.08 50 35.8 1.00 0.59 0.99 59 
Meloxicam 4.52 1.31 7.18 0.73 41.29 226.91 15 97 1.00 0.99 1.00 99 
metformin 0.01 0.10 873.50 873.50 873.50 873.50 500 52 1.00 0.39 1.00 39 
Methotrexate 0.01 0.19 0.50 0.01 0.13 0.97 50 70 1.00 0.57 1.00 57 
Pravastatin 0.86 0.35 0.05 0.14 6.89 51.05 20 18 1.00 0.77 0.99 77 
sulfamethoxazole 1.00 1.04 1.42 0.68 4.61 29.76 1000 100 1.00 0.97 1.00 97 
Sumatriptan 17.46 0.26 725.24 725.24 501.75 144.71 100 14 1.00 0.69 0.82 57 
Tetracycline 0.05 0.23 137.36 4.34 4.15 4.24 250 77 1.00 0.65 1.00 65 
Timolol 11.45 1.30 1231 1231 1149 549.98 20 75.8 1.00 0.99 0.88 87 
trimethoprim 26.44 2.35 290.36 187.47 4.20 1.03 160 63 1.00 1.00 0.75 75 
 
Figure 5.5 presents the relationship between the observed and the 
predicted oral bioavailabilities for the 22 drugs in this data set. A correlation of 
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rs = 0.4617 was observed with a RMSE = 33.6% and a ME = -7.4%. The model 
results were:  55% of data well predicted within the accepted ±20% error and 73% 
of data within the ±35% error, indicating acceptable quantitative but good 
qualitative prediction capabilities. When evaluating the reasons for wrong 
prediction, solubility was responsible for two cases (cephalexin and ganciclovir). In 
vitro Papp was responsible for 6 cases (amoxicillin, cephalexin, etoposide, 
gabapentin, hydrochlorothiazide and losartan) and in silico CLint was responsible 
for another 5 cases (clonidine, etoposide, losartan, pravastatin and sumatriptan) of 
badly predicted drugs. As mentioned above, some drugs were badly predicted due 
to more than one drug related parameter. 
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Figure 5.5 – Plot of the in vivo observed bioavailability vs the model predictict 
bioavailability by the PBPK model of absorption using In vitro data for Papp only. Solid line 
represents the line of unity and the dashed line the ±20% absolute tolerance value. Drugs 
outside the ±35% absolute tolerance value are also labelled. 
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Prediction using in silico data 
 
For the remaining drugs, included in table 5.6, only in silico Papp and CLint 
data were used.  
 
Table 5.6 – Drug parameters and predicted bioavailability by the 
pharmacokinetic model for the 68 drugs with only in silico based data. 
 Data parameters Obs. Predicted 
Drug 
In 
Silico 
CLint  
(L/h) 
In 
Silico 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml)
Sol 
pH4.6 
M 
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg) 
Foral 
(%) Fd Fabs Fmet
Foral 
(%) 
Alendronate 0.03 0.01 463.88 292.69 292.69 292.69 70 2 1.00 0.04 1.00 4 
Allopurinol 2.89 2.96 3.05 3.05 3.05 3.05 300 53 1.00 1.00 0.97 97 
Alprazolam 27.52 1.66 0.09 0.35 0.01 0.01 1000 88 0.31 0.99 0.75 23 
Amiodarona 109.31 9.10 0.33 16.55 0.05 0.01 400 46 1.00 1.00 0.43 43 
Amitriptyline 76.65 0.84 5.41 270.48 2.15 0.28 100 48 1.00 0.96 0.51 49 
amlodipine 7.26 0.85 564.47 564.47 145.09 23.53 10 74 1.00 0.96 0.92 88 
Aprepitant 114.69 2.75 10.18 1.31 0.00 0.00 125 65 1.00 1.00 0.41 41 
Buspirone 20.15 1.54 1932 17182 8.63 1.64 20 4 1.00 0.99 0.80 80 
Calcitriol 8.64 4.99 0.01 0.33 0.01 0.01 0.0042 61 0.90 1.00 0.90 81 
Candesartan 30.67 2.62 0.07 0.04 0.02 0.14 16 42 1.00 0.99 1.00 98 
cefixime 0.05 0.02 1.19 2.22 130.79 557.93 200 47 1.00 0.23 1.00 23 
Chlorthalidone 3.40 2.04 0.02 0.02 0.02 0.02 50 64 0.63 0.94 0.96 57 
Cinacalcet 13.68 2.21 1.18 59.18 0.37 0.05 75 20 1.00 1.00 0.86 85 
Clindamycin 114.78 0.73 996.41 996.41 75.59 15.43 150 87 1.00 0.95 0.41 39 
Cyclophosphamide 7.20 0.73 32.87 32.87 32.87 32.87 1500 88 1.00 0.95 0.92 87 
Dapsone 0.01 0.42 0.08 0.05 0.05 0.05 100 93 0.51 0.73 1.00 37 
Dicloxacillin 414.94 0.05 0.14 604.51 481.32 540.05 2000 50 1.00 0.23 0.73 17 
didanosine 12.28 2.00 15.25 11.57 11.57 11.84 400 38 1.00 1.00 0.87 87 
dofetilide 7.05 0.43 384.64 285.14 5.56 0.80 0.55 96 1.00 0.85 0.92 78 
Entacapone 66.46 0.23 1.08 1.08 1.76 6.53 400 42 1.00 0.66 0.97 64 
ethambutol 18.25 0.56 1952 1952 1447 955.86 800 77 1.00 0.90 0.82 74 
Finasteride 72.47 4.22 0.03 1.74 0.03 0.03 5 63 1.00 1.00 0.53 53 
Flecainide 5.26 1.03 104.09 5204 70.37 9.94 100 74 1.00 0.98 0.94 92 
flumazenil 88.89 0.78 0.87 0.44 0.44 0.44 200 16 1.00 0.95 0.48 45 
Fluorouracil 288.30 1.49 6.99 6.99 7.32 8.80 1050 28 1.00 0.99 0.22 22 
fluphenazine 41.20 3.35 234.99 2512 0.71 0.12 12 3 1.00 1.00 0.66 66 
galantamine 1.90 0.77 673.71 673.71 244.61 51.11 12 95 1.00 0.95 0.98 93 
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Table 5.6 – (Continued) 
 Data parameters Obs. Predicted 
Drug 
In 
Silico
CLint 
(L/h) 
In 
Silico 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml)
Sol 
pH4.6 
M 
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg) 
Foral 
(%) Fd Fabs Fmet
Foral 
(%) 
Glimepiride 75.25 0.20 0.05 3.16 1.05 7.96 3 100 1.00 0.60 0.99 60 
Glyburide 40.59 0.13 0.01 0.88 0.29 2.21 3 90 1.00 0.47 0.99 47 
Hydromorphone 137.61 0.85 668.97 668.97 211.55 42.21 4 42 1.00 0.96 0.37 36 
imatinib 139.77 1.20 2058 2412 0.65 0.12 400 98 1.00 0.99 0.37 36 
Irbesartan 4.74 3.22 2.36 2.09 0.02 0.02 50 70 1.00 1.00 0.94 94 
Isosorbide Dinitrate 88.48 0.22 0.92 0.92 0.92 0.92 20 22 1.00 0.64 0.48 31 
Isosorbide-5-
mononitrate 0.88 0.32 195.61 195.61 195.61 195.61 20 93 1.00 0.76 0.99 75 
Lamivudine 23.00 0.51 741.97 22.93 14.14 14.14 100 86 1.00 0.89 0.78 69 
Lansoprazole 8.30 0.27 97.16 19.34 0.24 0.25 15 81 1.00 0.71 0.91 64 
Letrozole 11.77 4.31 0.46 4.62 0.09 0.09 2.5 100 1.00 1.00 0.87 87 
Levetiracetam 2.10 3.45 60.40 60.40 60.40 60.40 500 100 1.00 1.00 0.97 97 
Levofloxacin 206.33 0.80 610.17 19.38 1.66 1.44 500 99 1.00 0.96 0.28 27 
Linezolid 9.29 2.10 35.96 1.50 1.44 1.44 600 100 1.00 1.00 0.90 90 
Melphalan 82.59 0.38 14.28 4.12 4.12 4.21 25 71 1.00 0.81 0.50 40 
Meperidine 56.04 0.50 566.69 28334 149.06 28.40 20 52 1.00 0.88 0.59 52 
mercaptopurine 0.02 1.92 0.57 0.57 0.61 0.92 100 12 1.00 1.00 1.00 100 
Methadone 63.77 0.40 23.48 1174 2.96 0.39 133 92 1.00 0.82 0.56 46 
metoclopramide 82.87 2.25 788.66 788.66 193.59 36.05 20 76 1.00 1.00 0.49 49 
Metronidazole 50.77 0.46 62.15 15.98 15.98 15.98 100 99 1.00 0.86 0.61 53 
Montelukast 269.11 3.56 0.01 0.06 0.00 0.02 10 62 0.66 0.95 0.94 60 
moxifloxacin 51.35 1.45 139.21 0.58 0.02 0.02 400 86 1.00 0.99 0.61 61 
Nalmefene 88.56 0.16 100.18 5009 7.96 1.10 50 40 1.00 0.54 0.48 26 
Nitrofurantoin 147.73 1.02 0.10 0.10 0.11 0.19 50 90 1.00 0.96 0.35 34 
Oxycodone 349.39 1.15 722.54 722.54 161.76 31.54 5 42 1.00 0.98 0.19 19 
Phenobarbital 2.55 1.60 0.44 0.44 0.49 0.79 90 100 1.00 0.99 0.97 96 
Quetiapine 124.58 0.91 1241 21028 12.41 2.53 250 9 1.00 0.97 0.39 38 
Quinine 27.95 2.44 893.64 44682 67.79 10.50 700 76 1.00 1.00 0.74 74 
Repaglinide 57.24 0.52 0.72 0.33 0.01 0.06 4 56 1.00 0.88 0.97 85 
Riluzole 494.00 0.03 52.44 9.97 0.12 0.12 50 64 1.00 0.14 0.14 2 
Risedronate 0.01 2.26 214.78 24.66 214.78 503.48 5 1 1.00 1.00 1.00 100 
Risperidone 142.81 0.01 593.41 17471 8.19 1.16 3 66 1.00 0.06 0.36 2 
Rizatriptan 15.73 0.35 1072 1072 309.30 72.51 10 47 1.00 0.79 0.84 66 
Tamsulosin 67.17 1.79 219.42 219.42 46.91 6.63 0.4 100 1.00 1.00 0.55 54 
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Table 5.6 – (Continued) 
 Data parameters Obs. Predicted 
Drug 
In 
Silico 
CLint  
(L/h) 
In 
Silico 
Peff 
(cm/h) 
Sol 
pH1.7 
(mg/ml)
Sol 
pH4.6 
M 
(mg/ml)
Sol 
pH6.5 
(mg/ml)
Sol 
pH7.5 
(mg/ml)
Dose 
Max 
(mg) 
Foral 
(%) Fd Fabs Fmet
Foral 
(%) 
Tegaserod 0.96 0.53 81.13 81.13 81.13 67.48 6 11 1.00 0.89 0.99 88 
terazosin 23.96 3.57 510.81 150.75 3.70 1.54 1 82 1.00 1.00 0.77 77 
Tramadol 19.77 0.40 692.87 34643 692.87 479.35 100 70 1.00 0.83 0.80 66 
Trazodone 5.22 3.25 1176 6448 3.17 1.32 100 81 1.00 1.00 0.94 94 
Valsartan 23.60 0.75 0.03 82.80 106.92 477.60 80 39 1.00 0.95 0.97 92 
Vinorelbine 1154.79 9.46 1004 14809 4.92 0.65 170 27 1.00 1.00 0.07 7 
Zaleplon 31.82 0.34 0.35 0.20 0.20 0.20 10 31 1.00 0.78 0.72 56 
Ziprasidone 168.26 0.50 180.27 1216 0.33 0.06 20 59 1.00 0.88 0.33 29 
 
Figure 5.6 presents the relationship between the observed and the 
predicted oral bioavailabilities for the 68 drugs in this data set. As expected, due to 
the increased prediction variability of the added in silico models, a weak 
correlation of rs = 0.1111 was observed with a RMSE = 38.6% and a ME = -2.7%. 
The model could only predict 46% of data within the accepted ±20% error but still 
was able to predict 66% of data within the ±35% error. When evaluating the 
reasons for wrong prediction, solubility was responsible for 2 cases (alprazolam 
and dapsone). In silico Papp was responsible for 14 cases (candesartan, cefixime, 
dapsone, dicloxacillin, flumazenil, fluphenazine, glimepiride, glyburide, 
mercaptopurine, rizulone, risedronate, risperidone, tegaserod and valsartan) and 
CLint was responsible for another 25 cases (allopurinol, aprepitant, buspirone, 
cinacalcet, clindamycin, didanosine, fluphenazine, imatinib, levofloxacin, 
melphalan, mercaptopurine, methadone, metoclopramide, metronidazole, 
moxifloxacin, nitrofurantoin, oxycodone, quetiapine, repaglinide, riluzole, 
risperidone, tamsulosin, tegaserod, zaleplon and ziprasidone) of badly predicted 
drugs.  
 
Chapter 5. Evaluation of a physiologically based model to 
predict oral bioavailability using in vitro and in silico drug 
related parameters 
164 Paulo J. P. A. Paixão, 2010 
 
allop
alpra
buspi
cande
cinac
clind
dapso
didan
fluph
glime
glybu
imati
levof
merca
methametro
nitro
riluz
rised
rispe
tamsu
tegas valsa
0
20
40
60
80
100
0 20 40 60 80 100
F (%)
F 
pr
ed
ic
te
d 
(%
)
 
Figure 5.6 – Plot of the in vivo observed bioavailability vs the model predictict 
bioavailability by the PBPK model of absorption using In silico data for both Papp and CLint. 
Solid line represents the line of unity and the dashed line the ±20% absolute tolerance 
value. Drugs outside the ±35% absolute tolerance value are also labelled. 
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Discussion  
 
Model structure 
 
We developed a compartmental model, based on the CAT model, which 
considers gastric and intestinal transit time, solubility, permeability and hepatic 
metabolism, as primary conditionants of drug bioavailability. Although some 
important factors were not considered, namely the effect of the GIT drug 
transporters, drug degradation in the GIT lumen, enterocyte metabolisation, to 
name a few, the considered drug characteristics are expectably the main factors to 
limit bioavailability for the majority of drugs. However, since CACO-2 cells present 
both metabolisation and transport systems (Vogel, 2006) these mechanisms may 
be included in the permeability estimation by the CACO-2 cells, if Papp values were 
collected outside the saturation zone and the drugs present proportional dose 
absorption. 
In order to characterize the dissolution of the drug in the GIT, it is necessary 
to consider the water volume in each compartment. With this purpose, a water 
model was built based on the described daily rates of secretions in the different 
parts of the GIT as well as the described percentage of water reabsorption. The 
sum of the steady-state values for the small intestine total a volume of 308 ml, 
which are in agreement with the in vivo experimental values of 165 ml (range 
25-350 ml) (Marciani et al., 2007). Additionally, the water absorption rate constant, 
with a value of 0.7015 h-1 (Peff = 1.7×10-4 cm⋅s-1) is also consistent with the 
experimental water (D2O) Peff values of 1.4 and 2.4×10-4 cm⋅s-1 under diffusion and 
convective conditions in humans (Fagerholm et al., 1999).   
The absorption rate of the drugs was assumed folow first order kinetics and 
be dependent on the jejunal effective permeability (Peff). Since CACO-2 apparent 
permeabilities (Papp) were used as estimators of Peff, a multiple linear regression 
model, using CACO-2 Papp values and RBN, was built to relate these parameters. 
Previous authors had used simple linear relationships with variable success 
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(Parrott and Lave, 2002; 2008; Sun et al., 2002). However, this may not reflect the 
fact that, if highly permeable drugs would most likely be absorbed in the upper part 
of the villus, low permeability drugs are likely to diffuse throughout the intervillous 
space and will have access to the majority of the absorptive area (Lennernas, 
1998; Palm et al., 1996). The RBN descriptor, since it is also related to the 
molecular weight, can account for the difference in surface area that exists, due to 
the lack of villus on CACO-2 cell, between CACO-2 cells and the human intestine 
for low permeability drugs system. Another described morphophysiological 
difference between CACO-2 and the intestinal epithelia is the larger density of tight 
junctions presented in CACO-2 (Collett et al., 1997). This fact implies that for 
drugs with important paracellular absorption, CACO-2 would down predict the 
actual in vivo value. RBN, that counts the number of bonds in the molecule that 
allow a free rotation around themselves and is a measure of the flexibility of the 
molecule, can also compensate this effect as proposed by others (Artursson et al., 
1993).  
Metabolisation of the drug was assumed to be primary at the liver, and the 
“well-stirred” model was used to simulate that organ. The choice of liver model 
does not seem to significantly influence the CLH predictive capacity both when 
using rat isolated microsomes and hepatocytes suspensions (Ito and Houston, 
2004). There is no significant difference for low metabolized drugs when using the 
“well-stirred”, the “parallel tube” and the “dispersion” models. However, drugs with 
relatively higher clearance values show a more pronounced dependence on the 
blood flow properties of dispersion and convection (Houston and Carlile, 1997; 
Niro et al., 2003) and the “dispersion” and “parallel tube” models usually present 
the best results (Iwatsubo et al., 1997). Even so, for the sake of simplicity and 
minor differences in the prediction of the in vivo CLH, the “Well-Stirred” model can 
be used for CLh prediction (Houston and Carlile, 1997; Ito and Houston, 2004; 
2005). Use of fu,B is also a question of debate. Neglecting this parameter in basic, 
zwitterionic and neutral drugs seems to improve CLH estimations both when using 
microsomes (Obach, 1999) or hepatocytes suspensions (Jacobson et al., 2007; 
Lau et al., 2002; McGinnity et al., 2004; Reddy et al., 2005). In an in silico 
approach to predict CLH, low clearance drugs were generally well predicted either 
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using fu,B for all drugs or just for acidic drugs. However, for high clearance drugs, 
neglecting fu,B for basic, neutral and zwitterionic drugs resulted in better predictions 
(Paixao et al., 2010a). 
 
Drug Parameters 
 
An important drug specific parameter involved in the dissolution is the drug 
solubility in the GIT medium. This may depend on a variety of factors, such as pH, 
surfactant, buffer capacity and ionic strength, that are difficult to simulate in vitro 
(Takano et al., 2006). As an approximation we used in silico intrinsic water 
solubility and the effect of pH in the drug ionization, and by consequence in its 
solubility, at the GIT pH values using ADME Boxes. Since various authors have 
indicated a relationship between drug lipophilicity and its increased solubility in the 
presence of bile salts (Mithani et al., 1996; Wiedmann and Kamel, 2002; 
Wiedmann et al., 2002), the surfactant effect was introduced by considering that 
drugs with logP values above 2.5 would be 50 times more soluble in the 
duodenum that the drug aqueous solubility at pH 4.5. Due to pH and water volume 
changes in the GIT, there is the possibility of drug precipitation when the dissolved 
drug transits from one compartment to the next. However, Box et al. (Box et al., 
2006) identified that about 95% of the acids and 75% of the bases they studied by 
using a potentiometric procedure to establish the aqueous solubility, were capable 
to form supersaturated solutions. In this context, it was assumed that no 
precipitation occurs. Parrot et al. (Parrott et al., 2005) using GastroplusTM without 
adjusted solubility for bile salt solubilisation adjuvant, observed that 27 of 29 
compounds with low solubility, 42% of the total studied drugs, presented their 
bioavailability under predicted. In our case, although simple approximations were 
made, only 3% of drugs presented bad predictions due to solubility issues. 
In order to quantify the drug absorption process, permeability data collected 
in CACO-2 cells was used. This cell system is a widely performed in vitro test with 
interesting properties when extrapolating results to bioavailability.  CACO-2 cells, 
which are polarized epithelial cells, can form a differentiated monolayer that 
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resembles the morphological and biochemical characteristics of the human 
intestinal epithelium (Vogel, 2006). Additionally, a sigmoid relationship between 
the Papp across CACO-2 cells and the fraction absorbed in humans has been 
shown for passively absorbed drugs (Artursson and Karlsson, 1991; Stenberg et 
al., 2001). Although a similar number of gene expression was observed between 
CACO-2 cells and the human duodenum, around 17% of gene sequences 
presented at least a 5-fold difference in expression (Sun et al., 2002). Due to this, 
extrapolating Papp CACO-2 values for drugs absorbed by carrier mediated 
mechanisms or subject to important metabolic degradation at the enterocyte is 
more difficult. For this reason, we used in vitro CACO-2 data describing mainly the 
passive diffusion mechanism of absorption (Paixao et al., 2010b) which resulted in 
around 87% of drugs with correct absorption prediction within the ±20% threshold 
value (Tables 5.3 and 5.5 data). Although some of the badly predicted drugs were 
indeed substrates of transporters, our results indicate that passive diffusion is the 
primary route of absorption for the vast majority of the studied drugs. These results 
were also observed with the in silico based Papp CACO-2 data. In this case (Tables 
5.4 and 5.6 data), around 83% of drugs presented correct absorption predictions 
indicating that the used in silico model may be a valid alternative to the in vitro 
model in the lead development phase when in vitro data is still not available. 
To characterize the first-pass effect at the liver, we used in vitro data 
obtained in suspensions of isolated human hepatocytes (Paixao et al., 2010a). 
Hepatocytes are intact cells with a complete set of phase I and II metabolizing 
enzymes that mimic the in vivo metabolisation of drugs (Gomez-Lechon et al., 
2003). Additionally, the presence of uptake and efflux transporters is also an 
important characteristic of this cell system with relevance in the drug 
metabolisation process (Hewitt et al., 2007). With the optimization of the 
cryopreservation protocols, an increased pool of liver sources is now available with 
a minimal loss of metabolic activity (Blanchard et al., 2005; Griffin and Houston, 
2004; McGinnity et al., 2004; Naritomi et al., 2003). Due to these facts, it appears 
to be the most promising tool to predict CLH in the development phase of new drug 
entities (Fagerholm, 2007). Our results confirm that using in vitro data from this 
model (Tables 5.3 and 5.4 data) is suitable to predict the first-pass effect, with 
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around 88% of drugs with correct predictions. When using the in silico model (data 
from Tables 5.5 and 5.6), lower prediction ability was observed, with around 67% 
of drugs with correct predictions within the ±20% threshold value. This value 
improved, however, to around 78% of drugs with correct predictions when the 
±35% threshold value was considered. 
 
Model performance 
 
The model statistical performance under the four studied scenarious is 
presented in table 5.7. As expected, the model best performance in predicting 
human bioavailability was obtained when using only in vitro Papp and CLint data. In 
this scenario, 82% of good predictions within the ±20 % accepted range was 
observed with the lower RMSE of all the simulations. Parrot and Lavé (Parrott and 
Lave, 2002) evaluated the performance of two commercial packages 
(GastroplusTM and iDEATM) in predicting the absorbable fraction in 28 drugs. A 
RMSE of 22% was described for both models, larger than the RMSE value 
obtained in our data considering the complete bioavailability process. De Buck et 
al. (De Buck et al., 2007b) in a retrospective analysis of 16 clinically tested drugs 
and using GastroplusTM with in vitro Papp CACO-2 (n = 13), in silico Papp CACO-2 
(n = 3) and in vitro CLint determined in Human and rat microsomes and 
hepatocytes suspensions obtained an average fold error of 1.06 and a RMSE of 
15%, similar to the present results. Cai et al. (Cai et al., 2006) evaluated an 
integrated in vitro - PBPK model to predict human bioavailabilities of another 16 
drugs. CLint was determined in human hepatocytes suspensions, and the source of 
the absorption data was obtained from the literature and in-house reports. Their 
method outperformed the commercial package iDEATM with 69% vs 63% of good 
predictions within the ±20% accepted range and a RMSE = 19% vs 25%. Our 
work, as well as these reports, indicate that in vitro data obtained in CACO-2 and 
Human hepatocytes suspensions, when used in various PBPK models of 
absorption, are capable of providing statistically relevant predictions of the drug 
bioavailability in humans. 
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It is frequent in the lead development, that not all the in vitro data is 
available at some time of the discovery phase. Additionally, in the beginning of the 
new drug discovery process, pure in silico methods are frequently used 
(Venkatesh and Lipper, 2000). We tested the ability of the proposed method to 
predict human bioavailability in the typical discovery pipeline, when not all data is 
yet available.  
The first situation explored considers that in vitro CLint in human 
hepatocytes suspensions data is available, but only in silico estimates of Papp in 
CACO-2 are possible to be used. In this case an ANN model, presenting a 
correlation of 0.774 and a RMSE of 0.601 log values in a validation group of 45 
drugs, was used (Paixao et al., 2010b). Using these inputs, the PBPK model 
presented 76% of good predictions within the ±20 % accepted range and a RMSE 
of 22.2%.  De Buck et al. (De Buck et al., 2007a), using in vitro CLint determined 
in rat microsomes, in silico Papp values and GastroplusTM, obtained a RMSE of 
32.1 and 63.3% of values within a 2-fold error when predicting the rat oral 
bioavailability. Parrott et al. (Parrott et al., 2005) when evaluating the utility of 
PBPK models in early drug discovery, using in vitro Papp in PAMPA, in vitro CLint in 
rat hepatocytes and GastroplusTM, obtained a RMSE of 31% and a r2 of 0.16 when 
predicting the rat oral bioavailability. Although different species were considered, 
our in silico Papp model provided better prediction capabilities than these models, 
even when in vitro PAMPA Papp data is considered.  
 
Table 5.7 – Statistical comparison of the performance of the 
pharmacokinetic model based in the introduction of the 
different data sources. 
 CLint In vitro  In silico  
 Papp In vitro In silico In vitro In silico  
rs  0.795 0.609 0.462 0.111 
RMSE (%F)  17.7 22.2 33.6 38.6 
ME (%F)  1.57 -2.87 -7.43 -2.75 
% correct values within ± 20%  81.6 76.0 54.5 47.1 
% correct values within ± 35%  91.8 88.0 72.7 66.2 
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The next situation explored considers that in vitro Papp CACO-2 data is 
available, but only in silico estimates of CLint in human hepatocytes suspensions 
are possible to be used. In this case an ANN method, able to predict 63% of in 
vivo logCLint within a 10-fold error in a validation group of 112 drugs, was used 
(Paixao et al., 2010a). When introduced in the proposed PBPK Model, 55% of 
good predictions within the ±20% accepted range and a RMSE of 33.6% were 
obtained. To our knowledge, the ANN model used for CLint predictions is the only 
described in silico model able to predict the metabolisation of drugs in human 
hepatocytes suspensions, limiting therefore the comparison of its performance 
with other models.  
The final situation explored, considers that no in vitro data is available, 
simulating the initial situation in the drug development process. When introducing 
only in silico derived data in the proposed PBPK model, only 46% of predictions 
within the ±20% range and a RMSE of 38.6% were obtained. A low correlation of 
rs = 0.111 was also obtained. This result was expected due to the increase of the 
predictive error presented in the in silico models, that combined in the PBPK 
model, resulted in a poor ability to quantitatively predict the Human oral 
bioavailability. Considering, however, that the model could correctly predict 66% of 
the drugs within a ±35% error, which is sufficient to the establishment of the 
qualitative class of absorption, indicates that this approach can still be used for the 
early candidate selection. Yoshida and Topliss (Yoshida and Topliss, 2000) 
developed a QSAR model for human oral bioavailability classification that was 
able to correctly predict the class of absorption of 24 in 40 drugs (60% success). 
Therefore, the model herein described, presents similar classification rates of 
previously published models, and additionaly provides mechanistical information 
for the reason of the drug limited absorption. 
 
Conclusions 
 
The presented methodology, a PBPK model of absorption considering drug 
dissolution and absorption in the GIT and drug metabolisation in the liver, is a 
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convenient approach to predict and characterise the human oral bioavailability in 
the drug development process. When based in in silico solubility drug values and 
in vitro absorption and metabolisation data, the model was able to correctly 
establish the oral bioavailability for the vast majority of the studied drugs. Inclusion 
of in silico permeability and metabolisation data degraded the model performance, 
especially when CLint is considered. If the absorption process seems to be 
sufficiently predicted based only on the molecular structure of the drug, in silico 
prediction of the metabolisation rate, in spite of the initial modelling efforts, is still 
prone to improvement. However, qualitative establishment of bioavailability was 
still statistically possible, which indicates that this model may be an important tool 
in the drug discovery pipeline, allowing the refinement of its predictions and 
indicating lines of investigation in order to improve the overall success rate of lead 
development.  
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Annex 1 
 
Differential equations of the model 
 
The presented physiologically based absorption model can be divided in four 
parts, namely, 1) the gastrointestinal track (GIT) water content; 2) the amount of 
drug in solid form; 3) the amount of drug in dissolved form and 4) the amount of 
drug metabolized by the liver. 
 
Part 1 
 
Considering the water volume, it is assumed that the GIT is in steady-state 
regarding the daily amounts of water released by endocrinal glands and the 
amount of water reabsorbed back to the blood circulation at the small intestine. 
The movement of water through the GIT follows the considerations of the original 
CAT model, namely water movement through the GIT can be viewed as a process 
flowing through a series of segments, each described by a single compartment 
with linear transfer kinetics from one to the next. Therefore, the rate of water 
content change in the stomach can be depicted by 
 
1RVkdt
dV
SS
S +⋅−=         (5.10) 
where VS is the water volume in the stomach, kS the rate constant of gastric 
emptying, t is the time and R1 is the water secretion by the salivary and 
gastric glands, assumed to be constant over time. 
  
Regarding the small intestine, this was divided in 7 compartments. The first one, 
corresponding to the duodenum, is depicted by 
 
( ) 32121 RRVkkVkdt
dV
OHtSS ++⋅+−⋅+=      (5.11) 
where V1 is the duodenum water volume, kt the rate constant of the small 
intestine transit, kH2O is the water absorption rate constant, R2 is the water 
secretion by the pancreatic and biliary glands and R3 is the water secretion 
by the intestinal mucus glands, both assumed to be constant over time.  
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The remaining 6 compartments, considering the jejunum and ileum are depicted 
by 
 
( ) 321 RVkkVkdt
dV
nOHtnt
n +⋅+−⋅+= − , 7,...,3,2=n    (5.12) 
 
The rate of water absorption from the small intestine into blood is calculated by, 
 
∑
=
⋅=
7
1
2
n
nOH
abs Vk
dt
dV         (5.13) 
 
where Vabs is the amount of water absorbed in the small intestine which  
can be calculated by, 
 
∫ ∑∞
=
⎟⎠
⎞⎜⎝
⎛ ⋅=
0
7
1
2 dtVkV
n
nOHabs        (5.14) 
 
The sum of water secretion in the GIT totals 6500 ml/day and kH2O was determined 
by non-linear regression in order to result in a steady-state amount of reabsorbed 
water of 5200 ml/day. The steady-state volumes of the different compartments 
were thereafter considered the initial condition volumes. With the administration of 
the drug, it is also considered the administration of 250 ml of water as a bolus 
directly to the stomach, which results in a temporal change of the amount of water 
throughout the GIT, as can be seen in figure 5.7.  
 
Figure 5.7 – Time course of the water volume in the stomach (VS) and small intestine 
(V1 - V7) after the ingestion of 250 ml of water as predicted by the proposed 
physiologically based water model. 
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Part 2 
 
Regarding the amount of drug in solid form, the model uses the Noyes-Whitney 
equation in order to describe its solubilisation and assumes that drug is 
administered as spherical particles, which maintain constant dimension over time. 
This is compatible with instant deaggregation of pharmaceutical solid forms, like 
oral suspensions, capsules and immediate release tablets. The movement of drug 
particles through the GIT follows again the considerations of the original CAT 
model. In this case, the solid drug content change over time in the stomach can be 
depicted by, 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −⋅⋅−⋅−=
S
SS
sPSdPSS
PS
V
MSMkMk
dt
dM      (5.15) 
where MPS is the amount of drug as particles in the stomach, Mss is the 
amount of dissolved drug in the stomach, SS is the drug solubility at the 
stomach pH and kd is determined by, 
 
p
d rh
Dk ⋅⋅
⋅= ρ
3          (5.16) 
where D is the diffusion coefficient, ρ is the density of drug, h is the 
diffusion layer thickness and rp the radius of the particles 
 
In the small intestine, the solid drug content change over time in the different 
compartments is described by, 
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dM , 7,...,2,1=n  (5.17) 
 
where MPn is the amount of drug as particles in the nth small intestine 
compartment, Msn is the amount of dissolved drug in the in the nth small 
intestine compartment, and Sn is the drug solubility in the nth small intestine 
compartment pH.  
 
Since different solubilities and water volumes exist in the different GIT 
compartments, movement of drug may result in a concentration of dissolved drug 
above the drug solubility. In this case, it is assumed the occurrence of a 
supersaturated solution without precipitation, which is mathematically described 
by, 
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The amount of solid drug reaching the colon was also modelled. Since it is 
assumed that no significant absorption of drug occurs at this part of the GIT, the 
amount of drug that enters the colon will not be available to exert its 
pharmacological action and will not be bioavailable. In this case, the rate of drug 
reaching the colon will be depicted by  
 
7Pt
PC Mk
dt
dM ⋅=         (5.19) 
 
where MPC is the amount of solid drug in the colon and MP7 the amount of 
solid drug in the 7th small intestine compartment.  
 
 
In the same way, the rate of drug being dissolved at any time will be, 
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where Md is the mass of drug dissolved.  
 
 
Regarding the global process of drug dissolution, when t → ∞ then,  
 
PCdo MMM +=         (5.21) 
where M0 is the administered drug dose.  
 
In this case, the relative amount of drug that was dissolved and available to be 
absorbed (Fd) can be determined by 
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Part 3 
 
Considering the amount of drug in dissolved form, the model assumes that 
absorption is only significant at the small intestine. In this case, the rate of change 
of dissolved drug content in the stomach can be depicted by,  
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dt
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where MSS is the amount of dissolved drug at the stomach.  
 
 
In the small intestine, the change of dissolved drug content over time in the 
different compartments is described by, 
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where MSn is the amount of dissolved drug in the nth small intestine 
compartment, Peff is the human effective permeability and rn is the 
intestinal radius in the nth small intestine compartment.  
 
 
The amount of dissolved drug reaching the colon that will not be bioavailable was 
also modelled. In this case, the rate of drug reaching the colon will be depicted by  
 
7St
SC Mk
dt
dM ⋅=         (5.25) 
 
where MSC is the amount of dissolved drug at the colon and MS7 the 
amount of dissolved drug in the 7th small intestine compartment.  
 
The rate of drug being absorbed at any time will be, 
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where Mabs is the mass of drug absorbed.  
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Considering only the process of drug absorption, and by the mass balance, 
when t→∞ then, 
SCabsd MMM +=         (5.27) 
 
In this case, the relative amount of dissolved drug that was absorbed (Fabs) 
can be determined by 
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Part 4 
 
Regarding the amount of drug metabolized in the liver, this organ was modelled 
according to the “well-stirred” model, assuming instant and homogenous drug 
dissolution in the liver. It is also assumed that metabolization is dose proportional. 
In this case, the drug content change over time in the liver can be depicted by,  
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where CL is the drug concentration in the liver, QH is the liver blood flow, VL 
is the liver volume, KL is the equilibrium liver:blood partition coefficient, 
CLint is the liver intrinsic clearance and fu,B is the fraction of unbound drug 
in blood.  
 
The rate of drug metabolization can be described as 
 
L
LBumet
K
Cf
CL
dt
dM ⋅⋅= ,int        (5.30) 
 
And the rate of drug not metabolized and reaching the systemic circulations by 
 
L
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dM ⋅=         (5.31) 
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Since the relative amount of drug metabolized in the liver (EH) in the “well-stirred” 
conditions can be defined as 
 
int,
int,
rate cedisapearanliver 
ratetion metaboliza
CLfQ
CLf
E
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Bu
H ⋅+
⋅==     (5.32) 
 
Then the relative amount of drug escaping the first-pass effect of the liver (Fmet) 
can be determined by 
 
Hmet EF −=1          (5.33) 
 
Finally, the absolute bioavailability, considered in the present model as dependent 
of drug solubilisation, absorption and metabolization, is calculated by 
 
metabsdoral FFFF ⋅⋅=         (5.34) 
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With the increasing understanding of the molecular basis of diseases, as 
well as with the recent advances in genomics and proteomics, the development of 
new drug entities is more and more targeted oriented. Computer aided design of 
new molecules is now an integral part of the drug development process. However, 
the number of new drugs reaching the market has remained relatively constant at 
around 20 new molecular entities per year between 1990 and 2009 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda).  
Since, in targeted orientated research, molecules are primary optimized in 
terms of their pharmacological properties, undesirable pharmacokinetic 
characteristics is still one of the major reasons for lead discontinuation. In this 
work an in silico approach to predict human oral bioavailability was pursued, with 
the following achievements: 
• An artificial neural network based only on calculated molecular descriptors 
for modelling 296 in vitro CACO-2 Papp drug values collected in the literature 
was built. The model resulted in correlations of 0.843 and 0.702 and RMSE 
of 0.546 and 0.791 for the train and test group respectively. External 
validation was made with an additional group of 45 drugs with a correlation 
of 0.774 and RMSE of 0.601 indicating good prediction abilities.  
• A systematic approach using mechanistic, partial least squares regression 
and artificial neural network models was undertaken in order to relate 
various in vitro and in silico molecular descriptors to a dataset of 93 drug Rb 
values collected in the literature. The ANN model resulted in the best 
overall approach, with r2 = 0.927 and r2 = 0.871 for the train and the test 
sets respectively. This model provided predictions of Rb with a percentage 
of correct values within a 1.25 fold error of 86%, 84% and 87% in the train, 
test and validation set of data. 
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• An artificial neural network for modelling In vitro CLint data obtained in 
human hepatocytes suspensions based only on calculated molecular 
descriptors was built. The model resulted in correlations of 0.953 and 0.804 
and RMSE of 0.236 and 0.544 for the train and test group respectively. A 
correlation of 0.467 and RMSE of 0.635 was obtained in an external group 
of 4 drugs. 
• The applicability of using CLint data from human hepatocytes suspensions, 
both from in silico and in vitro origin, and the “well-stirred” model of the liver 
to predict the Human CLH was explored. Higher prediction abilities were 
observed when drug blood binding was neglected for neutral, basic and 
zwitterionic drugs. 
• Inclusion of data from the previous models in a physiologically-based 
pharmacokinetic model of absorption in order to estimate the human 
absolute bioavailability was tested. Utilization of in vitro data for both Papp 
and Clint was able to predict the human absolute bioavailability with 
reasonable accuracy. Model performance was reduced with the introduction 
of the in silico estimated parameters, especially when CLint is considered. 
Utilization of in silico data for both Papp and Clint, due to the combination of 
variability from the computational models, only allowed a qualitative 
estimation of the human absolute bioavailability, but still within acceptable 
standards. 
 
From the presented results it can be concluded that in silico modelling can 
be used for the lead compound selection in a first line approach. However, its 
predictions should be prone to early confirmation. Since the presented models 
were based on in vitro data, which can be obtained early in the drug development 
process, its predictions are easily confirmed.  
Additionally, the use of a physiologically based absorption model allows the 
inclusion of data generated from the different time lines of the development 
process, namely it can be used to made initial in silico – PBPK predictions and 
subsequently be refined by in vitro or in vivo data. The results presented in this 
 Conclusions 
Paulo J. P. A. Paixão, 2010 191 
 
work showed that this approach is feasible and can be used for lead selection in 
the various phases of drug discovery and development. 
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In silico prediction of ADME characteristics of potential new drugs is, 
nowadays, already a reality. A search on Pubmed with the topics “QSAR” and 
“Pharmacokinetic” revealed that the number of research papers in the topic has 
been constant in the last 10 years, with around 45 papers a year which is around 
10% of the total publications on the single topic “QSAR” in the same time period. 
Although the use of QSAR models is well documented in early phases of drug 
development, its utility is still not evident when considering the rate of new drugs 
appearing in the market. The complete exploration of the reasons behind this fact 
is outside the scope of this work, but are often related to both efficacy and toxicity 
issues that were not foreseen in the early development. These facts emphasize 
the major limitation within the applicability of any QSAR model, namely, 
predictability.  
A limited model molecular space is one major drawback on the applicability 
and predictability in QSAR modelling. As a consequence, increasing the number 
and diversity of molecules in the data sets would result in improved models. The 
approach presented in this work bears its limitations on the number of compounds 
available on published works. It is fair to say that within the pharmaceutical 
industry the number of compounds with Papp, Rb and CLint data is far more 
numerous and if public available would allow the building of more robust models. It 
is interesting to note that, in line with this argument, the number of international 
consortiums with academia and pharmaceutical companies is increasing as well 
as the awareness that data sharing is fundamental to the evolution of scientific 
knowledge. It is expectable that in such scenario the applicability of QSAR models 
would increase substantially. 
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Another major limitation of QSAR models is within the type of data used. All 
the presented models, and the majority of similar ones published, are based on 
single concentration determinations. This assumes that, in the case of Papp, 
passive diffusion is the major mechanism of membrane transport and, in the case 
of CLint, metabolization is non-saturable. In the data sets used in this work these 
approximations were still able to correctly predict the oral bioavailability for the 
vast majority of drugs. However, the role of drug transporters both in absorption, 
metabolization and in drug interactions is being increasingly recognized. 
Expectably, due to the chemical characteristics of the newly developed targeted 
orientated drugs, the drug transporters importance should be even more evident in 
the future. In this case, the presented models are still usable, by providing the 
expected behaviour under passive diffusion conditions, as well as by providing the 
expectable concentration ranges to explore the relevance of the drug transporters 
kinetics in vitro. The physiologically based absorption model may also be adapted 
to include the enterocyte compartment where active transporters, efflux pumps 
and CYP3A4 isoenzymes are susceptible to interact in order to increase or reduce 
the drug bioavailability. The liver model may also consider saturable kinetics by 
including KM and Vmax values for drug metabolization. However, these 
considerations would require data that today is still not typically determined and 
so, not yet available in sufficient number to build predictive QSAR models.  
An increasing basis of experimental data and, in the case of our proposed 
approach, the development of more refined experimental in vitro protocols, will 
allow general structure-permeability relationships to be obtained. This will make 
experimental determinations of the ADME drug characteristics in drug discovery 
less necessary, with its consequences in terms of costs and animal testing. 
Ultimately, QSAR models will speed up the drug discovery and bring new drugs to 
the public faster. I hope that the methodologies and results presented in this work, 
in some way, can contribute to this. 
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